

Index to Volume 62

The index to Volume 62 is composed of three parts: a subject index, an author index, and an advertising index.

The subject index is made up mainly of terms constructed by *International Pharmaceutical Abstracts (IPA)*. The *IPA* index is an alphabetical, open-ended, controlled-vocabulary index that makes use of standardized headings. (The primary index terms for each article are listed routinely in *AJHP* as "index terms" after abstracts.) *IPA* covers all authored papers and editorials in *AJHP*, as well as selected letters and news reports. Items that were published in the ASHP Reports section, including official ASHP Statements and Guidelines, are indexed under "American Soci-

ety of Health-System Pharmacists," as well as being covered by *IPA* in many cases. The subject index also notes all regular *AJHP* columns and, under the respective column headings, the titles of items in the following: Alternative Therapies, Book Reviews, CD-ROM Reviews, Editorials, Frontline Pharmacist, Letters, Management Consultation, New Practitioners Forum, News, and Q&A. The subject index also contains, under the heading "Correction Notices," the title and issue of publication of items for which corrections were printed, as well as the page numbers on which the corrections appear.

Issue	Pages
January 1	1-102
January 15	103-220
February 1	221-330
February 15	331-440
March 1	441-546
March 15	547-656
April 1	657-766
April 15	767-872
April 15 Supplement	S1-S24
May 1	873-986
May 15	987-1096
May 15 Supplement	S1-S33
June 1	1097-1212
June 15	1213-1320
July 1	1321-1418

Issue	Pages
July 15	1419-1516
August 1	1517-1626
August 15	1627-1724
August 15 Supplement	S1-S23
September 1	1725-1842
September 15	1843-1940
September 15 Supplement	S1-S25
October 1	1941-2050
October 15	2051-2188
November 1	2189-2306
November 15	2307-2428
November 15 Supplement	S1-S15
December 1	2429-2570
December 15	2571-2674

Subject Index

A

Abbreviations
errors, medication, 917, 1559

Abciximab
incompatibilities, 1381

Absorption
anesthetics, local, 1445
azacitidine, 1567
butorphanol tartrate, 48
fentanyl hydrochloride, 1171
insulin human, 1359

Accidental falls
drugs, 2495

Accreditation
residencies, 1138, 1817

Accreditation Council for Graduate Medical Education
standards, 800

Acetaminophen
combination, hydrocodone, 2293
concomitant therapy, 2006

Acetylcysteine
incompatibilities, 828

N-Acetylcysteine, see *Acetylcysteine*

Acinetobacter baumannii
resistance, 39

Acne vulgaris
prescription drugs, 620

Acquired immunodeficiency syndrome
antiretroviral agents, 1108

Acyclovir
incompatibilities, 1299

Adderall, see *Amphetamine aspartate; combination, amphetamine sulfate, dextroamphetamine saccharate, dextroamphetamine sulfate*

Additives
injections, 2386

Administration
American Society of Health-System Pharmacists, 930, 1406
hospital pharmacy, 1385, 1390, 1391, 1392, 1393, 2539
hospitals, 975
leadership, 254, 343, 519, 805, 838, 845, 856, 1206, 1303, 1442, 1657, 1693, 1697, 1700, 2474
pharmacy, 139, 1067
policies and procedures, 78, 748, 1053, 1122, 1650, 1708, 1714, 1822

Administrators
clinical pharmacy, 805
pharmacists, 1206
pharmacists, hospital, 975
pharmacy, 845

Admixtures, see *Additives*

Adolescents
amphetamine aspartate, combination, amphetamine sulfate, dextroamphetamine saccharate, dextroamphetamine sulfate, 1494
serotonin-reuptake inhibitors, 806, 864

Adrenergic agents, see *Sympathomimetic agents*

Adsorption
tramadol hydrochloride, 1299

Adverse reactions, see *Drugs, adverse reactions*

Advertising
prescription drugs, 620

Advertising Index, 102, 219, 330, 440, 546, 656, 766, 872, 986, 1096, 1212, 1320, 1418, 1516, 1626, 1724, 1842, 1940, 2050, 2188, 2306, 2428, 2570, 2648

Aerosols
albuterol sulfate, 2271

Afghanistan
health care, 1950

Age
geriatrics, 1062
patients, 1357, 1468, 1775, 1983

Agency for Healthcare Research and Quality
errors, medication, 12
health care, 342

AIDS, see *Acquired immunodeficiency syndrome*

Air
control, quality, 1856

AJHP, see *American Journal of Health-System Pharmacy*

AJHP Continuing Education, 712, Apr 15 suppl S22, May 15 suppl S31, 1261, Aug 15 suppl S19, Sep 15 suppl S24, Nov 15 suppl S14

Albumin
replacement solutions, 637

Albuterol sulfate
inhalers, 1053
stability, 2271

Alcohol withdrawal delirium
folic acid, 355

Alcohols, ethyl
antidotes, 2344
solvents, 485
withdrawal, 355

Aldosterone antagonists
heart failure, 168

Alkalinizing agents
sodium bicarbonate, 834

Allergies
aprotinin, Sep 15 suppl S9
aspirin, 1398
latex, 1822
pantoprazole sodium, 1388
phenytoin sodium, 2295

Alosetron
colonic diseases, 700

Alternative medicine
guggulu oleoresin, 1012
sex disorders, 574
standards, 562

Alternative Therapies, 574, 1012
Dietary supplements for female sexual dysfunction, 574
Guggul for hypercholesterolemia, 1012

Aluminum
contamination, 312, 315

Aluminum hydroxide
hyperphosphatemia, 2355

Alzheimer disease
memantine hydrochloride, 420

Amaryl, see *Glimepiride*

Index to Volume 62

The index to Volume 62 is composed of three parts: a subject index, an author index, and an advertising index.

The subject index is made up mainly of terms constructed by *International Pharmaceutical Abstracts (IPA)*. The *IPA* index is an alphabetical, open-ended, controlled-vocabulary index that makes use of standardized headings. (The primary index terms for each article are listed routinely in *AJHP* as "index terms" after abstracts.) *IPA* covers all authored papers and editorials in *AJHP*, as well as selected letters and news reports. Items that were published in the ASHP Reports section, including official ASHP Statements and Guidelines, are indexed under "American Soci-

ety of Health-System Pharmacists," as well as being covered by *IPA* in many cases. The subject index also notes all regular *AJHP* columns and, under the respective column headings, the titles of items in the following: Alternative Therapies, Book Reviews, CD-ROM Reviews, Editorials, Frontline Pharmacist, Letters, Management Consultation, New Practitioners Forum, News, and Q&A. The subject index also contains, under the heading "Correction Notices," the title and issue of publication of items for which corrections were printed, as well as the page numbers on which the corrections appear.

Issue	Pages
January 1	1-102
January 15	103-220
February 1	221-330
February 15	331-440
March 1	441-546
March 15	547-656
April 1	657-766
April 15	767-872
April 15 Supplement	S1-S24
May 1	873-986
May 15	987-1096
May 15 Supplement	S1-S33
June 1	1097-1212
June 15	1213-1320
July 1	1321-1418

Issue	Pages
July 15	1419-1516
August 1	1517-1626
August 15	1627-1724
August 15 Supplement	S1-S23
September 1	1725-1842
September 15	1843-1940
September 15 Supplement	S1-S25
October 1	1941-2050
October 15	2051-2188
November 1	2189-2306
November 15	2307-2428
November 15 Supplement	S1-S15
December 1	2429-2570
December 15	2571-2674

Subject Index

A

Abbreviations
errors, medication, 917, 1559

Abciximab
incompatibilities, 1381

Absorption
anesthetics, local, 1445
azacitidine, 1567
butorphanol tartrate, 48
fentanyl hydrochloride, 1171
insulin human, 1359

Accidental falls
drugs, 2495

Accreditation
residencies, 1138, 1817

Accreditation Council for Graduate Medical Education
standards, 800

Acetaminophen
combination, hydrocodone, 2293
concomitant therapy, 2006

Acetylcysteine
incompatibilities, 828

N-Acetylcysteine, see *Acetylcysteine*

Acinetobacter baumannii
resistance, 39

Acne vulgaris
prescription drugs, 620

Acquired immunodeficiency syndrome
antiretroviral agents, 1108

Acyclovir
incompatibilities, 1299

Adderall, see *Amphetamine aspartate; combination, amphetamine sulfate, dextroamphetamine saccharate, dextroamphetamine sulfate*

Additives
injections, 2386

Administration
American Society of Health-System Pharmacists, 930, 1406
hospital pharmacy, 1385, 1390, 1391, 1392, 1393, 2539
hospitals, 975
leadership, 254, 343, 519, 805, 838, 845, 856, 1206, 1303, 1442, 1657, 1693, 1697, 1700, 2474
pharmacy, 139, 1067
policies and procedures, 78, 748, 1053, 1122, 1650, 1708, 1714, 1822

Administrators
clinical pharmacy, 805
pharmacists, 1206
pharmacists, hospital, 975
pharmacy, 845

Admixtures, see *Additives*

Adolescents
amphetamine aspartate, combination, amphetamine sulfate, dextroamphetamine saccharate, dextroamphetamine sulfate, 1494
serotonin-reuptake inhibitors, 806, 864

Adrenergic agents, see *Sympathomimetic agents*

Adsorption
tramadol hydrochloride, 1299

Adverse reactions, see *Drugs, adverse reactions*

Advertising
prescription drugs, 620

Advertising Index, 102, 219, 330, 440, 546, 656, 766, 872, 986, 1096, 1212, 1320, 1418, 1516, 1626, 1724, 1842, 1940, 2050, 2188, 2306, 2428, 2570, 2648

Aerosols
albuterol sulfate, 2271

Afghanistan
health care, 1950

Age
geriatrics, 1062
patients, 1357, 1468, 1775, 1983

Agency for Healthcare Research and Quality
errors, medication, 12
health care, 342

AIDS, see *Acquired immunodeficiency syndrome*

Air
control, quality, 1856

AJHP, see *American Journal of Health-System Pharmacy*

AJHP Continuing Education, 712, Apr 15 suppl S22, May 15 suppl S31, 1261, Aug 15 suppl S19, Sep 15 suppl S24, Nov 15 suppl S14

Albumin
replacement solutions, 637

Albuterol sulfate
inhalers, 1053
stability, 2271

Alcohol withdrawal delirium
folic acid, 355

Alcohols, ethyl
antidotes, 2344
solvents, 485
withdrawal, 355

Aldosterone antagonists
heart failure, 168

Alkalinizing agents
sodium bicarbonate, 834

Allergies
aprotinin, Sep 15 suppl S9
aspirin, 1398
latex, 1822
pantoprazole sodium, 1388
phenytoin sodium, 2295

Alosetron
colonic diseases, 700

Alternative medicine
guggulu oleoresin, 1012
sex disorders, 574
standards, 562

Alternative Therapies, 574, 1012
Dietary supplements for female sexual dysfunction, 574
Guggul for hypercholesterolemia, 1012

Aluminum
contamination, 312, 315

Aluminum hydroxide
hyperphosphatemia, 2355

Alzheimer disease
memantine hydrochloride, 420

Amaryl, see *Glimepiride*

- Ambulatory care**
 clerkships, 927
 drugs, adverse reactions, 1883
 pharmaceutical care, 2501
 pharmaceutical services, 1303
 pharmacy, 274
 prescribing, 2501, 2528
 residencies, 1868
 tests, 1802
- American College of Cardiology**
 protocols, 1953
- American Heart Association**
 protocols, 1953
- American Journal of Health-System Pharmacy**
 acknowledgment of reviewers, November 1, 2004, to October 31, 2005, 2634
 Internet, 134, 146
 procedure for submissions to, 93
 sections, 94
- American Society of Health-System Pharmacists**
 ASHP policy recommendations—invitation to comment, 748
 Board of Directors; actions, January 13–14, 2005 meeting, 930; actions, April 11–13, 2005, meeting, 1406; actions, June 11–14, 2005, meeting, 1821; actions, September 22–23, 2005, meeting, 2637
 Board of Directors Honor Award, 309
 council recommendations, 748
 clinical pharmacy, 2236
 data collection, 378
 Distinguished Leadership in Health-System Pharmacy Practice Award, 311
 drug use, 583, 585
 Executive Vice President and Chief Executive Officer; report of, 1700
 guidelines, 468, 1385, 1390, 1391, 1392, 1393, 1654, 1714, 2345
 Harvey A. K. Whitney Lecture Award; 2005, 1657
 health care, 1871, 1924
 Honorary Membership, 310
 House of Delegates; professional policies adopted by the 57th annual session, 1708; 2006 session, members of, 1713
 leadership, 845, 1657
 meetings, 519, 856, 930, 1303, 1352, 1406
 Midyear Clinical Meeting; call for papers, 634; program, 2072
 organizations, 123, 1693, 1697, 1700, 1703, 1708, 1821, 1890
 pharmaceutical services, 145, 2039
 policies and procedures, 748
 Practitioner Recognition Program—2005 fellows, 1195
 President and Chair of the Board; report of, 1697
 President-elect and Vice Chair of the Board; report of, 1693
 protocols, 1398, 1502, 2420
 residencies, 1138, 1562, 1766, 1817, 1868
 Summer Meeting; call for papers, 2037; program, 935
 Treasurer; report of, 1703
 World Wide Web, 1447
- Amino acids**
 arginine, 574
 parenteral nutrition, 289, 1177
- Aminocaproic acid**
 coronary artery bypass, Sep 15 suppl S9
- ε*-Aminocaproic acid**, see **Aminocaproic acid**
- Aminoglutethimide**
 breast neoplasms, 266
- Aminoglycosides**
 drug use, 1596
 gentamicin, 823
 gentamicin sulfate, 1548, 1613
- Amitriptyline hydrochloride**
 concomitant therapy, 2293
- Amlodipine**
 concomitant therapy, 1388, 2295
- Amlodipine besylate**
 concomitant therapy, 420
- Amoxicillin trihydrate**
 combination, clavulanate potassium, 2459
- Amphetamine aspartate**
 combination, amphetamine sulfate, dextroamphetamine saccharate, dextroamphetamine sulfate, 1494
- Amphotericin B**
 incompatibilities, 834
 mycoses, Apr 15 suppl S17
 zygomycosis, 2593
- Ampicillin**
 combination, sulbactam, 1299
- Analgesics and antipyretics**
 aspirin, 2495
 butorphanol tartrate, 48
 physical therapists, 1440
- Analysis**
 genetics, 296
- Anaphylaxis**
 pantoprazole sodium, 1388
- Anastrozole**
 breast neoplasms, 266
- Androgens**
 prasterone, 574
- Anemia**
 darbepoetin alfa, 54, 2597
 epoetin alfa, 54, 2597
- Anesthetics**
 desflurane, 63
 ketamine hydrochloride, 1190
 propofol, 1247
 sevoflurane, 63
 toxicity, 1247
- Anesthetics, local**
 compounding, 1445
 lidocaine, combination, phenylephrine, tetracaine, 450
- Angiotensin antagonists**
 irbesartan, 2381
 losartan, 2381
 telmisartan, 2381
 valsartan, 2381
- Angiotensin-converting-enzyme inhibitors**
 drug use, 626
 heart failure, 168
- Anidulafungin**
 incompatibilities, 834
- Antacids**
 interactions, 1033
- Antiarrhythmic drugs**, see **Cardiac drugs**
- Antibiotics**
 clindamycin, 1299
 colistin, 39
 daptomycin, 1143, 1145
 ertapenem sodium, 834
 vancomycin, 732, 1596
- Anticoagulants**
 argatroban, 247, 1381
 bivalirudin, 247
 dalteparin, Nov 15 suppl S10
 enoxaparin, Nov 15 suppl S10
 heparin, 247, 1494, 2338, Nov 15 suppl S7
 lepirudin, 247
 nadroparin, Nov 15 suppl S10
 pharmaceutical services, 274
 tests, 1802
 thromboembolism, 616, Nov 15 suppl S10
 thrombosis, Nov 15 suppl S7
 tinzaparin, Nov 15 suppl S10
 venous thrombosis, 593
 warfarin, 626, 1033, 1062, 1449, 1683, 1983, 2393, Nov 15 suppl S10
 ximelagatran, 1449, 1451
- Anticonvulsants**
 levetiracetam, 420
 phenytoin, 1969
 phenytoin sodium, 2295
 pregnancy, 1342
- Antidepressants**
 bupropion, 1502
 duloxetine, 2479, 2481
 insomnia, 1532
 serotonin-reuptake inhibitors, 806, 864, 1342
 toxicity, 1333
 tricyclic, 1502
 venlafaxine, 2479
- Antidiabetic agents**
 compliance, 198
 diabetes mellitus, 510, 1048
 errors, medication, 714
 exenatide, 173
 glimepiride, 35
- metformin, 36
 pramlintide acetate, 816, 2363
 withdrawal, 467
- Antidotes**
 alcohols, ethyl, 2344
 fomepizole, 2344
- Antiemetics**
 dolasetron, 1247
 dolasetron mesylate, 896
 droperidol, 1247
 granisetron, 1247
 ondansetron, 1247, 1299
 ondansetron hydrochloride, 2001
 palonosetron hydrochloride, 1998
 prochlorperazine, 1247
 promethazine, 1247
 protocols, 463
 scopolamine, 1247
- Antifungals**
 amphotericin B, 834, Apr 15 suppl S17, 2593
 anidulafungin, 834
 caspofungin, Apr 15 suppl S17
 drug use, 732
 fluconazole, Apr 15 suppl S17
 interactions, 1983
 itraconazole, Apr 15 suppl S17
 posaconazole, 2593
 posaconazole, Apr 15 suppl S17
 voriconazole, Apr 15 suppl S17
- Antifungal agents**
 dosage, 2288
 drug use, 74, 1967
 infections, 1143, 1748
 linezolid, 464
 metronidazole, 88
 protocols, 34, 732
 resistance, 1650
 shortages, 1444
- Antiinflammatory agents**
 celecoxib, 739
 COX-2 inhibitors, 668, 890
 ibuprofen lysinate, 630
 nabumetone, 739
 nonsteroidal, 997, 1333, 1336, 1543, 1983, 2495
 oxaprozin, 739
 pregnancy, 1342
 rofecoxib, 739
 valdecoxib, 997
- Antilipemic agents**
 atorvastatin, 1033, 1468
 atorvastatin calcium, 2491
 fluvastatin, 1468
 gemfibrozil, 1033
 HMG-CoA reductase inhibitors, 411, 979, 2420
 lovastatin, 455, 1444, 1468
 pravastatin, 1033, 1468
 rosuvastatin, 1033
 simvastatin, 1033, 1468
- Antineoplastic agents**
 aminoglutethimide, 266
 anastrozole, 266
 azacitidine, 1567
 bevacizumab, 1017, 1021
¹⁸B-l-boronophenylalanine, 2608
 carcinoma, 1365
 cisplatin, 475
 contamination, 471
 cyclophosphamide, 475, 1998
 etoposide, 182
 exemestane, 266
 fluorouracil, 475, 1021, 1788
 ifosfamide, 475, 1998
 letrozole, 266
 leucovorin, 1788
 medication orders, 1813
 paclitaxel, 2241
 tamoxifen, 266
 tegafur, 1365
 toxicity, 54, 83, 463, Nov 15 suppl S4, Nov 15 suppl S10
 uracil, 1365
 vincristine sulfate, 1606
- Antioxidants**
 lycopene, 899

ANNUAL INDEX

Antipsychotic agents

insomnia, 1532
olanzapine, 610
pimozide, 1983
risperidone, 610

Antiretroviral agents

HIV infections, 1108, 2332
protease inhibitors, 809
ritonavir, 809

Antituberculars

tuberculosis, 1431

Antivirals

acyclovir, 1299
cidofovir, 506
cytomegalovirus infections, Apr 15 suppl S3, Apr 15 suppl S7
drug use, 732
ganciclovir, Apr 15 suppl S14
valganciclovir, Apr 15 suppl S14

Anxiolytics, sedatives and hypnotics

droperidol, 1190
insomnia, 1532
lorazepam, 1494

Aortic valve stenosis

HMG-CoA reductase inhibitors, 979

Apparatus, see Equipment

Aprotinin

atrial fibrillation, 1370
coronary artery bypass, Sep 15 suppl S6, Sep 15 suppl S9, Sep 15 suppl S15, Sep 15 suppl S19

Argatroban

incompatibilities, 1381
thrombocytopenia, 247

Arginine

sex disorders, 574

Arimidex, see Anastrozole

Arthritis

Internet, 1184

Ascorbic acid

stability, 1073

Aseptic areas

clean rooms, 1271, 2386

ASHP, see American Society of Health-System Pharmacists

ASHP's CareerPharm, 97, 214, 325, 432, 541, 650, 762, 868, 982, 1090, 1200, 1315, 1412, 1515, 1620, 1721, 1834, 1937, 2043, 2180, 2298, 2423, 2555, 2643

Aspergillosis

antifungals, Apr 15 suppl S17

Aspirin

cardiovascular diseases, 1357, 1398
combination, butalbital, caffeine, 2293
concomitant therapy, 420, 2295
myocardial infarction, 1494
toxicity, 2495
use, 626

Asthma

albuterol sulfate, 1053

Atomoxetine

attention deficit disorder with hyperactivity, 1502

Atorvastatin

hypercholesterolemia, 1468
hyperlipidemia, 1033

Atorvastatin calcium

hyperlipidemia, 2491

Atosiban acetate

incompatibilities, 2459

Atrial fibrillation

aprotinin, 1370
magnesium sulfate, 397

Atrial flutter

aprotinin, 1370

Attention deficit disorder with hyperactivity

amphetamine aspartate, combination, amphetamine sulfate, dextroamphetamine saccharate, dextroamphetamine sulfate, 1494
protocols, 1502

Audits

hospitals, 189

Automation

compounding, 2345
dispensing, 1375, 1917, 2397

Availability, drugs, see Drugs, availability

Avastin, see Bevacizumab

Awards

hospitals, 343

Azacitidine

review, 1567

B

Bacillus Calmette-Guerin vaccines, see BCG vaccines

Bacterial infections

colistin, 39

BCG vaccines

tuberculosis, 1431

Belgium

hospital pharmacy, 321

Benchmarking

pharmacy, 1303

Benzodiazepines

insomnia, 1532

Beta-lactamase inhibitors

clavulanate potassium, combination, amoxicillin trihydrate, 2459
sulbactam, combination, ampicillin, 1299

Bevacizumab

colorectal neoplasms, 1017
neoplasms, 1021

Bextra, see Valdecoxib

Bid contracting, see Purchasing

BiDil, see Hydralazine hydrochloride; combination, isosorbide dinitrate

Billing

codes, 20, 1640
hospital pharmacy, 462

Bioavailability, see Drugs, availability

Biological warfare

disaster planning, 239, 1000

Biologicals

approvals, 348

Bivalirudin

thrombocytopenia, 247

Bladder diseases

prescription drugs, 620

Blindness

labels, 116

Blood

transfusions, 400, 1159, 1370, Sep 15 suppl S2, Sep 15 suppl S9, Sep 15 suppl S15, Sep 15 suppl S19

Blood levels

antifungals, Apr 15 suppl S17
aprotinin, Sep 15 suppl S9
azacitidine, 1567
bevacizumab, 1021
butorphanol tartrate, 48
cyclosporine, 391
daptomycin, 1145
exenatide, 173
gentamicin, 823
gentamicin sulfate, 1613
immunosuppressive agents, 1775
insulins, 816
linezolid, 464
pramlintide acetate, 816, 2363
protease inhibitors, 809
tiotropium bromide, 1263

Blood pressure

tests, 1802

Book Correction Notice, 353, 1134

Book Reviews, 437, 1210, 1838, 2047

Advancing Patient Safety in U.S. Hospitals: Basic Strategies for Success, 437

Civil War Pharmacy: A History of Drugs, Drug Supply and Provision, and Therapeutics for the Union and Confederacy, 1210

Handbook of Basic Pharmacokinetics . . . Including Clinical Applications, Sixth Edition, 2047

Health Behavior Change: A Guide for Practitioners, 1210
Let Them Eat Prozac: The Unhealthy Relationship between the Pharmaceutical Industry and Depression, 2047

Pagliaro's Comprehensive Guide to Drugs and Substances of Abuse, 438

Pain and Profits: The History of the Headache and Its Remedies in America, 1838

Powerful Medicines: The Benefits, Risks, and Costs of Prescription Drugs, 1840

Radical Evolution: The Promise and Peril of Enhancing Our Minds, Our Bodies—and What It Means To Be Human, 2048

The Mind of Norman Bethune, 438

The Mold in Dr. Florey's Coat: The Story of the Penicillin Miracle, 1838

¹⁰B-1-Boronophenylalanine

complexes, 2608

Breast neoplasms

antineoplastic agents, 266

Budgets

American Society of Health-System Pharmacists, 1703
Medicaid, 1852
pharmacy, 139

Bupropion

attention deficit disorder with hyperactivity, 1502

Butalbital

combination, aspirin, caffeine, 2293

Butorphanol tartrate

availability, 48

C

Caffeine

combination, aspirin, butalbital, 2293

Calcinosis

menaquinone, 1574
phytonadione, 1574

Calcium

incompatibilities, 1177

Calcium acetate

hyperphosphatemia, 2355

Calcium carbonate

hyperphosphatemia, 2355

Calcium phosphate dibasic

precipitation, 1177

Calculations

aluminum, 312, 315
decision-making, 2031
dosage, 823, 1663
epoetin alfa, 1867

Caloric agents

dextrose, 1177, 1375, 2260

Canada

pharmacists, 1067

Canadian Society of Hospital Pharmacists

organizations, 123

Cancer, see Antineoplastic agents

Cancer drugs, see Antineoplastic agents

Candesartan

hypertension, 2381

Candidiasis

antifungals, Apr 15 suppl S17

Carbapenems

drug use, 732

Carbonic anhydrase inhibitors

glaucoma, 691

Carcinoma

antineoplastic agents, 1365

Cardiac drugs

digoxin, 168
diltiazem hydrochloride, 1494
drugs, adverse reactions, 1883
milrinone, 291
nesiritide, 196, 291, 606, 2639

Cardiovascular diseases

aspirin, 1357, 1398
ethnic groups, 886
therapy, 1873

Cards

prescription drugs, 1482

Careers

hospital pharmacy, 2539
pharmacists, 1204, 1206, 1352, 1408, 1773, 1980, 2474
pharmacists, hospital, 1832
residencies, 1138

Carvedilol

concomitant therapy, 1388

Case Law, 306

Caspofungin

mycoses, Apr 15 suppl S17

- Catheters**
central, Nov 15 suppl S4
urinary tract infections, 74
- Cefotaxime**
use, 732
- Ceftazidime**
use, 732
- Ceftriaxone sodium**
toxicity, 2006
- Celecoxib**
use, 739
- CellCept**, see **Mycophenolate mofetil**
- Cellulitis**
linezolid, 464
- Centers for Disease Control and Prevention**
protocols, 34
- Centers for Medicare and Medicaid Services**
protocols, 34
reimbursement, 462, 1854
residencies, 1019
World Wide Web, 1118
- Central nervous system drugs**
atomoxetine, 1502
guanfacine, 1502
memantine hydrochloride, 420
- Central nervous system stimulants**
amphetamine aspartate, combination, amphetamine sulfate, dextroamphetamine saccharate, dextroamphetamine sulfate, 1494
attention deficit disorder with hyperactivity, 1502
methylphenidate, 1502
- Cephalosporins**
cefotaxime, 732
ceftazidime, 732
ceftriaxone sodium, 2006
- Cerebrovascular accident**
aprotinin, 1370
- Certification**
pharmacists, 259
technicians, 119, 2542
- Charity**
drug distribution, 1653
industry, pharmaceutical, 726, 1048
- Chemical warfare**
disaster planning, 1000
- Cholesterol**
tests, 1802
- Cholinesterase inhibitors**
dementia, 923
- Cidofovir**
stability, 506
- Cimetidine**
critical illness, May 15 suppl S4
- Ciprofloxacin**
use, 732
- Circadian rhythm**
atorvastatin calcium, 2491
- Cisplatin**
contamination, 475
- Classification**
drugs, 149, 1408
HMG-CoA reductase inhibitors, 2420
lovastatin, 455, 1444
outcomes, 2348
- Classified advertising**, see **ASHP's CareerPharm**
- Clavulanate potassium**
combination, amoxicillin trihydrate, 2459
- Clearance, see Excretion**
- Clindamycin**
incompatibilities, 1299
- Clinical Consultation**, 319, 537, 979, 1931
- Clinical pharmacists**
communication, 2528
disease management, 454
interventions, 1760, 1793
leadership, 805
role, 744, 1763, 2466
services, 1640
- Clinical pharmacy**
clerkships, 927
decision-making, 2236
education, pharmaceutical, 1510
leadership, 805
services, 20, 145, 321, 454, 560, 744, 1640, 1956, 2039
technicians, 2466
- Clinical studies**
antineoplastic agents, 266
estrogens, 69
ethnic groups, 1873
hospital pharmacy, 464
parenteral nutrition, 315
- Clonidine**
attention deficit disorder with hyperactivity, 1502
- Clonidine hydrochloride**
incompatibilities, 1968
- Closures**
latex, 1822
- Coatings**
enteric, 2252
- Codes**
bar, 530, 1075, 2413, 2619, 2626
billing, 20, 1640
reimbursement, 1956
- Cognition disorders**
drugs, adverse reactions, 1883
hydrochlorothiazide, 2630
- Cohen, M.**
pharmacists, 2222
- Colistin**
bacterial infections, 39
- Colloids**
anaphylaxis, 1388
replacement solutions, 637
- Colonic diseases**
gastrointestinal drugs, 700
- Color**
ascorbic acid, 1073
atosiban acetate, 2459
clonidine hydrochloride, 1968
gentamicin sulfate, 1548
pantoprazole sodium, 2410
sodium citrate, 1548
theophylline anhydrous, 2518
vasopressin, 1969
- Colorectal neoplasms**
bevacizumab, 1017, 1021
fluorouracil, 1021, 1788
- Combined therapy**
angiotensin antagonists, 2381
antidiabetic agents and insulins, 510
antiemetics, 1247
antiretroviral agents, 809
bevacizumab, 1017
bevacizumab and fluorouracil, 1021
cardiac drugs, 606
diuretics and angiotensin antagonists, 2381
estrogens and menaquinone, 1574
estrogens and progestins, 69
fluorouracil and bevacizumab, 1021
immunosuppressive agents, 391
insulins and antidiabetic agents, 510
menaquinone and estrogens or vitamin D, 1574
milrinone and nesiritide, 291
nesiritide and milrinone, 291
progestins and estrogens, 69
tegafur and uracil, 1365
uracil and tegafur, 1365
vitamin D and menaquinone, 1574
- Commentaries**, 210, 312, 422, 525, 637, 643, 864, 975, 1080, 1311, 1822, 2039, 2539, 2639
- Commiphora mukul**
guggulu oleoresin, 1012
gugulipid, 1690
- Committees**
risk management, 236
- Communication**
clinical pharmacists, 2528
computers, 499
drug information, 1333
errors, medication, 714
health professions, 1340
medication orders, 78
pharmacists, 364, 1311, 1654, 1714, 2039, 2342
- Complexes**
¹⁰B-1-boronophenylalanine and fructose, 2608
fructose and ¹⁰B-1-boronophenylalanine, 2608
- Compliance**
formularies, 378
hospital pharmacy, 464
hospitals, 189
- patients, 198, 411, 809, Apr 15 suppl S14, 1263, 1311, 1359, 1468, 1645, 1775, 2239, 2342
protocols, 34
standards, 1271
- Compounding**
anesthetics, local, 1445
cidofovir, 506
injections, 2386
lidocaine, combination, phenylephrine, tetracaine, 450
parenteral nutrition, 2345
solutions, 1550
sterile products, 285, 1271, 1856
theophylline anhydrous, 2518
vincristine sulfate, 1606
- Comprehension**
patient information, 620
patients, 364, 1184, 1873
- Computers**
bar codes, 2619, 2626
calculations, 2031
documentation, 1782
errors, medication, 243, 1340, 2265
hospitals, 499
information, 788, 1228
Internet, 134, 146, 355, 1118, 1184, 1333
medical records, 680, 2222
medication orders, 378, 416, 530, 1813
programs, 1793, 2393, 2604
World Wide Web, 1447
- Concentration**
acetylcysteine, 828
aluminum, 312, 315
amino acids, 289, 1177
anesthetics, local, 1445
argatroban, 1381
ascorbic acid, 1073
¹⁰B-1-boronophenylalanine, 2608
calcium, 1177
cidofovir, 506
daptomycin, 1145
dextrose, 1177
dolasetron mesylate, 896
droperidol, 1190
electrolytes, 1550
etoposide, 182
fenoterol hydrobromide, 828
fentanyl citrate, 1190
gentamicin sulfate, 1548
globulin immune, Aug 15 suppl S5
ibuprofen lysinate, 630
ipratropium bromide, 828
ketamine hydrochloride, 1190
levofloxacin, 88
metronidazole, 88
misoprostol, 1192
nafcillin sodium, 1347
pantoprazole sodium, 2410
phosphates, 1177
roxatidine acetate hydrochloride, 289
sodium chloride, Aug 15 suppl S12
sterile products, 1271
sugars, Aug 15 suppl S12
theophylline anhydrous, 2518
tramadol hydrochloride, 1299
triamcinolone acetonide, 485
vincristine sulfate, 1606
- Consultants**
quality assurance, 139
- Containers**
glass, 1190
polyolefin, 2001
polyvinyl chloride, 1190
- Contamination**
aluminum, 312, 315
antineoplastic agents, 471, 475
impurities, 182, 1381
injections, 2386
microbiological, 285, 506, 896, Aug 15 suppl S5, Aug 15 suppl S12, 2518
particles, 834, 1177, 1856, 1969
- Contraceptives**
dispensing, 1864
- Contracts**
pharmacy, 422

Contraindications

analgesics and antipyretics, 1440
guggulu oleoresin, 1012
influenza vaccines, 367
pneumococcal vaccines, 367
ximelagatran, 1451

Control, quality

alternative medicine, 562
blood transfusions, Sep 15 suppl S2
globulin immune, Aug 15 suppl S5, Aug 15 suppl S12
injections, 2386
parenteral nutrition, 2345
solutions, 1550
sterile products, 1271, 1856
vincristine sulfate, 1606

Controlled substances

laws, 306
prescriptions, 2278

Coronary artery bypass

aprotinin, Sep 15 suppl S6
cost-benefit analysis, Sep 15 suppl S2
magnesium sulfate, 397
therapy, Sep 15 suppl S9, Sep 15 suppl S15, Sep 15 suppl S19

Coronary disease

HMG-CoA reductase inhibitors, 2420
stents, 2241

Correction Notices, 462, 572, 679, 1134, 1241, 1438,

1966, 2352

Aluminum exposure through parenteral nutrition formulations: mathematical versus clinical relevance (Feb 1, 2005, Commentary), 679

ASHP survey of ambulatory care pharmacy practice in health systems—2004 (Feb 1, 2005, Report), 462

Bevacizumab in combination chemotherapy for colorectal and other cancers (May 15, 2005, Clinical Review), 1241

Blueprint for implementing USP chapter 797 for compounding sterile preparations (Jun 15, 2005, Report), 1966

FDA's annual event surveillance needs improvement, advise... (Jul 1, 2005, News), 1438

New heart-failure therapy takes race into account (Sep 1, 2005, News), 1966

Pharmacoeconomics of inhaled anesthetic agents: considerations for the pharmacist (Oct 15, 2004, Suppl), 572

Physical and chemical compatibility of drotrecogin alfa (activated) with 34 drugs during simulated Y-site administration (Dec 15, 2004, Report), 1134

Proceedings of a leadership retreat conducted by the ASHP Foundation and the John W. Webb Visiting Professor Program (Apr 15, 2005, ASHP Report), 1134

Some firms will use pharmacists in Medicare chronic care project (May 15, 2005, News), 2352

U.S. pharmacists respond to global AIDS crisis (Jun 1, 2005, News), 1241

Cortisporin Otic Solution, see **Hydrocortisone**;**combination**, **neomycin sulfate**, **polymyxin B sulfate****Cost-benefit**, see **Economics**; **cost-benefit analysis****Cost-effectiveness**, see **Economics**; **cost-benefit analysis****Costs**

antifungal agents, 34, 732, 1967, 2288

antineoplastic agents, 1365

bevacizumab, 1017

control, quality, 1271

coronary artery bypass, Sep 15 suppl S2

darbepoetin alfa, 2597

desflurane, 63

disaster planning, 239

discounts, 1482

drug distribution, 1444

drugs, 149, 189, 422, 691, 1645

duloxetine, 2481

epoetin alfa, 2597

gastrointestinal hemorrhage, 1159

globulin immune, Aug 15 suppl S5

health care, 570, 1617

infections, 1650

Medicaid, 1537

nonsteroidal antiinflammatory agents, 1543

opiates, 319

pharmacy, 139

prescription drugs, 233

product development, 779

proton-pump inhibitors, May 15 suppl S24

schizophrenia, 610

sevoflurane, 63

stents, 2241

tests, laboratory, 74

Creatine

poisoning, 1476

Crime

fraud, 1537, 2604

Critical care

insulin, 2260

pediatrics, 1763

Critical illness

albumin, 637

epoetin alfa, 400

gastrointestinal drugs, May 15 suppl S4

gastrointestinal hemorrhage, May 15 suppl S11

proton-pump inhibitors, May 15 suppl S24

sodium chloride, 637

water-electrolyte imbalance, 1663

Crystalloids

replacement solutions, 637

Current Literature, 437, 1210, 1838, 2047**Curriculum**

clerkships, 2539

clinical pharmacy, 1510

education, pharmaceutical, 2514

emergency rooms, 1832

leadership, 1442, 1657

residencies, 1488, 1562, 1766, 1817, 1868, 1980, 2283

Cyclophosphamide

contamination, 475

incompatibilities, 1998

Cyclosporine

interactions, 1033, 1983

transplantation, 391, 1775

Cytomegalovirus infections

antivirals, Apr 15 suppl S3, Apr 15 suppl S7

ganciclovir, Apr 15 suppl S14

valganciclovir, Apr 15 suppl S14

Cytotoxic agents, see **Antineoplastic agents****D****Dacizumab**

transplantation, 391

Dalteparin

thromboembolism, Nov 15 suppl S10

Daptomycin

infections, 1143

review, 1145

Darbepoetin alfa

anemia, 54

cost-benefit analysis, 2597

therapeutic substitution, 2416

Data collection

diabetes mellitus, 354

errors, medication, 2265

hospital pharmacy, 321, 1393

hospitals, 189

leadership, 845

patients, 463, 616

pharmaceutical services, 378

pharmacists, 492, 726, 1067, 2401, 2508

pharmacists, hospital, 78

pharmacy, 274

physical therapists, 1440

physicians, 739

residencies, 2226, 2283

state boards, 2278

technicians, 1992

women, 69

Death

anesthetics, local, 1445

epoetin alfa, 2524

lidocaine, combination, phenylephrine, tetracaine, 450

Debridement

zygomycosis, 2593

Decision-making

clinical pharmacy, 2236

evidence-based medicine, Sep 15 suppl S19

formularies, 378, 1498, May 15 suppl S24

health care, 342

methodology, 2031

Decontamination

antineoplastic agents, 475

Deferoxamine

zygomycosis, 2593

Dehydroepiandrosterone, see **Prasterone****Dementia**

accidental falls, 2495

cholinesterase inhibitors, 923

Department of Defense

medical records, 680

Department of Health and Human Services

quality assurance, 1950

Department of Veterans Affairs

hospital pharmacy, 464, 1385

medical records, 680

Depression

antidepressants, 2479, 2481

duloxetine, 2481

prescription drugs, 620

serotonin-reuptake inhibitors, 806, 864

Desflurane

surgery, 63

Desmopressin

coronary artery bypass, Sep 15 suppl S15

Developing countries

drug distribution, 2216

Devices

compliance, 411

infusion pumps, 917

inhalers, 1053

tests, 1802

Dexamethasone

concomitant therapy, 2006

postoperative nausea and vomiting, 1247

Dextrose

dilutents, 630, 1073, 1381, 2001, 2344

hypoglycemia, 2260

parenteral nutrition, 1177

use, 1375

DHEA, see **Prasterone****Diabetes mellitus**

antidiabetic agents, 198, 510, 714

disease management, 454, 1586

drug use, 1048

exenatide, 173

gatifloxacin, 2293

insulin human, 1359

insulins, 510, 816

outcomes, 354

pharmaceutical services, 274

pramlintide acetate, 816, 2363

prescription drugs, 620

therapy, 1873

zygomycosis, 2593

Diabetic neuropathies

duloxetine, 2481

Diagnosis

aortic valve stenosis, 979

attention deficit disorder with hyperactivity, 1502

heart failure, 1953

mycoses, Apr 15 suppl S17

venous thrombosis, 593

x-rays, 2026

zygomycosis, 2593

Dialysis

hemo, 1867

hyperphosphatemia, 2355

solutions, 1550

Dibasic calcium phosphate, see **Calcium phosphate****dibasic****Dietary supplements**

gugulipid, 1690

poisoning, 1476

sex disorders, 574

toxicity, 1582

Diethylhexyl phthalate

leaching, 182

Digoxin

heart failure, 168

Diltiazem hydrochloride

myocardial infarction, 1494

- Diluents**
dextrose, 630, 1073, 1381, 2001, 2344
injections, 917
sodium chloride, 630, 1073, 1190, 1381, 2001, 2410
water for injection, 630
- Diphenhydramine**
concomitant therapy, 2293
- Disaster planning**
biological warfare, 239
emergency services, 1000
pharmacists, 274, 1290, 2202
- Disasters**
pharmacists, 2202, 2321
- Disease management**
diabetes mellitus, 454
hyperlipidemia, 1586
Medicare, 1009
pharmaceutical services, 1956
- Diseases**
immunization, 1234
- Disinfectants**
clean rooms, 1271
- Dispensing**
automation, 1375, 1917, 2397
contraceptives, 1864
disaster planning, 1290
errors, medication, 243
HMG-CoA reductase inhibitors, 2420
hospital pharmacy, 1075
prescription drugs, 1437
technology, 1866
- Diuretics**
hydrochlorothiazide, 2630
hypertension, 2381
- Dobutamine**
anaphylaxis, 1388
- Dobutamine hydrochloride**
concomitant therapy, 196
- Documentation**
clean rooms, 1271
computers, 499, 1782
interventions, 1793
medication orders, 78
pharmaceutical services, 1491
research, 464
- Docusate sodium**
concomitant therapy, 2293
- Dolasetron**
postoperative nausea and vomiting, 1247
- Dolasetron mesylate**
stability, 896
- Dopamine**
anaphylaxis, 1388
- Dopamine agonists**
pergolide, 537
pramipexole, 537
ropinirole, 537
- Dopamine hydrochloride**
therapy, 2295
- Dosage**
albuterol sulfate, 1053, 2271
analgesics and antipyretics, 1904
anticoagulants, 593
antidiabetic agents, 714
antifungal agents, 2288
aprotinin, Sep 15 suppl S9
azacitidine, 1567
bevacizumab, 1021
butorphanol tartrate, 48
cyclosporine, 391
daptomycin, 1145
darbepoetin alfa, 54, 2416
duloxetine, 2479, 2481
electrolytes, 1663
epoetin alfa, 54, 400, 1867, 2524
errors, medication, 917
exenatide, 173
fomepizole, 2344
ganciclovir, Apr 15 suppl S14
gentamicin, 823
gentamicin sulfate, 1613
globulin immune, 720
guggulu oleoresin, 1012
heparin, Nov 15 suppl S7
histamine H2 antagonists, May 15 suppl S4
influenza vaccines, 367
insulin, 714, 2260
linezolid, 464
menaquinone, 1574
mycophenolate sodium, 2252
nesiritide, 196, 2639
opioids, 319
overdose, 1375, 1476
phytonadione, 1574
pneumococcal vaccines, 367
pramlintide acetate, 2363
proton-pump inhibitors, May 15 suppl S4, May 15 suppl S18, 1159
rosuvastatin, 1033
telithromycin, 905
tiotropium bromide, 1263
valganciclovir, Apr 15 suppl S14
vasopressin, 1931
venlafaxine, 2479
warfarin, 1062, 1683, 2393, Nov 15 suppl S7
ximelagatran, 1451
- Dosage forms**
proton-pump inhibitors, May 15 suppl S4, May 15 suppl S24
scopolamine hydrobromide, 2350
- Dosage schedules**
antivirals, Apr 15 suppl S3, Apr 15 suppl S7
atorvastatin calcium, 2491
heparins, Nov 15 suppl S7
protease inhibitors, 809
tiotropium bromide, 1263
ximelagatran, 1451
- Droperidol**
incompatibilities, 1190
postoperative nausea and vomiting, 1247
- Drug abuse**
oxycodone hydrochloride, 2604
sports, 2216
zygomycosis, 2593
- Drug administration**
antineoplastic agents, 1813
azacitidine, 1567
bar codes, 2619, 2626
daptomycin, 1145
duloxetine, 2481
errors, medication, 2413
globulin immune, Aug 15 suppl S5
influenza vaccines, 367
injections, 530
pneumococcal vaccines, 367
pramlintide acetate, 2363
proton-pump inhibitors, May 15 suppl S24
rosuvastatin, 1033
self-medication, 2508
telithromycin, 905
tiotropium bromide, 1263
ximelagatran, 1451
- Drug administration rate**
etoposide, 182
injections, 917
insulin, 2260
- Drug administration routes**
inhalation, 1359
intranasal, 48
intravenous, May 15 suppl S18, May 15 suppl S24
oral, Apr 15 suppl S14, May 15 suppl S18, May 15 suppl S24
subcutaneous, 173
- Drug comparisons**
albumin and sodium chloride, 637
anticoagulants, Nov 15 suppl S10
antineoplastic agents, 266
atorvastatin and rosuvastatin, 1033
darbepoetin alfa and epoetin alfa, 54, 2597
desflurane and sevoflurane, 63
epoetin alfa and darbepoetin alfa, 54, 2597
filgrastim and sargramostim, 83
ipratropium and tiotropium bromide, 1263
mycophenolate mofetil and mycophenolate sodium, 2252
mycophenolate sodium and mycophenolate mofetil, 2252
olanzapine and risperidone, 610
pravastatin and rosuvastatin, 1033
risperidone and olanzapine, 610
rosuvastatin and antilipemic agents, 1033
salmeterol and tiotropium bromide, 1263
sargramostim and filgrastim, 83
sevoflurane and desflurane, 63
simvastatin and rosuvastatin, 1033
sodium chloride and albumin, 637
tiotropium bromide and ipratropium or salmeterol, 1263
- Drug distribution**
alcohols, ethyl, 2344
antiretroviral agents, 1108
developing countries, 2216
disaster planning, 1290
globulin immune, 2329
influenza vaccines, 247
prescription drugs, 1653
residencies, 800
shortages, 1444
- Drug distribution systems**
bar codes, 1075
- Drug Enforcement Administration**
laws, 306
- Drug information**
education, pharmaceutical, 2514
pharmaceutical services, 378
physical therapists, 1440
pregnancy, 1342
telepharmacy, 406
toxicity, 1333
- Drug information centers**
directories, 1348
services, 2511
- Drug interactions**
antacids and rosuvastatin, 1033
cholinesterase inhibitors, 923
cyclosporine and rosuvastatin, 1033
duloxetine, 2481
estrogens and menaquinone, 1574
fluorouracil, 1788
food and warfarin, Nov 15 suppl S7
gemfibrozil and rosuvastatin, 1033
guggulu oleoresin, 1012
heparins, Nov 15 suppl S7
histamine H2 antagonists, May 15 suppl S4
insulins and pramlintide acetate, 816
interventions, 1760
leucovorin and fluorouracil, 1788
medicinal plants and warfarin, Nov 15 suppl S7
menaquinone and estrogens, 1574
milrinone and nesiritide, 291
mycophenolate mofetil, 2252
mycophenolate sodium, 2252
nesiritide and milrinone, 291
pharmaceutical services, 1645
pramlintide acetate and insulins, 816
prescription claims database, 1983
proton-pump inhibitors, May 15 suppl S4
rosuvastatin, 1033
telithromycin, 901, 905
tiotropium bromide, 1263
warfarin, 1449, Nov 15 suppl S7
warfarin and rosuvastatin, 1033
- Drug product selection, see Substitution, therapeutic**
- Drug use**
aminoglycosides, 1596
analgesics and antipyretics, 1440, 1904
angiotensin antagonists, 2381
anticoagulants, 1449
antidiabetic agents, 467
antifungal agents, 34, 74, 732, 1967, 2288
antineoplastic agents, 266
attention deficit disorder with hyperactivity, 1502
bar codes, 1075
celecoxib, 739
cholinesterase inhibitors, 923
costs, 149
darbepoetin alfa, 54
dextrose, 1375
diabetes mellitus, 1048
emergency rooms, 1832
epoetin alfa, 54, 400
errors, medication, 2265
ethnic groups, 205
evaluation, 83
geriatrics, 626

- globulin immune, 720, Aug 15 suppl S5, Aug 15 suppl S12, 2329
- hospital pharmacy, 468
- hospitals, 189
- insomnia, 1532
- nabumetone, 739
- naloxone, 1375
- nonsteroidal antiinflammatory agents, 1543
- oxaprozin, 739
- oxycodone hydrochloride, 2604
- pediatrics, 806
- pharmaceutical services, 259, 378, 430, 560, 1645, 1654, 1714
- pharmacists, 583, 585
- prescribing, 2528
- prescription drugs, 1764
- replacement solutions, 637
- rofecoxib, 739
- surgery, 36
- vancomycin, 1596
- Drug withdrawal**
- alcohols, ethyl, 355
- antidiabetic agents, 467
- surgery, 36
- Drugs**
- approvals, 149
- counterfeit, 527
- generic, 149
- latented, Apr 15 suppl S14, 1451, 2252
- new, 348
- reconstitution, 285
- selection, 593, Nov 15 suppl S10
- unlabeled use, 1532
- Drugs, adverse reactions**
- see also **Toxicity**
- amphetamine aspartate, combination, amphetamine sulfate, dextroamphetamine saccharate, dextroamphetamine sulfate, 1494
- aprotinin, Sep 15 suppl S9
- epoetin alfa, 2524
- errors, medication, 1592
- hydrochlorothiazide, 2630
- latex, 1822
- pantoprazole sodium, 1388
- pharmaceutical services, 274
- phenytoin sodium, 2295
- postmarketing surveillance, 1428
- regulations, 1754
- reports, 1336, 1375, 1883
- Drugs, availability**
- butorphanol tartrate, 48
- ganciclovir, Apr 15 suppl S14
- mycophenolate sodium, 2252
- protease inhibitors, 809
- valganciclovir, Apr 15 suppl S14
- Drugs, body distribution**
- gentamicin, 823
- insulin human, 1359
- linezolid, 464
- Drugs, nonprescription**
- analgesics and antipyretics, 1440
- HMG-CoA reductase inhibitors, 2420
- lovastatin, 1444
- Drugs, over the counter**
- costs, 149
- lovastatin, 455
- Duloxetine**
- depression, 2479
- review, 2481
- Dyspnea**
- opiates, 319
- E**
- Economics**
- attention deficit disorder with hyperactivity, 1502
- cost-benefit analysis, 34, 74, 367, 406, 499, 732, Apr 15 suppl S14, 896, 1017, May 15 suppl S24, 1271, 1357, 1365, 1596, Aug 15 suppl S5, 1764, 1793, 1802, 1852, Sep 15 suppl S2, 1967, 2222, 2241, 2265, 2288, 2363, 2416, 2528, 2597, 2619, 2626, 2639
- drug distribution, 1444
- drug use, 149
- financial management, 1703
- gene therapy, 1018
- genetics, 296
- hospitals, 124
- infections, 1650
- information, 1228
- laws, 1740
- pain, 1904
- pharmacy, 139
- prescription drugs, 726
- product development, 779
- residencies, 1019
- wholesalers, 525
- Editorials**, 145, 471, 583, 805, 901, 1017, 1143, 1357, 1449, 1653, 1773, 1871, 2239, 2479
- ASHP's role in eliminating health disparities, 1871
- Battle for funding of pharmacy residency programs, 1019
- Bevacizumab: improved survival at what cost?, 1017
- Clinical leadership, 805
- Collaborating for successful medication therapy management programs, 583
- Continuity of care: a basis for professional unity in pharmacy, 1654
- Daptomycin: we'll make more, they'll make more, 1143
- Demand clean vials, 471
- Increasing medication access for the uninsured and underinsured, 1653
- Improving clinical services through the ASHP 2015 Initiative, 145
- Lesson from the saga of selective serotonin-reuptake inhibitors, 806
- Low-dose aspirin: major benefits, minimal cost, 1357
- Moving beyond balance for a better antidepressant, 2479
- New online services for *AJHP* readers and authors, 146
- Pharmacists' role in preventing stent thrombosis, 2239
- Pharmacists as laboratorians, 1773
- Researching the human genome, 1018
- Telithromycin: do we really need this antimicrobial?, 901
- Uncertain times for oral anticoagulation therapy, 1449
- Education**
- health professions, 676, 1290, 1683
- personnel, 1271
- pharmacists, hospital, 1871, 1924
- Education, pharmaceutical**
- administration, 1067
- clerkships, 927, 2501, 2539
- clinical pharmacy, 805
- drug information, 2501, 2514
- educators, 1204, 1352
- emergency rooms, 1832
- hospital pharmacy, 246
- India, 1510
- Jordan, 2548
- leadership, 254, 1442, 1657
- pharmaceutical care, 2501
- pharmacists, 274, 1015
- pharmacists, hospital, 560
- policies and procedures, 748
- preceptors, 519
- professionalism, 142
- quality assurance, 1693
- residencies, 800, 1019, 1138, 1488, 1562, 1766, 1817, 1868, 1980, 2041, 2226, 2283
- technicians, 1992
- Thailand, 1408
- Educators**
- pharmacy, 1204, 1352
- Electrolytes**
- magnesium sulfate, 397
- solutions, 1550
- water-electrolyte imbalance, 1663
- Elimination, see Metabolism**
- Emergencies**
- pharmaceutical services, 2321
- pharmacists, 1290, 2202
- Emergency services**
- disaster planning, 1000
- Employment**
- pharmacists, 492, 1015
- Enoxaparin**
- thromboembolism, Nov 15 suppl S10
- Enzyme inhibitors**
- breast neoplasms, 266
- Ephedra species**
- poisoning, 1476
- Epidemiology**
- cytomegalovirus infections, Apr 15 suppl S3, Apr 15 suppl S7
- infections, 1143
- influenza, 1748
- mycoses, Apr 15 suppl S17
- thrombosis, Nov 15 suppl S4
- tuberculosis, 1431
- zygomycosis, 2593
- Epinephrine**
- therapy, 2295
- Epoetin alfa**
- adverse reactions, 2524
- anemia, 54
- cost-benefit analysis, 2597
- dosage, 1867
- protocols, 400
- therapeutic substitution, 2416
- Eptifibatide**
- incompatibilities, 1381
- myocardial infarction, 1494
- Equations**
- dosage, 1663
- Equipment**
- compounding, 2345
- dispensing, 1917
- hospital pharmacy, 321
- Errors**
- pricing, 422
- Errors, medication**
- abbreviations, 1559
- antidiabetic agents, 714
- antineoplastic agents, 1813
- bar codes, 1075
- computers, 499, 1228
- dispensing, 1917
- drug administration, 2413, 2619, 2626
- emergency rooms, 1832
- epoetin alfa, 1867
- galantamine hydrobromide, 35
- glimepiride, 35
- injections, 530, 917
- Institute of Medicine, 12
- insulin, 714
- medical records, 2222
- medication orders, 78, 378, 416
- parenteral nutrition, 2345
- pharmaceutical services, 259, 430
- pharmacy, 139
- physicians, 1592
- prevention, 570
- prophylaxis, 1754
- quality assurance, 343, 1303, 1340, 1528
- reports, 1375, 1740, 2265
- risk management, 236
- technicians, 1992
- technology, 243, 355
- Ertapenem sodium**
- incompatibilities, 834
- Erythema multiforme**
- epoetin alfa, 2524
- Erythromycin lactobionate**
- incompatibilities, 2459
- Estrogens**
- menopause, 889
- osteoporosis, 1574
- postmenopause, 69
- Ethanol, see Alcohols, ethyl**
- Ethics**
- gene therapy, 1018, 1080
- guidelines, 361
- industry, pharmaceutical, 1827
- pharmacists, 1067, 1827, 1864
- pharmacists, hospital, 838
- research, 1890
- Ethnic groups**
- health care, 676, 886, 1852, 1871, 1873, 1924
- Hispanic Americans, 210
- patients, 205
- Ethyl vinylacetate**
- tubing, 182

- Etoposide**
contamination, 182
- Evidence-based medicine**
decision-making, Sep 15 suppl S19
- Examinations**
clerkships, 927
technicians, 2542
- Excipients**
fructose, 2608
sodium chloride, Aug 15 suppl S12
sodium citrate, 1548
- Excretion**
butorphanol tartrate, 48
daptomycin, 1145
gentamicin, 823
melagatran, 1451
mycophenolate sodium, 2252
pramlintide acetate, 2363
- Exemestane**
breast neoplasms, 266
- Exenatide**
diabetes mellitus, 173
- Extracts**
guggulu oleoresin, 1012
gugulipid, 1690
- Exubera**, see **Insulin human**
- F**
- Factor VIIa**
coronary artery bypass, Sep 15 suppl S15
- False Claims Act**
Medicaid, 1537
- Federal Emergency Management Agency**
pharmacists, 2202, 2321
- Fenoterol hydrobromide**
incompatibilities, 828
- Fentanyl**
concomitant therapy, 2006
- Fentanyl citrate**
incompatibilities, 1190
- Fentanyl hydrochloride**
pain, 1171
- Ferrous sulfate**
concomitant therapy, 2524
- Filgrastim**
neutropenia, 83
- Filters**
HEPA, 1856
- Fiorinal**, see **Aspirin; combination, butalbital, caffeine**
- Flow**
etoposide, 182
- Fluconazole**
mycoses, Apr 15 suppl S17
- Fluorouracil**
colorectal neoplasms, 1021
contamination, 475
interactions, 1788
- Fluvastatin**
hypercholesterolemia, 1468
- Folic acid**
alcohol withdrawal delirium, 355
- Fomepizole**
antidotes, 2344
- Food**
interactions, Nov 15 suppl S7
- Food and Drug Administration (U.S.)**
approvals, 348
drug information, 1333
lovastatin, 455
nonsteroidal antiinflammatory agents, 997
pharmacogenetics, 1226
postmarketing surveillance, 1428
regulations, 312, 315, 668, 1444, 1754
risk management, 236, 1336
- Forms**
prescriptions, 2278
- Formularies**
antiinfective agents, 732
decision-making, 1498
hospitals, 189, 378, 917
prescription drugs, 1122
proton-pump inhibitors, May 15 suppl S24
tiotropium bromide, 1263
- Formulations**
anesthetics, local, 1445
globulin immune, Aug 15 suppl S5, Aug 15 suppl S12, 2329
insulin human, 1359
parenteral nutrition, 289, 2345
theophylline anhydrous, 2518
triamcinolone acetonide, 485
- Frontline Pharmacist**, 364
Counseling patients with low health literacy, 364
- Fructose**
complexes, 2608
- Furosemide**
concomitant therapy, 2293, 2524
- G**
- Galantamine hydrobromide**
errors, medication, 35
- Ganciclovir**
cytomegalovirus infections, Apr 15 suppl S14
- Gastric emptying**
exenatide, 173
- Gastrointestinal drugs**
alosetron, 700
histamine H2 antagonists, May 15 suppl S4, May 15 suppl S11, May 15 suppl S18
misoprostol, 1192
pantoprazole sodium, 1388, 1494, 2410
proton-pump inhibitors, May 15 suppl S4, May 15 suppl S11, May 15 suppl S18, May 15 suppl S24, 1159
ranitidine, 1299
roxatidine acetate hydrochloride, 289
tegaserod, 700
- Gastrointestinal hemorrhage**
gastrointestinal drugs, May 15 suppl S11, May 15 suppl S18
nonsteroidal antiinflammatory agents, 1543
proton-pump inhibitors, May 15 suppl S24
therapy, 1159
- Gatifloxacin**
toxicity, 2293
- Gels**
anesthetics, local, 1445
lidocaine, combination, phenylephrine, tetracaine, 450
- Gemfibrozil**
interactions, 1033
- Gene therapy**
research, 1018, 1080
- Genetics**
history, 1018, 1080
technology, 296
- Gentamicin**
blood levels, 823
- Gentamicin sulfate**
dosage, 1613
incompatibilities, 1548
- Geriatrics**
accidental falls, 2495
aspirin, 1357
cholinesterase inhibitors, 923
drug use, 626
globulin immune, 720
health care, 1873
life expectancy, 24
Medicare, 1234
nonsteroidal antiinflammatory agents, 1543
pantoprazole sodium, 1388
pharmaceutical services, 1491
prescription drugs, 1646
warfarin, 1062
- Ginkgo biloba**
sex disorders, 574
- Glass**
containers, 1190
- Glaucoma**
therapy, 691
- Glimepiride**
errors, medication, 35
- Globulin immune**
distribution, 2329
toxicity, 720
use, Aug 15 suppl S12, Aug 15 suppl S5
- Glycerin**
solvents, 485
- Graft occlusion**
aprotinin, 1370
- Graft rejection**
immunosuppressive agents, 391, 1775
- Granisetron**
postoperative nausea and vomiting, 1247
- Grants**
pharmacists, 2222
- Guanfacine**
attention deficit disorder with hyperactivity, 1502
- Guggul**, see **Guggulu oleoresin**
- Guggulu oleoresin**
hypercholesterolemia, 1012
- Gugulipid**
hyperlipidemia, 1690
- Guidelines**
American Society of Health-System Pharmacists, 468, 1385, 1390, 1391, 1392, 1393, 1654, 1697, 1714, 2345
clinical pharmacy, 744
control, quality, 1271
education, pharmaceutical, 246
ethics, 361
intensive care units, 1763
leadership, 838
- Guidelines, treatment**, see **Protocols**
- H**
- Half-life**
atorvastatin calcium, 2491
linezolid, 464
melagatran, 1451
mycophenolate sodium, 2252
pramlintide acetate, 2363
- Haloperidol**
concomitant therapy, 2006
- Health care**
Afghanistan, 1950
costs, 149
decision-making, 342
ethnic groups, 205, 676, 886, 1871, 1924
genetics, 296
home, 1491, 1883
information, 788, 1228
Japan, 1617
life expectancy, 24
Medicaid, 1852
Medicare, 1234
nomenclature, 364
policies and procedures, 748
quality assurance, 1873, 1890
reform, 570
team, 626
- Health Care Financing Administration**, see **Centers for Medicare and Medicaid Services**
- Health maintenance organizations**
see also **Managed care systems**
telepharmacy, 406
- Health professions**
communication, 1340
education, 1290, 1683
ethics, 361
HIV infections, 2332
professional competence, 676
professional relations, 1015
team, 1813
- Health-benefit programs**
billing, 20
Medicaid, 1537, 1852
Medicare, 124, 462, 583, 585, 1009, 1234, 1482, 1596, 1645, 1646, 1854
prescription drugs, 1653, 1764
third party, 726, 1873, 1956
- Heart failure**
drugs, adverse reactions, 1883
hydralazine hydrochloride, combination, isosorbide dinitrate, 1745
milrinone, 291
nesiritide, 196, 291, 606, 2639
protocols, 1953
therapy, 168

Heart Failure Society of America
protocols, 168

Heavy metal antagonists
deferroxamine, 2593

Hematopoietic agents

darbepoetin alfa, 54, 2416, 2597
epoetin alfa, 54, 400, 1867, 2416, 2524, 2597
filgrastim, 83
sargramostim, 83

Hemostatics

aminocaproic acid, Sep 15 suppl S9
aprotinin, 1370, Sep 15 suppl S6, Sep 15 suppl S9, Sep 15
suppl S15, Sep 15 suppl S19
factor VIIa, Sep 15 suppl S15
tranexamic acid, Sep 15 suppl S9

Heparin

concomitant therapy, 2006
myocardial infarction, 1494
thrombosis, Nov 15 suppl S7
toxicity, 247
venous thrombosis, 2338

Heparins

low molecular weight, Nov 15 suppl S4, Nov 15 suppl S7,
Nov 15 suppl S10

History

genetics, 1018, 1080
leadership, 838
pharmacy, 2548

HIV infections

antiretroviral agents, 809, 1108
toxicity, environmental, 2332

HMOs, see Managed care systems

Home, health care, see Health care; home

Home tests

devices, 1802

Hospital pharmacy, see Pharmacy, institutional, hospital

Hospitals

accidental falls, 2495
administration, 975
Afghanistan, 1950
albuterol sulfate, 1053
antifungal agents, 34, 732, 1967, 2288
awards, 343
bar codes, 2619, 2626
blood transfusions, Sep 15 suppl S2
computers, 499
darbepoetin alfa, 2597
disaster planning, 1000
drug distribution, 1444
drug interactions, 1760
drug use, 189
emergency rooms, 616, 788, 1793, 1832, 1917
epoetin alfa, 2597
errors, medication, 243, 530, 714, 917, 1592, 2265, 2413
formularies, May 15 suppl S24, 1498
guidelines, 361
heart failure, 168
intensive care units, 400, May 15 suppl S24, 1763
length of stay, 397, 1159, 1370, 1596, 2416
medication orders, 416
policies and procedures, 1650, 1822
quality assurance, 1118, 1528
reimbursement, 124, 1617, 1646, 1854
steroids, cortico-, 1976
venous thrombosis, 2338

Hours

physicians, 1592
residencies, 800

Human Genome Project

research, 1018, 1080

Hydralazine hydrochloride

combination, isosorbide dinitrate, 1745

Hydrochlorothiazide

adverse reactions, 2630
concomitant therapy, 2295

Hydrocodone

combination, acetaminophen, 2293

Hydrocortisone

combination, neomycin sulfate, polymyxin B sulfate,
2006

Hydrofluoroalkanes

propellants, 2271

Hydrogen ion concentration

acetylcysteine, 828
atosiban acetate, 2459
cidofovir, 506
fenoterol hydrobromide, 828
gentamicin sulfate, 1548
ibuprofen lysinate, 630
ipratropium bromide, 828
parenteral nutrition, 1177
sodium citrate, 1548
theophylline anhydrous, 2518

Hyperalimentation, see Nutrition; parenteral

Hypercholesterolemia

guggulu oleoresin, 1012
HMG-CoA reductase inhibitors, 1468
prescription drugs, 620

Hyperglycemia

errors, medication, 714
steroids, cortico-, 1976

Hyperlipidemia

atorvastatin, 1033
atorvastatin calcium, 2491
disease management, 1586
gugulipid, 1690
HMG-CoA reductase inhibitors, 2420
lovastatin, 1444
pharmaceutical services, 1798
pravastatin, 1033
rosuvastatin, 1033
simvastatin, 1033

Hyperphosphatemia

phosphate binders, 2355

Hypertension

angiotensin antagonists, 2381
nesiritide, 606

Hypoglycemia

errors, medication, 714
insulin, 2260

Hypoproteinemia

drugs, adverse reactions, 1883

Hypotensive agents

clonidine, 1502
clonidine hydrochloride, 1968
hydralazine hydrochloride, combination, isosorbide
dinitrate, 1745

I

Iatrogenic diseases, see Drugs, adverse reactions

Ibuprofen lysinate

stability, 630

Identification

technology, 1115

Ifosfamide

contamination, 475
incompatibilities, 1998

Immobilization

thrombosis, Nov 15 suppl S4

Immune globulin, see Globulin immune

Immunization

diseases, 1234
influenza, 367
pneumococcal infections, 367
tuberculosis, 1431
vaccines, 1748

Immunogenicity

influenza vaccines, 367
pneumococcal vaccines, 367

Immunoglobulin, see Globulin immune

Immunosuppression

zygomycosis, 2593

Immunosuppressive agents

cyclosporine, 391, 1033, 1775, 1983
daclizumab, 391
mycophenolate mofetil, 391, 2252
mycophenolate sodium, 2252
transplantation, Apr 15 suppl S3, Apr 15 suppl S7, Apr
15 suppl S17, 1775

Implants

patient information, 355

Imports

drugs, 1303
prescription drugs, 233

Incompatibilities

abacimab and argatroban, 1381
acyclovir and tramadol hydrochloride, 1299
amoxicillin trihydrate, combination, clavulanate potas-
sium and atosiban acetate, 2459
amphotericin B and anidulafungin, 834
ampicillin, combination, sulbactam and tramadol hy-
drochloride, 1299
anidulafungin, 834
argatroban and abacimab, eptifibatide or tirofiban hy-
drochloride, 1381
atosiban acetate, 2459
clindamycin and tramadol hydrochloride, 1299
clonidine hydrochloride, 1968
cyclophosphamide, ifosfamide and palonosetron hydro-
chloride, 1998
droperidol, fentanyl citrate and ketamine hydrochlo-
ride, 1190
eptifibatide and argatroban, 1381
ertapenem sodium and anidulafungin, 834
erythromycin lactobionate and atosiban acetate, 2459
fenoterol hydrobromide and acetylcysteine, 828
fentanyl citrate, droperidol and ketamine hydrochlo-
ride, 1190
gentamicin sulfate and sodium citrate, 1548
ifosfamide, cyclophosphamide and palonosetron hydro-
chloride, 1998
insulins and pramlintide acetate, 816
ipratropium bromide and acetylcysteine, 828
ketamine hydrochloride, droperidol and fentanyl cit-
rate, 1190
ketanserin tartrate and atosiban acetate, 2459
levofloxacin and metronidazole, 88
magnesium sulfate and atosiban acetate, 2459
methylprednisolone sodium succinate and ondansetron
hydrochloride, 2001
metronidazole and levofloxacin, 88
ondansetron and tramadol hydrochloride, 1299
ondansetron hydrochloride and methylprednisolone so-
dium succinate, 2001
palonosetron hydrochloride, cyclophosphamide and if-
osfamide, 1998
parenteral nutrition, 1177
phenytoin and vasopressin, 1969
pramlintide acetate and insulins, 816
ranitidine and tramadol hydrochloride, 1299
roxatidine acetate hydrochloride, 289
sodium bicarbonate and anidulafungin, 834
sodium citrate and gentamicin sulfate, 1548
tirofiban hydrochloride and argatroban, 1381
tramadol hydrochloride, 1299
vasopressin, 1969

India

pharmaceutical education, 1510

Indomethacin

concomitant therapy, 2293

Industry, pharmaceutical

antineoplastic agents, 471
charity, 1048, 1653
contracts, 422
economics, 525, 527
ethics, 361, 1827
Jordan, 2548
pharmacists, 2401
pharmacogenetics, 1226
postmarketing surveillance, 1428
prescription drugs, 726, 1122
Thailand, 1408

Infections

aminoglycosides, 1596
antifungal agents, 1143, 1650
therapy, 1748
vancomycin, 1596

Influenza

epidemiology, 1748

Influenza vaccines

immunization, 367
manufacturing, 247

Information

computers, 788
technology, 1228

Infusion devices, see Devices; infusion pumps

Inhalers

see also **Aerosols**
devices, 1053

- insulin human, 1359
metered dose, 2271
opiates, 319
tiotropium bromide, 1263
- Injections**
abciximab, 1381
alcohols, ethyl, 2344
anidulafungin, 834
antineoplastic agents, 471, 475
argatroban, 1381
ascorbic acid, 1073
atosisan acetate, 2459
¹⁰B-L-boronophenylalanine, 2608
cidofovir, 506
clonidine hydrochloride, 1968
contamination, 285, 2386
cyclophosphamide, 1998
dolasetron mesylate, 896
droperidol, 1190
eptifibatide, 1381
errors, medication, 530, 917
etoposide, 182
fentanyl citrate, 1190
globulin immune, 2329, Aug 15 suppl S5, Aug 15 suppl S12
ibuprofen lysinate, 630
ifosfamide, 1998
insulins, 816
ketamine hydrochloride, 1190
levofloxacin, 88
methylprednisolone sodium succinate, 2001
metronidazole, 88
nafcillin sodium, 1347
ondansetron hydrochloride, 2001
palonosetron hydrochloride, 1998
pantoprazole sodium, 2410
pramlintide acetate, 816
tirofiban hydrochloride, 1381
tramadol hydrochloride, 1299
vasopressin, 1969
vincristine sulfate, 1606
- Insomnia**
anxiolytics, sedatives and hypnotics, 1532
- Institute for Safe Medication Practices**
abbreviations, 1559
grants, 2222
- Institute of Medicine**
alternative medicine, 562
errors, medication, 12, 1340
life expectancy, 24
postmarketing surveillance, 1428
- Institutional Review Boards**
research, 1890
- Insulin**
diabetes mellitus, 2293
errors, medication, 714
protocols, 2260
- Insulin human**
diabetes mellitus, 1359
- Insulins**
diabetes mellitus, 510
insulin, 714, 2260, 2293
insulin human, 1359
interactions, 816
- International Normalized Ratio**
anticoagulants, 593
warfarin, 1683, 2393, Nov 15 suppl S7
- International Pharmaceutical Federation**
meetings, 2216
- International Standards Organization**
sterile products, 1856
- Internet**
American Journal of Health-System Pharmacy, 134, 146
American Society of Health-System Pharmacists, 1447
arthritis, 1184
drug information, 1333
hospitals, 499, 1118
Physicians' Desk Reference, 355
- Interventions**
anti-infective agents, 34
clinical pharmacists, 1760, 1793
drug interactions, 1983
hyperlipidemia, 1586
pharmacists, 626, 1491
pharmacists, community, 1798
pharmacists, hospital, 400, 1596, 1782, 1967, 2338
- Interviews**
patients, 1311, 2342
pharmacists, 1352
residencies, 1138
- Inventory**
drugs, 1290
economics, 525
hospital pharmacy, 462, 2344
- Investments**
American Society of Health-System Pharmacists, 1703
- Iontophoresis**
fentanyl hydrochloride, 1171
- Ipratropium**
lung diseases, 1263
- Ipratropium bromide**
incompatibilities, 828
- Iraq**
pharmaceutical services, 753
- Irbesartan**
hypertension, 2381
- Isosorbide dinitrate**
combination, hydralazine hydrochloride, 1745
- Itraconazole**
mycoses, Apr 15 suppl S17
- IVIG, see Globulin immune**
- J**
- Japan**
reimbursement, 1617
- Job satisfaction**
administrators, 845
pharmacists, 845, 2474
- Joint Commission on Accreditation of Healthcare Organizations**
abbreviations, 1559
standards, 1528
- Jordan**
pharmacy, 2548
- K**
- Kava**
poisoning, 1476
- Ketamine hydrochloride**
incompatibilities, 1190
- Ketanserin tartrate**
incompatibilities, 2459
- Ketek, see Telithromycin**
- Ketolides**
telithromycin, 901, 905
- Kidney diseases**
colistin, 39
- Kidney failure**
aprotinin, 1370
bevacizumab, 1021
ganciclovir, Apr 15 suppl S14
globulin immune, 720
histamine H2 antagonists, May 15 suppl S4
hyperphosphatemia, 2355
proton-pump inhibitors, May 15 suppl S4
valganciclovir, Apr 15 suppl S14
- L**
- Labeling**
compounding, 450
COX-2 inhibitors, 668
drugs, 1342
nonsteroidal antiinflammatory agents, 997
parenteral nutrition, 312
prescription drugs, 620
- Labels**
technology, 116
- Laboratories**
pharmacists, 1773
- Lansoprazole**
concomitant therapy, 2630
- Lanthanum carbonate**
hyperphosphatemia, 2355
- Lasers**
glaucoma, 691
- Latanoprost**
concomitant therapy, 420
- Latex**
adverse reactions, 1822
- Laws**
errors, medication, 1740
False Claims Act, 1537
gene therapy, 1018, 1080
imports, 233
Medicare, 1646
Medicare Prescription Drug, Improvement, and Modernization Act of 2003, 583, 585
sexually transmitted diseases, 643
suicides, 306
- Leaching**
diethylhexyl phthalate, 182
latex, 1822
- Legislation**
dispensing, 1864
- Lepirudin**
thrombocytopenia, 247
- Letrozole**
breast neoplasms, 266
- Letters**, 34, 246, 354, 462, 896, 1347, 1440, 1543, 1760, 1864, 1967, 2226, 2338, 2459
Accuracy of parenteral nutrition solutions compounded with automated systems and by hand, 2345
Antihyperglycemics during the perioperative period, 467
Availability of different dosage forms of scopolamine, 2350
Clinical pharmacists: essential members of the pediatric critical care team, 1763
Compliance of a VA pharmacy with documentation requirements for human research, 464
Corticosteroids an important cause of hyperglycemia, 1976
Darbepoetin versus epoetin, 1552
Direct thrombin inhibitors in heparin-induced thrombocytopenia, 247
Duplicate publication, 1979
Effects of antimicrobial drug shortages, 1444
Effect of on-call infectious-diseases pharmacists on antibiotic expenditures, 1987
Ethical beliefs and professional duty, 1864
Factors influencing pursuit of residency training, 2226
Folic acid in alcohol-withdrawal delirium, 355
From "drug-related problems" to "negative clinical outcomes," 2348
Hazard of compounded anesthetic gel, 1445
Hazards of colchicine, 1350
Humanistic-outcomes questionnaires in diabetes research and practice, 354
Identification of patients taking NSAIDs at high risk for GI bleeding, 1543
Inaccessibility of online PDR to pharmacists, 355
Increasing hospital pharmacy revenue, 462
Influence of temperature and drug concentration on nafcillin precipitation, 1347
Interventions to improve compliance with guidelines on surgical prophylaxis, 34
Linezolid pharmacokinetics in an obese patient, 464
Look-alike, sound-alike drug errors with Reminyl and Amaryl, 35
Lycopene: a word of caution, 899
Medications during the perioperative period, 36
Ohio guidelines for advanced-practice hospital rotations for pharmacy students, 246
Patients' response to revised practices for treating chemotherapy-induced nausea and vomiting, 463
Pharmacist intervention when interacting drugs are prescribed despite alerts, 1760
Pharmacist position monitoring health-system employees' drug plan, 1764
Physical therapists' knowledge, attitudes, and professional use of nonprescription analgesics, 1440
Potential and perils of implantable microchip, 355
Prevention of venous thromboembolism in the medical-ly ill, 2338
Prohibited abbreviations, 1559
Putting motivational interviewing in perspective, 2342
Reform of U.S. vaccine management, 247

ANNUAL INDEX

- Remote checking of prescriptions in Navy health facilities, 1866
- Risks of a nonprescription lovastatin, 1444
- Stability and sterility of dolasetron mesylate in syringes stored at room temperature, 896
- Standardized doses of epoetin alfa for hemodialysis patients, 1867
- Technique for removing samples from bags of dialysate solution, 1550
- The Student Leadership Institute, 1442
- Unavailability of 10% alcohol in 5% dextrose injection, 2344
- Update of directory of drug information centers, 1348
- Visual compatibility of atosiban acetate with four drugs, 2459
- Visual compatibility of clonidine with selected drugs, 1968
- Visual compatibility of gentamicin sulfate and 4% sodium citrate solutions, 1548
- Visual compatibility of vasopressin with other injectable drugs, 1969
- Leucovorin**
interactions, 1788
- Leukemia**
pharmaceutical services, 744
- Levetiracetam**
seizures, 420
- Levofloxacin**
incompatibilities, 88
use, 732
- Lichen planus**
triamcinolone acetonide, 485
- Lidocaine**
combination, phenylephrine, tetracaine, 450
- Life expectancy**
Institute of Medicine, 24
- Linezolid**
pharmacokinetics, 464
- Liposomes**
vincristine sulfate, 1606
- Liver diseases**
ceftriaxone sodium, 2006
- Liver failure**
bevacizumab, 1021
- Long-term-care facilities**
drugs, adverse reactions, 1883
- Lorazepam**
concomitant therapy, 2006
myocardial infarction, 1494
- Losartan**
hypertension, 2381
- Lovastatin**
classification, 455, 1444
hypercholesterolemia, 1468
- Lung diseases**
albuterol sulfate, 1053
ipratropium, 1263
salmeterol, 1263
tiotropium bromide, 1263
- Lycopene**
prostatic neoplasms, 899
- M**
- Macrolides**
erythromycin lactobionate, 2459
- Magnesium sulfate**
coronary artery bypass, 397
incompatibilities, 2459
- Managed care systems**
see also **Health maintenance organizations**
billing, 20
- Management, see Administration**
- Management Case Study**, 1498, 1813, 1917, 2416, 2528
- Management Consultation**, 139, 2466
- Balancing costs and outcomes through partnerships with consultants, 139
- Pharmacy technicians supporting clinical functions, 2466
- Manpower**
disaster planning, 239
Food and Drug Administration, 1754
hospital pharmacy, 1693
- pharmacists, 492
pharmacy, 259, 1992
- Manufacturing**
antineoplastic agents, 471, 475
globulin immune, Aug 15 suppl S5, Aug 15 suppl S12, 2329
influenza vaccines, 247
- Mechanism of action**
alcohols, ethyl, 2344
aminocaproic acid, Sep 15 suppl S9
antidepressants, 2479
antiemetics, 1247
antineoplastic agents, 266
aprotinin, Sep 15 suppl S6, Sep 15 suppl S9, Sep 15 suppl S15
azacitidine, 1567
bevacizumab, 1021
COX-2 inhibitors, 890
duloxetine, 2481
exenatide, 173
fomepizole, 2344
ganciclovir, Apr 15 suppl S14
gastrointestinal drugs, 700
globulin immune, Aug 15 suppl S12
guggulu oleoresin, 1012
gugulipid, 1690
histamine H2 antagonists, May 15 suppl S4
HMG-CoA reductase inhibitors, 979
hydralazine hydrochloride, combination, isosorbide dinitrate, 1745
lycopene, 899
menaquinone, 1574
mycophenolate mofetil, 2252
mycophenolate sodium, 2252
nesiritide, 2639
opiates, 319
paclitaxel, 2241
phytonadione, 1574
pramlintide acetate, 2363
prescription drugs, 620
proton-pump inhibitors, May 15 suppl S4
serotonin-reuptake inhibitors, 864
telithromycin, 905
tiotropium bromide, 1263
tranexamic acid, Sep 15 suppl S9
valganciclovir, Apr 15 suppl S14
vasopressin, 1931
- Media**
estrogens, 69
- Medicare Prescription Drug, Improvement, and Modernization Act of 2003**
drug use, 583, 585
- Medication errors, see Errors, medication**
- Medication orders**
computers, 416, 530, 1813
errors, medication, 243, 917
hospitals, 378
telephone, 78
- Medication-Use Technology**, 416, 1075, 2413, 2619, 2626
- Medmarx**
errors, medication, 2265
- Meetings**
American Society of Health-System Pharmacists, 856, 930, 1303, 1352, 1406, 1821, 1890, 2226
Institute of Medicine, 24
International Pharmaceutical Federation, 2216
preceptors, 519
World Health Care Congress, 570
- Melagatran**
metabolites, 1451
- Memantine hydrochloride**
toxicity, 420
- Membership**
American Society of Health-System Pharmacists, 1697, 1924
- Menaquinone**
osteoporosis, 1574
- Menopause**
therapy, 889
- Metabolism**
mycophenolate sodium, 2252
rosuvastatin, 1033
ximelagatran, 1451
- Metformin**
withdrawal, 36
- Methodology**
anti-infective agents, 2288
clinical studies, 315
compliance, 198, 411
consultation, 1311, 2342
contamination, 285
control, quality, 1550
data collection, 354
decision-making, 2031
dosage, 823, 1663
drugs, adverse reactions, 1375
errors, medication, 917, 2413
formularies, 378, 1498
gentamicin sulfate, 1613
gugulipid, 1690
hydralazine hydrochloride, combination, isosorbide dinitrate, 1745
nonsteroidal anti-inflammatory agents, 1543
quality assurance, 1813
reimbursement, 1617
research, 1890
toxicity, 2397
- Methylphenidate**
attention deficit disorder with hyperactivity, 1502
- Methylprednisolone**
therapy, 2295
- Methylprednisolone sodium succinate**
incompatibilities, 2001
- Metoprolol tartrate**
concomitant therapy, 2293
- Metronidazole**
concomitant therapy, 2006
incompatibilities, 88
- Mevacor, see Lovastatin**
- Mexican Association of Hospital Pharmacists**
organizations, 123
- Midazolam**
concomitant therapy, 1388, 2006
- Migraine**
prescription drugs, 620
- Military**
dispensing, 1866
pharmaceutical services, 753
- Milrinone**
concomitant therapy, 196
heart failure, 291
- Minerals**
zinc, 1476
- Minoxidil**
concomitant therapy, 2524
- Miotics**
pilocarpine, 691
- Misoprostol**
stability, 1192
- Models**
dispensing, 2420
quality assurance, 1813
- Mortality**
bacterial infections, 39
coronary artery bypass, Sep 15 suppl S15, Sep 15 suppl S19
coronary disease, 2241
critical illness, 637
cytomegalovirus infections, Apr 15 suppl S7
gastrointestinal hemorrhage, May 15 suppl S11, May 15 suppl S18, 1159
heart failure, 1745, 2639
infections, 1596
mycoses, Apr 15 suppl S17
postoperative complications, 1370
thromboembolism, Nov 15 suppl S10
thrombosis, Nov 15 suppl S4
water-electrolyte imbalance, 1663
- Mouthwashes**
triamcinolone acetonide, 485
- Mucolytic agents**
acetylcysteine, 828
- Mycophenolate mofetil**
transplantation, 391, 2252
- Mycophenolate sodium**
transplantation, 2252
- Mycophenolic acid glucuronide**
metabolites, 2252

Mycoses

antifungals, Apr 15 suppl S17

Myelodysplastic syndromes

azacitidine, 1567

Myfortic, see Mycophenolate sodium**Myocardial infarction**amphetamine aspartate, combination, amphetamine sulfate, dextroamphetamine saccharate, dextroamphetamine sulfate, 1494
aprotinin, 1370**N****Nabumetone**

use, 739

Nadroparin

thromboembolism, Nov 15 suppl S10

Nafcillin sodium

stability, 1347

Naloxone

use, 1375

Nasal preparations

butorphanol tartrate, 48

National Cancer Institute

product development, 779

National Committee for Quality Assurance

standards, 464

National Health Service (Great Britain)

drug use, 189

Natural products

product development, 779

Nausea

antiemetics, 463, 1247

Nebraska

pharmacists, 1290

Nebulizersacetylcysteine, 828
fenoterol hydrobromide, 828
ipratropium bromide, 828**Neomycin sulfate**

combination, hydrocortisone, polymyxin B sulfate, 2006

Neoplasm metastasisbevacizumab, 1017, 1021
fluorouracil, 1021**Neoplasms**bevacizumab, 1021
COX-2 inhibitors, 890
therapy, 1873
thromboembolism, Nov 15 suppl S10
thrombosis, Nov 15 suppl S4, Nov 15 suppl S7**Nervous system diseases**

hydrochlorothiazide, 2630

Nesiritideheart failure, 196, 291, 2639
hypertension, 606**Neutropenia**filgrastim, 83
sargramostim, 83**New Practitioners Forum, 142, 254, 468, 800, 1015,**

1138, 1352, 1562, 1766, 1868, 1980, 2236, 2474

A resident's perspective on professionalism in pharmacy, 142

Adoption of duty-hour standards in a pharmacy residency program, 800

ASHP's Clinical Skills Competition: a problem-solving framework, 2236

Developing new practitioners' leadership potential, 254

Interviewing for a faculty position at the ASHP Midyear Clinical Meeting, 1352

New practitioners' role in achieving the ASHP Health-System Pharmacy 2015 Initiative, 468

Oncology pharmacy practice residency programs, 1980

Pharmacy practice residency programs, 1562

Residency programs in primary and ambulatory care pharmacy practice, 1868

Selecting the right residency program, 1138

Specialized pediatric residency programs, 1766

The value of mentorship, 2474

Transitioning into the life of a practicing pharmacist, 1015

News, 12, 116, 233, 342, 450, 560, 668, 779, 886, 997, 1108, 1226, 1333, 1428, 1528, 1640, 1740, 1852, 1950, 2202, 2321, 2440, 2580

Afghanistan struggles to rebuild health care system, 1950

Appointments & Promotions, 119, 1120, 1534, 1855, 1953, 2216, 2332, 2590

ASHP joins Mexican, Canadian societies in compact, 123

ASHP past president Donald F. Beste Jr. dies at 67, 460

Audible medication vials slowly gain momentum, 116

Better renal-function estimates not expected to alter drug dosing right away, 2442

Billing codes for pharmacy clinical services advance, 20

Biometrics offers alternative to password entry, 1115

Changes in IVIG marketplace challenge pharmacists, 2329

Clinical pharmacy demonstration program gets a review, 454

CMS releases 2005-06 rule for inpatient Medicare payments, 1854

CMS Web site reports hospital quality, 1118

Conference focuses on health care reform, lack of technology, 570

COX-2 inhibitors still eyed for cancer prevention, 890

Defense and Veterans Affairs move toward patient information sharing, 680

Drug information confuses pregnant patients' health care providers, 1342

Drug regulatory process is focused on safety, officials claim, 1754

Experts find huge gaps in understanding, treating menopause symptoms, 889

Experts take on tuberculosis, 1431

FDA advisers vote against nonprescription lovastatin, 455

FDA labors over NSAID decisions, 668

FDA ponders future of NSAIDs, 997

FDA revisits DTC advertising, 2580

FDA's adverse-event surveillance needs improvement, advisers say, 1336

FDA's drug safety initiative: resolutions or more questions?, 1333

Five years after IOM report, experts gauge progress of patient safety, 12

Four countries shed light on drug-review policies, 1122

Government answers need for cultural competency resource, 676

Government leadership, investment crucial to health care's IT success, 1228

Health centers squeezed by tightened Medicaid budgets, 1852

Heart failure guidelines revised, 1953

HIV occupational exposure guidelines revised, 2332

Impact to health systems unclear after OPSS, Part B payment changes, 124

Importation reports spur more debate about drug prices, 233

Infectious diseases expected to capture headlines, attention in months ahead, 1748

Insomnia sufferers need better care, experts say, 1532

International pharmacy group to pursue better medication access in developing countries, 2216

IOM panel hears concerns about U.S. drug safety system, 1428

IOM panel mulls over adverse-event reporting, 2590

IOM panel reviews lessons for medication safety, 1340

JCAHO views medication reconciliation as adverse-event prevention, 1528

Language, reporting of safety undergoing change, 2451

Long-awaited patient safety bill enacted, 1740

Longer life span not in foreseeable future, 24

Medicare Part D creates challenges for safety-net providers and law enforcement, 1646

Milton W. Skolaut, ASHP past president, dies at 84, 792

Money matters in infection control policy, 1650

More Americans than ever lack health insurance, 2583

Nation is unprepared for bioterrorism threat, study finds, 239

National billing codes announced for pharmacists' clinical services, 1640

Nature is vital to drug product discovery, 779

New drug and biological product approvals, 2004, 348

New drugs and dosage forms, 31, 131, 243, 456, 688, 790, 895, 1010, 1122, 1238, 1437, 1858, 1966, 2337

New heart-failure therapy takes race into account, 1745

News Briefs, 132, 350, 461, 682, 895, 1011, 1134, 1241,

1346, 1542, 1862, 2334, 2591

Oklahoma allows limited medication recycling, 1437

Pharmacists play vital roles in Katrina response, 2202

Pharmacy clinic offers glimpse into future Medicare service, 1645

Pharmacy helps hospital win national quality award, 343

Pharmacy teams lack FEMA support, 2321

Policymakers, experts review evidence-based medicine, 342

Project advances health system's clinical pharmacy services, 560

PTCB turns 10, 119

Quality of Medicare services a mixed picture, experts say, 1234

Race is on for electronic medical record adoption, 2222

Racial, ethnic minorities less likely to receive good cardiac care, studies find, 886

Recent changes to FDA-approved labeling, 33, 126, 352, 572, 794, 1004, 1242, 1540

Regions work to exchange health information, 788

Report urges scientific standards for alternative medicine, 562

Residency program fills medication safety void, 2450

Revisions continue on USP sterile-compounding chapter, 1856

Safety advisory group gets mixed marks from members, 236

Safety expert receives \$500,000 MacArthur grant, 2222

Scientists focus on pharmacogenomics at FDA Science Forum, 1226

Senate tackles Medicaid fraud and abuse, 1537

Six new editorial board members join *AJHP*, 26

Some firms will use pharmacists in Medicare chronic care project, 1009

Standards-setting group seeks to improve medication adherence, 2440

States, hospitals learn emergency-preparedness lessons in TOPOFF 3, 1000

Student's death sparks concerns about compounded preparations, 450

Technology hasn't eliminated medication errors yet, USP reports, 243

Upcoming Meetings, 454, 570, 1234

U.S. pharmacists respond to global AIDS crisis, 1108

Use of new CPT codes depends on practice arrangement, 1956

Niacin

concomitant therapy, 2293

Nitrates

concomitant therapy, 1388

Nomenclature

billing, 20

codes, 1956

errors, medication, 35

health care, 364

pharmacy services, 1640

toxicity, 2348

Norepinephrine

anaphylaxis, 1388

Nursing homes

prescription drugs, 1437

Nutrition

enteral, May 15 suppl S11

parenteral, 289, 312, 315, 1177, 2345

O**Obesity**

linezolid, 464

Odors

theophylline anhydrous, 2518

Ohio

education, pharmaceutical, 246

Oklahoma

prescription drugs, 1437

Olanzapine

concomitant therapy, 420

schizophrenia, 610

Oncology

residencies, 1980

Ondansetron
incompatibilities, 1299
postoperative nausea and vomiting, 1247

Ondansetron hydrochloride
incompatibilities, 2001

Opiate antagonists
naloxone, 1375

Opiates
dyspnea, 319
fentanyl citrate, 1190
fentanyl hydrochloride, 1171
overdose, 1375
oxycodone hydrochloride, 2495, 2604
postoperative pain, 1904, 2019
toxicity, 1247, 2019, 2495
tramadol hydrochloride, 1299

Optic nerve diseases
prophylaxis, 691

Organizations
American Society of Health-System Pharmacists, 123, 930, 1406, 1693, 1697, 1700, 1703, 1708, 1821, 1890, 1924
Canadian Society of Hospital Pharmacists, 123
Mexican Association of Hospital Pharmacists, 123
pharmacy, 254
Pharmacy Technician Certification Board, 119

Osmolality
acetylcysteine, 828
fenoterol hydrobromide, 828
ipratropium bromide, 828

Osmolarity
globulin immune, Aug 15 suppl S5, Aug 15 suppl S12

Osteoporosis
estrogens, 1574
menaquinone, 1574
phytonadione, 1574
prescription drugs, 620
vitamin D, 1574

Outcomes
clinical, 1048, 1596, 2348
patient care, 1798
quality of life, 354

Outpatients, see Patients; outpatients

Oxaprozin
use, 739

Oxycodone hydrochloride
abuse, 2604

OxyContin, see Oxycodone hydrochloride
Oxymetazoline
concomitant therapy, 2006

P

Package inserts
vincristine sulfate, 1606

Packaging
bar codes, 1075
globulin immune, Aug 15 suppl S5
unit dose, 1437

Paclitaxel
restenosis, 2241

Pain
analgesics and antipyretics, 1904, 2109
fentanyl hydrochloride, 1171

Palonosetron hydrochloride
incompatibilities, 1998

Pantoprazole sodium
adverse reactions, 1388
myocardial infarction, 1494
stability, 2410

Parasympatholytic agents
ipratropium, 1263
ipratropium bromide, 828
scopolamine hydrobromide, 2350
tiotropium bromide, 1263

Parasympathomimetic agents
galantamine hydrobromide, 35
glaucoma, 691

Parenterals, see Injections

Parkinson disease
dopamine agonists, 537

Particle size

albuterol sulfate, 2271
cyclophosphamide, 1998
ifosfamide, 1998
palonosetron hydrochloride, 1998

Particles

atosiban acetate, 2459
contamination, 834, 1856, 1969

Patches transdermal
scopolamine, 1247

Patents

drugs, 149

Patient care
computers, 499
disease management, 1009
ethics, 1827
ethnic groups, 886
outcomes, 1798
pharmaceutical care, 2501
pharmaceutical services, 430, 1654, 1714
quality assurance, 1303, 1693, 1854
residencies, 1019

Patient information

antineoplastic agents, 266
cardiovascular diseases, 1398
compounding, 450
consultation, 205, 210, 364, 1311, 1342, 1491, 2239, 2342
diabetes mellitus, 510
hyperlipidemia, 1586
lovastatin, 455
medical records, 680
pharmaceutical services, 274
prescription drugs, 620
sexually transmitted diseases, 643
technology, 355
telepharmacy, 406

Patient-controlled analgesia
fentanyl hydrochloride, 1171

Patients

attitudes, 463, 616
compliance, 198, 411, 809, Apr 15 suppl S14, 1263, 1311, 1359, 1468, 1645, 1775, 2239, 2342
comprehension, 364
outpatients, 124, 616

Pediatrics

attention deficit disorder with hyperactivity, 1502
intensive care units, 1763
neonates, 823, 1613, 2593
parenteral nutrition, 315, 1177
residencies, 1766
serotonin-reuptake inhibitors, 806, 864

Penicillins

amoxicillin trihydrate, combination, clavulanate potassium, 2459
ampicillin, combination, sulbactam, 1299
nafcillin sodium, 1347

Pergolide

toxicity, 537

Personnel

clean rooms, 1271

Personnel, pharmacy
supportive, 119, 259, 285, 1992, 2386, 2466, 2542

Pharmaceutical
services, 744

Pharmaceutical care
ambulatory care, 2501
documentation, 1782
Hispanic Americans, 210
home health care, 1491
pharmacists, 1873
services, 1714

Pharmaceutical education, see Education, pharmaceutical

Pharmaceutical services

ambulatory care, 274, 1303
anticoagulants, 2393
clinical, 20, 145, 321, 454, 560, 1640, 1793, 2039, 2236, 2466, 2501
compliance, 1645
disaster planning, 1290
disasters, 2202
disease management, 1009
drug information, 2501, 2514
drug use, 259, 583, 585, 1654, 1714

emergencies, 2321
ethnic groups, 205
Hispanic Americans, 210
home health care, 1491
hospitals, 378, 430, 975, 1385, 1390, 1391, 1392, 1393, 1596, 1700, 1782
hyperlipidemia, 1798
laboratories, 1773
military, 753
pharmaceutical care, 2501
policies and procedures, 748
quality assurance, 1693
reimbursement, 1956
telepharmacy, 406
tests, 1802

Pharmacists

attitudes, 726, 845, 1067, 2401
careers, 1204
Cohen, M., 2222
compounding, 285, 2386
consultation, 364, 1311, 2342
disaster planning, 1290
disasters, 2202
dispensing, 1866
drug information centers, 2511
drug use, 583, 585
emergencies, 2321
ethics, 1827, 1864
gene therapy, 1080
interventions, 626, 1491
interview, 1352
Jordan, 2548
laboratories, 1773
leadership, 1206, 2474, 2501
manpower, 492
pharmaceutical care, 2501
Physicians' Desk Reference, 355
prescribing, 2501, 2508
professional relations, 1654, 1714
professionalism, 259, 1015
role, 116, 274, 510, 643, 1009, 1653, 1802, 1873, 1904, 1950, 1992, 2039, 2216, 2239, 2332
shortage, 492
telepharmacy, 406
Thailand, 1408
volunteers, 1108

Pharmacists, clinical, see Clinical pharmacists
Pharmacists, community
interventions, 1798

Pharmacists, hospital

administrators, 975
attitudes, 78
drug use, 189
emergency rooms, 1832
interventions, 400, 1596, 1782, 1967, 2338
leadership, 838, 856, 1657, 1697, 1700
quality assurance, 1693
role, 367, 378, 430, 468, 560, 1764, 1871, 1924

Pharmacodynamics

bevacizumab, 1021
daptomycin, 1145
exenatide, 173
fluorouracil, 1788
histamine H2 antagonists, May 15 suppl S4
insulins, 816
pramlintide acetate, 816
proton-pump inhibitors, May 15 suppl S4, May 15 suppl S24
roentgenographic agents, 2026

Pharmacoeconomics

cost-benefit analysis, 610, 1122, 1159

Pharmacoeconomics

cost-benefit analysis, 1543

Pharmacogenetics

research, 1226

Pharmacokinetics

anticoagulants, 593
atorvastatin calcium, 2491
azacitidine, 1567
bevacizumab, 1021
butorphanol tartrate, 48
daptomycin, 1145
duloxetine, 2481
exenatide, 173
fluorouracil, 1788

- ganciclovir, Apr 15 suppl S14
gentamicin, 823
heparin, Nov 15 suppl S7
histamine H2 antagonists, May 15 suppl S4
insulin human, 1359
insulins, 510, 816
linezolid, 464
mycophenolate sodium, 2252
opiates, 319
pramlintide acetate, 816, 2363
protease inhibitors, 809
proton-pump inhibitors, May 15 suppl S4, May 15 suppl S24
rosuvastatin, 1033
telithromycin, 905
tiotropium bromide, 1263
valganciclovir, Apr 15 suppl S14
ximelagatran, 1451
- Pharmacy**
administration, 139, 1067
ambulatory care, 274
contamination, 475
contracts, 422
educators, 1204, 1352
errors, medication, 1340, 1992
globulin immune, 2329
Internet, 1482
Jordan, 2548
leadership, 254, 845, 1206, 1303
mail order, 1482
practice, 259, 1868, 2041
prescription drugs, 1482
professionalism, 142
purchasing, 527
residencies, 1980
security, 1115
state boards, 2278
students, 142, 246, 254, 845, 927, 1138, 1442, 1488, 1562, 1657, 1766, 2041, 2226, 2236, 2283, 2514, 2539
Thailand, 1408
- Pharmacy Abroad**, 321, 1408, 1510, 1617, 2548
- Pharmacy and therapeutics committee**
antiinfective agents, 732
formularies, 1498
hospitals, 378
- Pharmacy benefit management companies**
drug interactions, 1983
- Pharmacy, clinical**, see **Clinical pharmacy**
- Pharmacy, education**, see **Education, pharmaceutical**
- Pharmacy personnel**, see **Personnel, pharmacy**
- Pharmacy services**
see also **Pharmaceutical services**
telepharmacy, 1866
- Pharmacy Technician Certification Board**
examinations, 2542
organizations, 119
- Pharmacy, institutional, hospital**
antidotes, 2344
bar codes, 1075
Belgium, 321
clerkships, 2539
computers, 499
education, pharmaceutical, 246
errors, medication, 2265
leadership, 838, 856, 1657, 1697, 1700
policies and procedures, 748
quality assurance, 123, 343, 468, 1385, 1390, 1391, 1392, 1393, 1693
reimbursement, 462
research, 464
services, 378, 430, 560, 975, 1596, 1782, 2393
technicians, 2466
- Phenylephrine**
combination, lidocaine, tetracaine, 450
- Phenytoin**
incompatibilities, 1969
- Phenytoin sodium**
adverse reactions, 2295
- Phosphate binders**
aluminum hydroxide, 2355
calcium acetate, 2355
calcium carbonate, 2355
lanthanum carbonate, 2355
sevelamer hydrochloride, 2355
- Phosphates**
incompatibilities, 1177
- Photodecomposition**
ibuprofen lysinate, 630
- Physical therapists**
attitudes, 1440
- Physicians**
errors, medication, 1592
medication orders, 416, 530
prescribing, 168, 626, 739, 1760, 1813, 1967, 2528
suicides, 306
- Physicians' Desk Reference**
Internet, 355
- Phytonadione**
osteoporosis, 1574
therapy, 1683
- Pilocarpine**
glaucoma, 691
- Pimozide**
interactions, 1983
- Pituitary hormones**
desmopressin, Sep 15 suppl S15
vasopressin, 1931, 1969
- Planning and design**
clean rooms, 1271
- Plants**
medicinal, 779, 1012, 1582, Nov 15 suppl S7
- Plasticizers**
diethylhexyl phthalate, 182
- Platelet aggregation inhibitors**
abciximab, 1381
aspirin, 626, 1357, 1398, 1494
eptifibatide, 1381, 1494
thrombosis, 2239
tirofiban hydrochloride, 1381
- Pneumococcal vaccines**
immunization, 367
- Pocanazole**
zygomycosis, 2593
- Poisoning**
dietary supplements, 1476
opiates, 1375
- Policies and procedures**, see **Administration**
- Polyethylene**
tubing, 182
- Polymers**
ethyl vinylacetate, 182
polyethylene, 182
polyvinyl chloride, 182
- Polymyxin B sulfate**
combination, hydrocortisone, neomycin sulfate, 2006
- Polyolefin**
containers, 2001
- Polypropylene**
syringes, 2410
- Polyvinyl chloride**
containers, 1190
tubing, 182
- Posaconazole**
mycoses, Apr 15 suppl S17
- Postmarketing surveillance**
drugs, 1333
drugs, adverse reactions, 1336, 1428, 1754
- Postmenopause**
antineoplastic agents, 266
estrogens, 69
- Postoperative complications**
aprotinin, 1370
- Postoperative nausea and vomiting**
antiemetics, 1247
scopolamine hydrobromide, 2350
- Postoperative pain**
opioids, 1904, 2019
- Potassium phosphate**
concomitant therapy, 2006
- Practice Spotlight**, 205, 1491
- Pramipexole**
toxicity, 537
- Pramlintide acetate**
diabetes mellitus, 2363
interactions, 816
- Prasterone**
sex disorders, 574
- Pravastatin**
hypercholesterolemia, 1468
hyperlipidemia, 1033
- Preceptors**
education, pharmaceutical, 519
- Precipitation**
ascorbic acid, 1073
clonidine hydrochloride, 1968
gentamicin sulfate, 1548
nafcillin sodium, 1347
parenteral nutrition, 1177
phenytoin, 1969
sodium citrate, 1548
vasopressin, 1969
- Pregnancy**
drugs, 1342
- Prescribing**
antidiabetic agents, 714
antiinfective agents, 732
drugs, 1502
epoetin alfa, 400
errors, medication, 1592
insulin, 714
oxycodone hydrochloride, 2604
pharmaceutical services, 378
pharmacists, 2508
physicians, 168, 626, 739, 1760, 1813, 1967, 2528
- Prescriptions**
drugs, 116, 149, 233, 455, 492, 583, 585, 620, 726, 1048, 1122, 1437, 1444, 1482, 1528, 1645, 1646, 1653, 1764, 1866, 1983, 2508, 2604
forms, 2278
- Pricing**
drugs, 149, 422
prescription drugs, 233, 1482
- Primary care**
residencies, 1868
- Primers**, 296, 1802, 1894, 1904, 2019
- Prochlorperazine**
postoperative nausea and vomiting, 1247
- Product development**
antiinfective agents, 1143
drugs, 149
natural products, 779
pharmacogenetics, 1226
- Product withdrawal**
COX-2 inhibitors, 668
nonsteroidal antiinflammatory agents, 997
- Productivity**
pharmacy, 1303
- Professional competence**
health professions, 676
- Professional relations**
health professions, 1015
pharmacists, 1654, 1714, 1827, 2039
pharmacists, hospital, 1700
- Professionalism**
education, pharmaceutical, 142
pharmacists, 259, 1015, 1864
- Progestins**
postmenopause, 69
- Promethazine**
postoperative nausea and vomiting, 1247
- Propellants**
hydrofluoroalkanes, 2271
- Propofol**
concomitant therapy, 2006
postoperative nausea and vomiting, 1247
- Propranolol hydrochloride**
concomitant therapy, 2630
- Propylene glycol**
solvents, 485
- Prostaglandins**
glaucoma, 691
- Prostatic neoplasms**
lycopene, 899

ANNUAL INDEX

Protocols

- alcohol withdrawal delirium, 355
- algorithms, 198
- American Society of Health-System Pharmacists, 1502, 2420
- anticoagulants, Nov 15 suppl S10
- antiemetics, 463
- antifungal agents, 34, 732, 1650
- antineoplastic agents, 266
- aspirin, 1357, 1398
- blood transfusions, Sep 15 suppl S2
- diabetes mellitus, 510
- drugs, 189
- epoetin alfa, 400, 1867
- ethics, 361
- gentamicin, 823
- gentamicin sulfate, 1613
- health care, 1873
- heart failure, 1953
- Heart Failure Society of America, 168
- hematopoietic agents, 2416
- HIV infections, 2332
- influenza vaccines, 367
- insulin, 2260
- latex, 1822
- pneumococcal vaccines, 367
- proton-pump inhibitors, May 15 suppl S24
- replacement solutions, 637
- research, 464
- venous thrombosis, 2338
- water-electrolyte imbalance, 1663

Proventil, see Albuterol sulfate

Pseudomonas aeruginosa

- resistance, 39, 732

Psychotherapeutic agents

- adverse reactions, 1883

Publications

- American Journal of Health-System Pharmacy, 134, 146

Purchasing

- group, 422, 527
- pharmacy, 422, 527

Purity

- globulin immune, Aug 15 suppl S5
- sterile products, 1271

Q

Q&A, 134, 361, 1447

- Disclosing conflicts of interest involving clinicians who prepare therapeutic guidelines, 361
- Electronic access to *AJHP*, 134
- Making ASHP's Web site easier to search, 1447

Quality assurance

- antifungal agents, 34
- dispensing, 1866
- drug distribution, 1075
- drug information centers, 2511
- errors, medication, 12, 1340, 1528, 1740, 1813
- formularies, 1498
- health care, 342, 676, 788, 1228, 1871, 1873, 1890, 1924, 1950
- hospital pharmacy, 123, 464, 468, 1385, 1390, 1391, 1392, 1393, 1693, 1700, 2393
- hospitals, 343, 975, 1118
- Internet, 1184
- laboratories, 1773
- Medicare, 1234
- patient care, 1854
- pharmaceutical services, 145, 430, 1645
- pharmacy, 139, 1303, 2026
- policies and procedures, 748
- residencies, 1817
- telepharmacy, 406

Quality control, see Control, quality

Quality improvement, see Quality assurance

Quality of life

- azacitidine, 1567
- drugs, 378
- hydralazine hydrochloride, combination, isosorbide dinitrate, 1745
- menopause, 889
- outcomes, 354
- tiotropium bromide, 1263

Quinapril

- concomitant therapy, 2295

Quinolones

- ciprofloxacin, 732
- gatifloxacin, 2293
- levofloxacin, 88, 732

R

Race

- African Americans, 1745
- patients, 886, 1871, 1873, 1924

Radio

- technology, 116

Radiopaque drugs, 2026

Ranitidine

- concomitant therapy, 2293
- incompatibilities, 1299

Rate constants

- butorphanol tartrate, 48
- gentamicin, 823

Rational therapy

- aminoglycosides, 1596
- analgesics and antipyretics, 1904
- anticoagulants, 1449
- antifungal agents, 34, 732, 1143, 1967, 2288
- attention deficit disorder with hyperactivity, 1502
- cholinesterase inhibitors, 923
- computers, 499
- drug use, 189
- drugs, 1760
- emergency rooms, 1832
- epoetin alfa, 400
- folic acid, 355
- geriatrics, 626, 1234
- insomnia, 1532
- oxycodone hydrochloride, 2604
- polypharmacy, 1645, 1883
- prescribing, 2528
- prescription drugs, 1764
- replacement solutions, 637
- vancomycin, 1596
- venous thrombosis, 2338

Reconstitution, see Drugs; reconstitution

Records

- medical, 680, 2222
- prescription drugs, 1528

References

- Internet, 355

Reflections, 95, 753, 2041

Regulations

- compounding, 450
- drugs, 1754, 2420
- Food and Drug Administration, 312, 315, 668, 1444
- laboratories, 1773
- Medicare, 1854
- pharmacy, 2548
- policies and procedures, 748
- postmarketing surveillance, 1428
- prescription drugs, 1122
- prescriptions, 2278

Reimbursement

- globulin immune, Aug 15 suppl S5
- hospital pharmacy, 462
- hospitals, 1617
- Medicaid, 1852
- Medicare, 124, 1646, 1854
- pharmaceutical care, 2501
- pharmaceutical services, 20, 1802, 1956
- prescription drugs, 1122

Release

- mycophenolate sodium, 2252
- vincristine sulfate, 1606

Religion

- gene therapy, 1018

Reminyl, see Galantamine hydrobromide

Replacement solutions

- albumin, 637
- sodium chloride, 637

Reports

- drugs, adverse reactions, 1336, 1375, 1754, 1883
- errors, medication, 1375, 1740, 2265
- toxicity, 2397

Research

- antifungal agents, 1143
- diabetes mellitus, 354
- gene therapy, 1018, 1080
- genetics, 296
- health care, 342, 1890
- hospital pharmacy, 464
- natural products, 779
- pharmacogenetics, 1226
- pharmacy, 2548

Residencies, see Education, pharmaceutical; residencies

Resistance

- antifungals, Apr 15 suppl S17
- antifungal agents, 34, 39, 74, 732, 1143, 1444, 1650, 1748, 2288
- antineoplastic agents, 1365
- antituberculars, 1431
- antivirals, Apr 15 suppl S3, Apr 15 suppl S7
- daptomycin, 1145
- ganciclovir, Apr 15 suppl S14
- protease inhibitors, 809
- telithromycin, 901, 905

Respiratory smooth muscle relaxants

- theophylline anhydrous, 2518

Respiratory tract infections

- telithromycin, 901, 905

Restenosis

- paclitaxel, 2241

Restless legs syndrome

- dopamine agonists, 537

Rhinitis

- prescription drugs, 620
- telepharmacy, 406

Rifamycins

- interactions, 1983

Risk management

- blood transfusions, Sep 15 suppl S2
- Food and Drug Administration, 236, 1336

Risperidone

- schizophrenia, 610

Ritonavir

- HIV infections, 809

Rivastigmine tartrate

- concomitant therapy, 420

Roentgenographic agents

- x-rays, 2026

Rofecoxib

- use, 739

Ropinivole

- toxicity, 537

Rosuvastatin

- hyperlipidemia, 1033

Roxatidine acetate hydrochloride

- stability, 289

S

Saline, see Sodium chloride

Salmeterol

- lung diseases, 1263

Sargramostim

- neutropenia, 83

Schizophrenia

- olanzapine, 610
- risperidone, 610

Scopolamine

- postoperative nausea and vomiting, 1247

Scopolamine hydrobromide

- dosage forms, 2350

Security

- technology, 1115

Seizures

- mefenamine hydrochloride, 420

Serotonin antagonists

- ketanserin tartrate, 2459

Sertraline hydrochloride

- concomitant therapy, 420

Serums

- globulin immune, 720, 2329, Aug 15 suppl S5, Aug 15 suppl S12

Sevelamer hydrochloride

- hyperphosphatemia, 2355

- Sevoflurane**
surgery, 63
- Sex**
patients, 1357, 1775, 1873
- Sex disorders**
dietary supplements, 574
- Sexually transmitted diseases**
therapy, 643
- Shock**
vasopressin, 1931
- Simvastatin**
concomitant therapy, 1388, 2293
hypercholesterolemia, 1468
hyperlipidemia, 1033
- Site of action**
pharmacogenetics, 1226
- Skin diseases**
daptomycin, 1145
- Sleep stages**
pergolide, 537
pramipexole, 537
ropinirole, 537
- Sociology**
attention deficit disorder with hyperactivity, 1502
gene therapy, 1018, 1080
genetics, 296
health care, 1871, 1924
low income, 454, 726, 886, 1048, 1437, 1646, 1653, 1775, 1852, 1873
- Sodium bicarbonate**
concomitant therapy, 2524
incompatibilities, 834
- Sodium chloride**
diluent, 630, 1073, 1190, 1381, 2001, 2410
excipients, Aug 15 suppl S12
replacement solutions, 637
- Sodium citrate**
incompatibilities, 1548
- Sodium phosphate**
concomitant therapy, 2006
- Solubility**
triamcinolone acetonide, 485
- Solutions**
atosiban acetate, 2459
dialysis, 1550
parenteral nutrition, 2345
- Solvents**
alcohols, ethyl, 485
glycerin, 485
propylene glycol, 485
- Specialties**
pharmacists, hospital, 1832
residencies, 1766, 1868, 1980
- Spectrum microbial**
antifungals, Apr 15 suppl S17
daptomycin, 1145
telithromycin, 901, 905
- Spinal cord injuries**
urinary tract infections, 74
- Spiriva**, see **Tiotropium bromide**
- Sports**
drug abuse, 2216
- Stability**
acetylcysteine, 828
albuterol sulfate, 2271
anidulafungin, 834
argatroban, 1381
ascorbic acid, 1073
atosiban acetate, 2459
"B-t-boronophenylalanine, 2608
cidofovir, 506
clonidine hydrochloride, 1968
cyclophosphamide, 1998
dolasetron mesylate, 896
droperidol, 1190
etoposide, 182
fenoterol hydrobromide, 828
fentanyl citrate, 1190
gentamicin sulfate, 1548
globulin immune, Aug 15 suppl S5
ibuprofen lysinate, 630
ifosfamide, 1998
injections, 285
insulins, 816
ipratropium bromide, 828
ketamine hydrochloride, 1190
levofloxacin, 88
methylprednisolone sodium succinate, 2001
metronidazole, 88
misoprostol, 1192
nafcillin sodium, 1347
ondansetron hydrochloride, 2001
palonosetron hydrochloride, 1998
pantoprazole sodium, 2410
parenteral nutrition, 1177
proton-pump inhibitors, May 15 suppl S24
roxatidine acetate hydrochloride, 289
sodium citrate, 1548
solutions, 1550
theophylline anhydrous, 2518
tramadol hydrochloride, 1299
triamcinolone acetonide, 485
vasopressin, 1969
vincristine sulfate, 1606
- Stabilizers**
sucrose, Aug 15 suppl S5
sugars, Aug 15 suppl S12
- Standards**
alternative medicine, 562
American Society of Health-System Pharmacists, 1654, 1708, 1714
examinations, 2542
health care, 1924
hospital pharmacy, 1385, 1390, 1391, 1392, 1393
Joint Commission on Accreditation of Healthcare Organizations, 1528
National Committee for Quality Assurance, 464
residencies, 800
United States Pharmacopeia, 1271, 1856
- Staphylococcus aureus**
resistance, 732
- Stents**
coronary disease, 2241
thrombosis, 2239
- Sterile products**
compounding, 285, 1271, 1856
- Sterility**
cidofovir, 506
dolasetron mesylate, 896
sterile products, 1271
- Steroids, cortico-**
dexamethasone, 1247
lung diseases, 1263
methylprednisolone, 2295
methylprednisolone sodium succinate, 2001
toxicity, 1976
transplantation, 391
triamcinolone acetonide, 485
- Storage**
acetylcysteine, 828
albuterol sulfate, 2271
anidulafungin, 834
argatroban, 1381
ascorbic acid, 1073
atosiban acetate, 2459
"B-t-boronophenylalanine, 2608
cidofovir, 506
clonidine hydrochloride, 1968
cyclophosphamide, 1998
dolasetron mesylate, 896
droperidol, 1190
drugs, 1290
etoposide, 182
fenoterol hydrobromide, 828
fentanyl citrate, 1190
gentamicin sulfate, 1548
globulin immune, Aug 15 suppl S5
ibuprofen lysinate, 630
ifosfamide, 1998
injections, 285
ipratropium bromide, 828
ketamine hydrochloride, 1190
levofloxacin, 88
methylprednisolone sodium succinate, 2001
metronidazole, 88
misoprostol, 1192
nafcillin sodium, 1347
ondansetron hydrochloride, 2001
palonosetron hydrochloride, 1998
pantoprazole sodium, 2410
parenteral nutrition, 1177
proton-pump inhibitors, May 15 suppl S24
roxatidine acetate hydrochloride, 289
sodium citrate, 1548
solutions, 1550
theophylline anhydrous, 2518
tramadol hydrochloride, 1299
triamcinolone acetonide, 485
vasopressin, 1969
vincristine sulfate, 1606
- Substitution**
globulin immune, 2329
therapeutic, 2416, May 15 suppl S24
- Sucrose**
stabilizers, Aug 15 suppl S5
- Sugars**
stabilizers, Aug 15 suppl S12
- Suicides**
laws, 306
serotonin-reuptake inhibitors, 806, 864
- Sulbactam**
combination, ampicillin, 1299
- Suppositories**
misoprostol, 1192
- Surgery**
analgesics and antipyretics, 1904
antidiabetic agents, 467
anti-infective agents, 34
carcinoma, 1365
desflurane, 63
drug withdrawal, 36
fentanyl hydrochloride, 1171
gastrointestinal hemorrhage, 1159
glaucoma, 691
sevoflurane, 63
thrombosis, Nov 15 suppl S4
- Suspensions**
theophylline anhydrous, 2518
- Sustained-action medications**
oxycodone hydrochloride, 2604
- Sympatholytic agents**
alpha blockers, 691
beta-blockers, 168, 626, 691
- Sympathomimetic agents**
albuterol sulfate, 1053, 2271
dobutamine, 1388
dopamine, 1388
dopamine hydrochloride, 2295
epinephrine, 2295
fenoterol hydrobromide, 828
norepinephrine, 1388
phenylephrine, combination, lidocaine, tetracaine, 450
salmeterol, 1263
- Syringes**
cidofovir, 506
dolasetron mesylate, 896
polypropylene sodium, 2410
- T**
- Tablets**
mycophenolate sodium, 2252
- Tamoxifen**
breast neoplasms, 266
- Taste**
palatability, May 15 suppl S24, 2518
- Team**
ambulatory care, 274
disease management, 1009
health care, 626
health professions, 1813
hospitals, Sep 15 suppl S2
intensive care units, 1763
- Technicians, pharmacy**, see **Personnel, pharmacy; supportive**

Technology

American Society of Health-System Pharmacists, 1697
bar codes, 1075, 2413, 2619, 2626
compounding, 1271
computers, 1782, 1793
decision-making, 2031
dispensing, 1866, 1917
errors, medication, 243, 530
genetics, 296
health care, 570
information, 788, 1228
labels, 116
medical records, 2222
patient information, 355
pharmaceutical services, 560
quality assurance, 1303
security, 1115

Tegafur

carcinoma, 1365

Tegaserod

colonic diseases, 700

Telepharmacy

health maintenance organizations, 406
pharmacy services, 1866

Telephone

disease management, 1586
medication orders, 78

Telithromycin

respiratory tract infections, 901
review, 905

Telmisartan

hypertension, 2381

Temperature

albuterol sulfate, 2271
"B-t-boronophenylalanine, 2608
cidofovir, 506
dolasetron mesylate, 896
droperidol, 1190
fentanyl citrate, 1190
gentamicin sulfate, 1548
ketamine hydrochloride, 1190
methylprednisolone sodium succinate, 2001
misoprostol, 1192
nafcillin sodium, 1347
ondansetron hydrochloride, 2001
pantoprazole sodium, 2410
roxatidine acetate hydrochloride, 289
sodium citrate, 1548
triamcinolone acetonide, 485
vincristine sulfate, 1606

Teratogenicity

drugs, 1342

Tests

devices, 1802

Tests, laboratory

pharmacists, 1773
urinary tract infections, 74

Tetracaine

combination, lidocaine, phenylephrine, 450

Thailand

pharmacy, 1408

Theophylline, anhydrous

stability, 2518

Therapeutic interchange, see Substitution; therapeutic

Thrombocytopenia

argatroban, 247
bivalirudin, 247
heparin, 247
lepirudin, 247

Thromboembolism

anticoagulants, 616, Nov 15 suppl S10

Thrombosis

globulin immune, 720
neoplasms, Nov 15 suppl S4
stents, 2239
therapy, Nov 15 suppl S7

Time studies

drug information centers, 2511
Food and Drug Administration, 1754
pharmacists, 726

Tinzaparin

thromboembolism, Nov 15 suppl S10

Tiotropium bromide

lung diseases, 1263

Tirofiban hydrochloride

incompatibilities, 1381

Tissue levels

insulin human, 1359
linezolid, 464

Tocolytics

atosiban acetate, 2459
magnesium sulfate, 2459

Tolerance

histamine H2 antagonists, May 15 suppl S4, May 15
suppl S11
proton-pump inhibitors, May 15 suppl S4, May 15 suppl
S11

Topical preparations

lidocaine, combination, phenylephrine, tetracaine, 450

Toxicity

see also **Drugs, adverse reactions**

albuterol sulfate, 1053
alcohols, ethyl, 2344
alternative medicine, 562
aluminum, 312, 315
aluminum hydroxide, 2355
aminoglycosides, 1596
analgesics and antipyretics, 1904
anesthetics, 1247
anesthetics, local, 1445
anticoagulants, 593, 616, Nov 15 suppl S10
antidepressants, 1502, 2479, 2481
antidiabetic agents, 467, 714
antineoplastic agents, 54, 83, 266, 463, 1813, Nov 15
suppl S10, Nov 15 suppl S4
antiretroviral agents, 2332
aprotinin, Sep 15 suppl S15, Sep 15 suppl S19, Sep 15
suppl S9
argatroban, 247
arginine, 574
aspirin, 1357, 1398
azacitidine, 1567
bevacizumab, 1017, 1021
bivalirudin, 247
blood transfusions, Sep 15 suppl S2
butorphanol tartrate, 48
catheters, Nov 15 suppl S4
ceftriaxone sodium, 2006
cholinesterase inhibitors, 923
colistin, 39
COX-2 inhibitors, 668, 890
cyclosporine, 391
daptomycin, 1145
deferoxamine, 2593
desflurane, 63
dietary supplements, 1476, 1582
drug interactions, 1760, 1983
drugs, 12, 36, 236, 416, 499, 530, 691, 905, 917, 1122,
1333, 1342, 1528, 1645, 1782, 1832, 2031, 2348, 2495,
2619, 2626
duloxetine, 2481
errors, medication, 1740
estrogens, 889
exenatide, 173
fentanyl hydrochloride, 1171
filgrastim, 83
fluorouracil, 1788
fomepizole, 2344
galantamine hydrobromide, 35
gastrointestinal drugs, 700
gatifloxacin, 2293
gentamicin, 823
gentamicin sulfate, 1613
Ginkgo biloba, 574
glimepiride, 35
globulin immune, 720, Aug 15 suppl S5, Aug 15 suppl
S12
guggulu oleoresin, 1012
gugulipid, 1690
heparin, 247, 2338, Nov 15 suppl S7
heparins, Nov 15 suppl S7
histamine H2 antagonists, May 15 suppl S4
HMG-CoA reductase inhibitors, 2420
influenza vaccines, 367
insulin, 714, 2260
insulin human, 1359
insulins, 816
lepirudin, 247

leucovorin, 1788

lidocaine, combination, phenylephrine, tetracaine, 450

lovastatin, 455, 1444

lycopene, 899

memantine hydrochloride, 420

menaquinone, 1574

milrinone, 291

mycophenolate mofetil, 2252

mycophenolate sodium, 2252

nesiritide, 196, 291, 606, 2639

nonsteroidal antiinflammatory agents, 997, 1543

opiates, 319, 1247

pergolide, 537

phytonadione, 1574

pneumococcal vaccines, 367

pramipexole, 537

pramlintide acetate, 816, 2363

prasterone, 574

prescription drugs, 233

protease inhibitors, 809

proton-pump inhibitors, May 15 suppl S4, May 15 suppl
S24

replacement solutions, 637

reports, 2397

ropinirole, 537

rosuvastatin, 1033

sargramostim, 83

serotonin-reuptake inhibitors, 806, 864

sevoflurane, 63

steroids, cortico-, 1976

sucrose, Aug 15 suppl S5

telithromycin, 901, 905

tiotropium bromide, 1263

vancomycin, 1596

vasopressin, 1931

warfarin, 1449, 1683, 2393, Nov 15 suppl S7

ximelagatran, 1449, 1451

Toxicity, environmental

HIV infections, 2332

Tramadol hydrochloride

incompatibilities, 1299

Tranexamic acid

coronary artery bypass, Sep 15 suppl S9

Transplantation

bone marrow, 744, 2593
organs, Apr 15 suppl S14, Apr 15 suppl S17, Apr 15
suppl S3, Apr 15 suppl S7
renal, 391, 1775, 2252
stem cells, Apr 15 suppl S7

Triamcinolone acetonide

lichen planus, 485

Tuberculosis

epidemiology, 1431

Tubing

polymers, 182

Turbidity

anidulafungin, 834
atosiban acetate, 2459
cyclophosphamide, 1998
ifosfamide, 1998
palonosetron hydrochloride, 1998

U

Ulcers

gastrointestinal drugs, May 15 suppl S18
proton-pump inhibitors, May 15 suppl S24

United States

computers, 1228
pharmacists, 492, 1067

pharmacy, 274

United States Pharmacopeia

standards, 1271, 1856

Uracil

carcinoma, 1365

Urinary incontinence

duloxetine, 2481

Urinary tract infections

catheters, 74

V

- Vaccines**
BCG, 1431
immunization, 1234, 1748
influenza, 247, 367
pneumococcal, 367
- Valacyclovir**
concomitant therapy, 2630
- Valdecoxib**
product withdrawal, 997
- Valerian**
poisoning, 1476
- Valganciclovir**
cytomegalovirus infections, Apr 15 suppl S14
- Valsartan**
hypertension, 2381
- Vancomycin**
concomitant therapy, 2006
use, 732, 1596
- Vasodilating agents**
isosorbide dinitrate, combination, hydralazine hydrochloride, 1745
- Vasopressin**
incompatibilities, 1969
shock, 1931
- Venlafaxine**
depression, 2479
- Venous thrombosis**
anticoagulants, 593
prophylaxis, 2338
- Ventolin**, see **Albuterol sulfate**
- Vials**
antineoplastic agents, 475
closures, 1822
contamination, 471
- Vincristine sulfate**
compounding, 1606
- Vitamin D**
osteoporosis, 1574

Vitamin D derivatives

hyperphosphatemia, 2355

Vitamin E

concomitant therapy, 420

Vitamin K1, see **Phytonadione**

Vitamins

ascorbic acid, 1073
concomitant therapy, 420
folic acid, 355
menaquinone, 1574
phytonadione, 1574, 1683
vitamin D, 1574

Volume

globulin immune, Aug 15 suppl S12, Aug 15 suppl S5

Volume of distribution, see **Drugs, body distribution**

Volunteers

pharmacists, 1108, 2202

Vomiting

antiemetics, 463

Voriconazole

mycoses, Apr 15 suppl S17

W

Warfarin

dosage, 1062, 2393
interactions, 1033, 1983
therapy, 1449
thromboembolism, Nov 15 suppl S10
thrombosis, Nov 15 suppl S7
toxicity, 1683
use, 626

Water for Injection

diluent, 630

Water-electrolyte imbalance

therapy, 1663

Weight

neonates, 1613
tests, 1802

Weight loss

dietary supplements, 1582

Wholesalers

contracts, 422
economics, 525, 527

Withdrawal, see **Drug withdrawal**

Women

aspirin, 1357
attitudes, 69
health care, 1873
sex disorders, 574

Workload

computers, 499
residencies, 800

World Health Care Congress

meetings, 570

World Health Organization

tuberculosis, 1431

World Wide Web

American Journal of Health-System Pharmacy, 134, 146
American Society of Health-System Pharmacists, 1447
arthritis, 1184
drug information, 1333
hospitals, 499, 1118

X

X-rays

diagnosis, 2026

Ximelagatran

review, 1451
therapy, 1449

Z

Zinc

poisoning, 1476

Zygomycosis

therapy, 2593

Author Index

A

- Abanmy, Norah O.** Compatibility of tramadol hydrochloride injection with selected drugs and solutions, 1299
- Ablin, Richard J.** Lycopen: a word of caution (letter), 899
- Abraham, Prasad** see **Ling, Jennifer M.**, 1793
- Acharya, Pinak S.** see **Kasbekar, Nishamini**, 905
- Adachi, Wayne** Use of failure mode and effects analysis in improving the safety of i.v. drug administration, 917
- Adams, Dale W.** Pharmacist position monitoring health-system employees' drug plan (letter), 1764
- Adams, Jamie** Vitamin K in the treatment and prevention of osteoporosis and arterial calcification, 1574
- Adamson, Robert** Therapeutic interchange of darbepoetin alfa for epoetin alfa in a multiinstitution health care system (Management Case Study), 2416
- Adkinson, N. Franklin Jr.** see **Hamilton, Robert G.**, 1822
- Alboul-Younes, Abia** see **Al-Wazaifi, Mayyada**, 2548
- Alfaro, Raul M.** see **Connor, Thomas H.**, 475
- Allen, Pamela** see **Adamson, Robert**, 2416
- Allinson, Temitayo T.** Perceived accuracy of drug orders transmitted orally by telephone, 78
- Alrawi, Ahmad** see **Walker, Paul C.**, 2495
- Altman, Julie S.** The value of mentorship (New Practitioners Forum), 2474
- Alvarez, William Jr.** Pharmacists' role in preventing stent thrombosis (editorial), 2239

Al-Wazaifi, Mayyada Pharmacy in Jordan (Pharmacy Abroad), 2548

Amato, Alaina Severe case of phenytoin-induced anticonvulsant hypersensitivity syndrome, 2295

Ambizas, Emily M. see **Balbi, Ebrahim A.**, 2508

Anderson, Lakisha M. see **Connor, Thomas H.**, 475

Anderson, Roger W. see **Trissel, Lawrence A.**, 285

Ansani, Nicole T. Practical approach to grading evidence for formulary recommendations (Management Case Study), 1498

Ansani, Nicole T. Quality of arthritis information on the Internet, 1184

Archer, Sanford M. see **Davis, George A.**, 48

Armistead, John see **Martin, Craig**, 732

Armistead, John A. see **Smith, Kelly M.**, 800

B

Badgett, Robert see **Wen, Lonnie**, 2031

Badia, M. B. see **Berlana, David**, 39

Bagel-Boithias, Sandrine Leaching of diethylhexyl phthalate from multilayer tubing into eposide infusion solutions, 182

Baillie, G. Mark Clinical update on opportunistic infections in transplantation. Introduction, Apr 15 suppl S2

Baillie, G. Mark Clinical update on opportunistic infections in transplantation. Pharmacokinetics of antiviral agents for the treatment of cytomegalovirus infection, Apr 15 suppl S14

Baker, Daniel E. Rationale for using serotonergic agents to treat irritable bowel syndrome, 700

Baker, James see **Birk, Carol W.**, 34

Balbi, Ebrahim A. Self-prescribing of noncontrolled substances among pharmacists, 2508

Balen, Robert M. see **Raybardhan, Sumit**, 1782

Ball, Amanda M. see **Miller, April D.**, 2236

Ballow, Mark Practical considerations for the use of IGIV therapy. Clinical and investigational considerations for the use of IGIV therapy, Aug 15 suppl S12

Banks, David Pharmacists, pharmaceutical

manufacturers, and conflicts of interest, 1827

Baquet, Claudia see **Mullins, C. Daniel**, 1873

Barber, Gerard R. Daptomycin: we'll make more, they'll make more (editorial), 1143

Barker, Brian Visual compatibility of vasopressin with other injectable drugs (letter), 1969

Barletta, Jeffrey F. see **Devlin, John W.**, 637

Barnes, Barbara see **Tortorici, Michael A.**, 1350

Barnhart, Donna see **Gonzalez, Luis S. III**, 1890

Baron, Alain D. see **Kolterman, Orville G.**, 173

Barrs, Thomas J. X-rays and radiopaque drugs, 2026

Barrels, Cathy L. see **Wilson, Amy Friedman**, 2514

Basskin, Lorne E. see **Krupp, Eric L.**, 2597

Bauer, Jerald B. Nesiritide for outpatient treatment of heart failure, 2639

Beckmann, Gwendolyn see **Connor, Thomas H.**, 475

Benis, Lois J. see **Kozakiewicz, Janet M.**, 1813

Benner, Joshua S. Association between short-term effectiveness of statins and long-term adherence to lipid-lowering therapy, 1468

Bennett, Marialice S. see **Mehta, Bella H.**, 2501

Berberet, Bradley R. Unavailability of 10% alcohol in 5% dextrose injection (letter), 2344

Berlana, David Use of colistin in the treatment of multiple-drug-resistant gram-negative infections, 39

Bilmes, Robyn see **Stull, Dawn Marie**, 83

Bilos, Appie see **Connor, Thomas H.**, 475

Bing, Michael R. see **Connor, Thomas H.**, 475

Birk, Carol W. Interventions to improve compliance with guidelines on surgical prophylaxis (letter), 34

ANNUAL INDEX

- Bistrain, Bruce R. see Parikh, Mansi J., 1177
 Black, Beverly L. see Knapp, Katherine K., 274
 Blalock, Susan J. see McIntosh, Jennifer, 69
 Blatt, Lisa see Mullins, C. Daniel, 1873
 Blitz, Sandra see Charrois, Theresa L., 1798
 Boccia, Ralph V. see Herrington, Jon D., 54
 Boggie, Daniel T. see Harris, Jessica, 1543
 Boggie, Daniel T. see also Plowman, Brian K., 537
 Boggis, Douglas Lee Interviewing for a faculty position at the ASHP Midyear Clinical Meeting (New Practitioners Forum), 1352
 Bolon, Maureen K. see Scheetz, Marc H., 1967
 Bonan, Brigitte see Hennere, Gaëlle, 506
 Bond, C. A. (CAB) Clinical and economic outcomes of pharmacist-managed aminoglycoside or vancomycin therapy, 1596
 Bond, Jack see Ragan, Robert, 1075
 Boone, Sarah A. Dietary supplements for female sexual dysfunction (Alternative Therapies), 574
 Botts, Sheila Moving beyond balance for a better antidepressant (editorial), 2479
 Bougouin, Christelle Compatibility of ondansetron hydrochloride and methylprednisolone sodium succinate in multilayer polyolefin containers, 2001
 Bourdeau, Daniel see Bagel-Boithias, Sandrine, 182
 Boyer, Anne see Bagel-Boithias, Sandrine, 182
 Brackbill, Marcia L. Magnesium sulfate for prevention of postoperative atrial fibrillation in patients undergoing coronary artery bypass grafting, 397
 Branch, Robert see Ansani, Nicole T., 1498
 Brinker, Allen Patient characteristics associated with outpatient prescriptions for nabumetone and oxaprozin versus celecoxib and rofecoxib, 739
 Brouse, Sara D. Prevention of venous thromboembolism in the medically ill (letter), 2338
 Brouwers, Jacobus R. B. see Jansman, Frank G. A., 1788
 Brown, Jack Zygomycosis: an emerging fungal infection, 2593
 Brown, Robert H. see Hamilton, Robert G., 1822
 Bruce, Susan P. Program for guiding pharmacy students through residency selection, 1488
 Brushwood, David B. Defining "legitimate medical purpose," 306
 Btaiche, Imad F. see Kraft, Michael D., 1663
 Buccini, Kathryn K. see Possidente, Carl J., 1311, 2343
 Buck, Gary see Birk, Carol W., 34
 Buck, Katie Tillman see Kreiner, Thane, 296
 Bullano, Michael F. see Benner, Joshua S., 1468
 Burda, Anthony M. see Berberet, Bradley R., 2344
 Burda, Michelle see Ansani, Nicole T., 1184
 Burkiewicz, Jill S. see Bruce, Susan P., 1488
 Burkiewicz, Jill S. see also Fit, Kathy E., 2226
 Bush, Paul see Cummings, Joseph, 2626
 Busser, James R. see Zed, Peter J., 616
- C**
- Caballero, Joshua Selective serotonin-reuptake inhibitors and suicidal ideation and behavior in children, 864
 Campbell, Ronald J. New practitioners' role in achieving the ASHP Health-System Pharmacy 2015 Initiative (New Practitioners Forum), 468
 Canada, Todd W. Aluminum exposure through parenteral nutrition formulations: mathematical versus clinical relevance, 315
 Cannon, Joan P. see Shah, Palak S., 74
 Cantwell, Kathleen M. Collaborating for successful medication therapy management programs (editorial), 583
 Carlson, Leah see Hendeles, Leslie, 1053
 Chan, Agnes L. F. Pharmacist intervention when interacting drugs are prescribed despite alerts (letter), 1760
 Chan, Henry see Plowman, Brian K., 537
 Chan, Juliana C. N. see Cheng, Caroline W. R., 411
 Chan, Raymond C. Pharmacy practice in Thailand (Pharmacy Abroad), 1408
 Chan, Vivien Influence of temperature and drug concentration on nalcillin precipitation (letter), 1347
 Chao, Blenda A. Evaluating the educational consent of direct-to-consumer fulfillment materials, 620
- Charrois, Theresa L. Relationship between number, timing, and type of pharmacist interventions and patient outcomes, 1798
 Chen, Chi-Ming see Lee, Tzung-Yi, 828
 Chen, David F. 2015 Initiative: update and overview, 1390
 Chen, Hsiang-Yin see Lee, Tzung-Yi, 828
 Chen, Steven Low-dose aspirin: major benefits, minimal cost (editorial), 1357
 Cheng, Caroline W. R. Assessing adherence to statin therapy using patient report, pill count, and an electronic monitoring device, 411
 Chernin, Eric see Golembiewski, Julie, 1247, 2350
 Chiadmi, Fouad see Haffassou, Halim, 1192
 Chiang, Yi-Chun see Lee, Tzung-Yi, 828
 Chicella, Michael F. Clinical pharmacists: essential members of the pediatric critical care team (letter), 1763
 Chin, Alfred Extended stability of ascorbic acid in 5% dextrose injection and 0.9% sodium chloride injection, 1073
 Ching, Pui Ling (Amy) see Chan, Raymond C., 1408
 Chisholm, Marie A. Increasing medication access for the uninsured and underinsured (editorial), 1653
 Chisholm, Marie A. Medicare-approved drug discount cards and prescription drug prices, 1482
 Chisholm, Marie A. Patient factors associated with adherence to immunosuppressant therapy in renal transplant recipients, 1775
 Chock, Alan W. Y. see Stading, Julie A., 2293
 Choi, In see Oh, Junghyun, 289
 Chopineau, Jean see Bagel-Boithias, Sandrine, 182
 Chopra, Tania see Golembiewski, Julie, 1247, 2350
 Cingolani, Andrea see Volonté, Maria G., 630
 Clause, Steven L. see Triller, Darren M., 1883
 Clauson, Kevin A. see Netzer, Jennifer, 2278
 Coughlin, Daniel J. Medication use in the emergency department: why are we placing patients at risk?, 1832
 Codina, Carles see Gratacos, Laura, 1388
 Coenen, Jules L. L. see Jansman, Frank G. A., 1788
 Coeytaux, Remy R. see Spencer, Donald C., 416
 Cohen, Henry see Plakogiannis, Roda, 2491
 Cohn-Oswald, Leslie see Weber, Eric, 2466
 Colburn, Susan see Sakowski, Julie, 2619
 Coleman, Craig I. see Gillespie, Effie L., 1370
 Connor, Thomas H. Surface contamination of chemotherapy drug vials and evaluation of new vial-cleaning techniques: results of three studies, 475
 Cooke, Jonathan Medication management in English National Health Service hospitals, 189
 Coons, Timothy J. see Hendeles, Leslie, 1053
 Cornell, John see Wen, Lonnie, 2031
 Correr, Cassiano J. see Melchior, Ana Carolina, 354
 Corrigan, Melissa Murer see Muenzen, Patricia M., 2542
 Couldry, Rick see Thomas, Mark, 2386
 Crespin-Maillard, Fabienne see Bougouin, Christelle, 2001
 Crill, Catherine M. Accuracy of parenteral nutrition solutions compounded with automated systems and by hand (letter), 2345
 Cummings, Joseph Bar-coding medication administration overview and consensus recommendations (Medication-Use Technology), 2626
 Cusick, Michael A. see Schneider, Brandi L., 2393
 Czarska, Barbara see O'Dell, Kate M., 606
- D**
- Dager, William E. see Nutescu, Edith A., 1449
 Daniels, Rowell see Spencer, Donald C., 416
 Danziger, Larry H. see Schriever, Christopher A., 1145
 Darcy, Teresa P. Pharmacists as laboratorians (editorial), 1773
 Data, Joann see Weyer, Christian, 816
 Daugherty, Kimberly K. Cognitive and neurologic impairment with hydrochlorothiazide, 2630
 Davidson, Stephen L. see Herrington, Jon D., 54
 Davis, George A. Bioavailability of intranasal butorphanol administered from a single-dose sprayer, 48
 de Graaf, Jacques C. see Jansman, Frank G. A., 1788
 DeChristoforo, Robert see Connor, Thomas H., 475
 DeLattre, Melissa L. see Harris, Jessica, 1543
 DeLattre, Melissa L. see Plowman, Brian K., 537
 Degg, Robert see Barker, Brian, 1969
 Dennehy, Cathi E. Dietary supplement-related adverse events reported to the California Poison Control System, 1476
- Desselle, Shane P. Certified pharmacy technicians' views on their medication preparation errors and educational needs, 1992
 Devlin, John W. Albumin for fluid resuscitation: Implications of the Saline Versus Albumin Fluid Evaluation, 637
 Devlin, John W. Treatment options and formulary considerations in the management of acid suppression in critically ill patients. Introduction, May 15 suppl S2
 Devlin, John W. Treatment options and formulary considerations in the management of acid suppression in critically ill patients. Proton pump inhibitors for acid suppression in the intensive care unit: formulary considerations, May 15 suppl S24
 Dexter, Franklin see Macario, Alex, 63
 Deyo, Kelly see Sprandel, Kelly A., 88
 DiBona, John R. see O'Connor, Paul J., 139
 Dice, James E. see Chicella, Michael F., 1763
 Dilkush, Dimple Insulin infusion protocol for critical care units, 2260
 DiPiro, Joseph T. see Chisholm, Marie A., 1482
 Dopheide, Julie A. ASHP Therapeutic Position Statement on the Appropriate Use of Medications in the Treatment of Attention-Deficit/Hyperactivity Disorder in Pediatric Patients, 1502
 Driscoll, David F. see Driscoll, MaryBeth, 312
 Driscoll, David F. see also Parikh, Mansi J., 1177
 Driscoll, MaryBeth Calculating aluminum content in total parenteral nutrition admixtures, 312
 Drummond, Michael F. see Cooke, Jonathan, 189
 Dubb, Jeffrey W. see Verme-Giboney, Catherine, 247
 Duke, Kathryn Saenz Patient-assistance programs: assessment of and use by safety-net clinics, 726
 Dumas, Greg see Parikh, Mansi J., 1177
 Duncan, Babette see Malone, Daniel C., 1983
 Dunehew, Allen Changing dynamics in the pharmaceutical supply chain: a GPO perspective, 527
 Dunehew, Allen R. Contract price integrity for pharmaceuticals, 422
 Durham, Christopher R. see Hale, LaDonna S., 1613
- E**
- Eidem, Leslie see Ragan, Robert, 1075
 Empey, Kerry see Martin, Craig, 732
 Emptage, Ruth E. Providing homebound patients with pharmaceutical services (Practice Spotlight), 1491
 Enfant, Christopher M. see Szumita, Paul M., 1931
 Engles, Laura Advancing patient safety and improving coronary artery bypass graft outcomes. Review and application of serine protease inhibition in coronary artery bypass graft surgery, Sep 15 suppl S9
 Estes, Lynn L. see Wilson, John W., 499
 Evangelista, David see Dunehew, Allen R., 422
 Evans, Martin see Martin, Craig, 732
 Ezeala, Gladys U. see Gandhi, Pritesh J., 1494
- F**
- Fadey, Michael O. Book Review, 1838
 Faris, Richard J. Perceived importance of pharmacy management skills, 1067
 Farthing-Papineau, Emily Christel Pharmacists' perceptions of the pharmaceutical industry, 2401
 Faulkner, Michele A. see Stading, Julie A., 2293
 Faus, Maria Jose see Fernandez-Llmos, Fernando, 2348
 Favale, Maria Progress of Veterans Affairs pharmacies toward goals and objectives of ASHP's 2015 Initiative, 1385
 Favier, Mireille see Bougouin, Christelle, 2001
 Fedde, Sarah see Barker, Brian, 1969
 Fedutes-Henderson, Bethany A. see Ansani, Nicole T., 1184
 Fedutes-Henderson, Bethany A. see Ansani, Nicole T., 1498
 Fernández, Cristina see Schriever, Christopher A., 1145
 Fernandez-Llmos, Fernando From "drug-related problems" to "negative clinical outcomes", (letter), 2348
 Fernández-Llmos, Fernando see Melchior, Ana Carolina, 354
 Feroli, E. Robert see Hamilton, Robert G., 1822

- Ferrández, Olivia Effects of antimicrobial drug shortages (letter), 1444
- Ferrara, Marcelo see Volonté, María G., 630
- Ferraresi, Victoria Inhaled opioids for the treatment of dyspnea, 319
- Fichtl, Rick see Stull, Dawn Marie, 83
- Filiatrault, Lyne see Zed, Peter J., 616
- Fine, Michael J. see Kilbourne, Amy M., 198
- Fineman, Mark S. see Kolterman, Orville G., 173
- Fineman, Mark S. see also Weyer, Christian, 816
- Finley, Patrick R. Book Review, 2047
- Fish, Douglas N. Telithromycin: do we really need this antimicrobial? (editorial), 901
- Fisher, Susan M. see Kozakiewicz, Janet M., 1813
- Fit, Kathy E. Factors influencing pursuit of residency training (letter), 2226
- Fjortoft, Nancy see Tran, Kim, 1442
- Flatau, Lindy K. Transitioning into the life of a practicing pharmacist (New Practitioners Forum), 1015
- Fontan, Jean-Eudes see Haffirassou, Halim, 1192
- Ford-LaPointe, Trisha Developing new practitioners' leadership potential (New Practitioners Forum), 254
- Fort, E. see Berlana, David, 39
- Foster, Leigh Anne see Birk, Carol W., 34
- Fotis, Michael see Schetz, Marc H., 1967
- Fotis, Michael A. see Mycyk, Mark B., 1592
- Fotis, Michael A. see also Patel, Jean A., 168
- Frye, Carla B. Disclosing conflicts of interest involving clinicians who prepare therapeutic guidelines (Q&A), 361
- G**
- Galler, Marilyn see Than, Min, 1550
- Gandhi, Prithesh J. Myocardial infarction in an adolescent taking Adderall, 1494
- Garrelts, James C. see Ragan, Robert, 1075
- Gayken, John see Westanmo, Anders D., 2481
- Gbarayor, Confidence M. see Mullins, C. Daniel, 1873
- Gentempo, Joseph A. see Trissel, Lawrence A., 285
- Gerzentshtein, Lana see Schetz, Marc H., 1967
- Gill, Mark A. see Chin, Alfred, 1073
- Gillespie, Effie L. Effect of aprotinin on the frequency of postoperative atrial fibrillation or flutter, 1370
- Glassman, Peter see Goodman, Francine D. C., 2604
- Glossner, Scott see Tran, Kim, 1442
- Golan, Yoav Clinical update on opportunistic infections in transplantation. Overview of transplant mycology, Apr 15 suppl S17
- Golembiewski, Julie Availability of different dosage forms of scopolamine (letter), 2350
- Golembiewski, Julie Prevention and treatment of postoperative nausea and vomiting, 1247
- Gong, William C. see March, Kristi L., 210
- Gonzalez, Luis S. III Institutional review board approval of projects presented as posters at an ASHP Midyear Clinical Meeting, 1890
- Gonzalez, Luis S. III What are pharmacists, and what do they do? 2039
- Good, Chester B. see Kilbourne, Amy M., 198
- Goodin, Susan Cancer-associated thrombosis: new considerations in the treatment and prevention of recurrent venous thromboembolism. Introduction, Nov 15 suppl S3
- Goodin, Susan Cancer-associated thrombosis: new considerations in the treatment and prevention of recurrent venous thromboembolism. Selecting an anticoagulant for recurrent venous thromboembolism in cancer, Nov 15 suppl S10
- Goodman, Francine D. C. Evaluating potentially aberrant outpatient prescriptions for extended-release oxycodone, 2604
- Gordon, Jenny O. Automated medication-dispensing system in two hospital emergency departments (Management Case Study), 1917
- Gouveia, William A. Clinical leadership (editorial), 805
- Gouveia, William A. see also Knoer, Scott J., 2539
- Gouveia, William A. see also Shane, Rita, 430
- Gowda, Hema Pharmacy clinic offers glimpse into future Medicare service (News), 1645
- Grafenreed, Kimm M. Folic acid in alcohol-withdrawal delirium (letter), 356
- Graff, Larissa R. see Wu, Helen T., 744
- Graner, Kevin K. see Wilson, John W., 499
- Granko, Robert P. see Spencer, Donald C., 416
- Gratacos, Laura Apparent anaphylaxis associated with pantoprazole, 1388
- Grau, Santiago see Ferrández, Olivia, 1444
- Green, Larry see Herrington, Jon D., 54
- Greenwood, Bonnie see Szumita, Paul M., 1931
- Greinacher, Andreas see Spinler, Sarah A., 248
- Gryskiewicz, Kristen A. see Gillespie, Effie L., 1370
- Guharoy, Roy Ethical beliefs and professional duty (letter), 1864
- Guharoy, Roy Potential and perils of implantable microchip (letter), 355
- Guharoy, Roy Reform of U.S. vaccine management (letter), 247
- Guharoy, Roy Risks of a nonprescription lovastatin (letter), 1444
- Gulseth, Michael P. Ximelagatran: an orally active direct thrombin inhibitor, 1451
- Gulseth, Michael P. see also Schneider, Brandi L., 2393
- Gum, Michael O. see Hartis, Charles E., 1683
- Gwak, Hyesun see Oh, lunghyun, 289
- H**
- Hadsall, Ronald S. see Gordon, Jenny O., 1917
- Haffirassou, Halim Stability of misoprostol in suppositories, 1192
- Hahn, Kristine see Sullivan, Meaghan, 1567
- Haigh, Robert see Westanmo, Anders D., 2481
- Haines, Stuart T. Current and emerging treatment options for venous thrombosis: a case discussion, 593
- Hak, Emily B. see Crill, Catherine M., 2345
- Hale, LaDonna S. A simple, weight-based, extended-interval gentamicin dosage protocol for neonates, 1613
- Hamilton, Robert A. see Triller, Darren M., 1883
- Hamilton, Robert G. Administering pharmaceuticals to latex-allergic patients from vials containing natural rubber latex closures, 1822
- Hansten, Philip see Malone, Daniel C., 1983
- Hardin, Laurie R. Counseling patients with low health literacy (Frontline Pharmacist), 364
- Harris, Brittany N. see Strum, Matthew W., 1048
- Harris, Jessica Identification of patients taking NSAIDs at high risk for GI bleeding (letter), 1543
- Harrison, Bruce R. see Connor, Thomas H., 475
- Harsono, Rusly see Lee, Derek K. T., 1190
- Hartis, Charles E. Use of specific indicators to detect warfarin-related adverse events, 1683
- Hasagawa, Guy R. Book Review, 1210
- Hatton, Randy C. see Hendele, Leslie, 1053
- Haupt, Heather see Malone, Daniel C., 1983
- Havard, Laurent see Hennessee, Gail, 506
- Helling, Dennis K. see Stubbings, Troy, 406
- Helm, Richard A. see Crill, Catherine M., 2345
- Hendele, Leslie Automatic replacement of albuterol nebulizer therapy by metered-dose inhaler and valved holding chamber, 1053
- Hennere, Gail Stability of cidofovir in extemporaneously prepared syringes, 506
- Hepfinger, Charley see Weber, Eric, 2466
- Hepfinger, Charley A. see Sahni, Sona, 1690
- Herrier, Richard N. Putting motivational interviewing in perspective (letter), 2342
- Herrington, Jon D. Darbepoetin versus epoetin (letter), 1552
- Herrington, Jon D. Utilization of darbepoetin alfa and epoetin alfa for chemotherapy-induced anemia, 54
- Hess, Philip J. Jr. Advancing patient safety and improving coronary artery bypass graft outcomes. Systemic inflammatory response to coronary artery bypass graft surgery, Sep 15 suppl S6
- Higginbotham, Eve Duplicate publication (letter), 1979
- Higginbotham, Eve J. see Lee, David A., 691
- Hilas, Olga see Favale, Maria, 1385
- Hoffman, James M. Projecting future drug expenditures—2005, 149
- Hogben, Matthew see McCree, Donna Hubbard, 643
- Hontz, Karrie M. see Hoffman, James M., 149
- Hopkins, Robert see Strum, Matthew W., 1048
- Horn, Angela J. see Dennehy, Cathi E., 1476
- Horowitz, Sheryl see Gillespie, Effie L., 1370
- Houghton, Chad Making ASHP's Web site easier to search (Q&A), 1447
- Hoven, Ardis see Martin, Craig, 732
- Howe, Andrew see Ling, Jennifer M., 1793
- Hoye, William L. Effects of extreme temperatures on drug delivery of albuterol sulfate hydrofluoroalkane inhalation aerosols, 2271
- Humphrey, Chester see Gillespie, Effie L., 1370
- Humphries, Tammy L. see Stubbings, Troy, 406
- Hunkler, Robert J. see Hoffman, James M., 149
- Hursting, Marcie J. see Patel, Kamlesh, 1381
- Hutchins, David S. see Malone, Daniel C., 1983
- I**
- Iacovino, Lori-Ann see Nguyen, Timothy V., 1867
- Ingle, Gordon R. Cyclosporine-sparing effects of dactinib in renal allograft recipients, 391
- Ingle, Gordon R. Enteric-coated mycophenolate sodium for transplant immunosuppression, 2252
- Ishikawa, Kazuhiro New prospective payment system in Japan (Pharmacy Abroad), 1617
- Ismali, Agron see Min, Bokyoung, 1582
- Ivey, Marianne F. 2005 Report of the Treasurer: investing in our members and the future of the profession through strong financial management, 1703
- Ivey, Marianne F. Rationale for having a chief pharmacy officer in a health care organization, 975
- J**
- Jansen, Anita J. A. see Jansman, Frank G. A., 1788
- Jansman, Frank G. A. Assessing the clinical significance of drug interactions with fluorouracil in patients with colorectal cancer, 1788
- Jew, Rita Lesson from the saga of selective serotonin-reuptake inhibitors (editorial), 806
- Jewesson, Peter J. see Raybardhan, Sumit, 1782
- Jódar, R. see Berlana, David, 39
- Jódar, Ramón see Juvany, Roser, 36
- Johns, Thomas see Smith, Wendy D., 714
- Johnson, Cary E. Stability of anhydrous theophylline in extemporaneously prepared alcohol-free oral suspensions, 2518
- Johnson, Cary E. Stability of pantoprazole in 0.9% sodium chloride injection in polypropylene syringes, 2410
- Johnson, Jeffrey A. see Charrois, Theresa L., 1798
- Johnson, Paul see Pucalau, Georgeta, 1606
- Jones, William N. Hazards of colchicine (letter), 1350
- Jordan, Stanley C. see Ingle, Gordon R., 391
- Jorde, Ulrich P. see Smull, David L., 291
- Justice, Amy C. see Kilbourne, Amy M., 198
- Juvany, Roser Medications during the perioperative period (letter), 36
- K**
- Kahalch, Abir (Abby) Ohio guidelines for advanced-practice hospital rotations for pharmacy students (letter), 246
- Kalus, James S. see O'Dell, Kate M., 606
- Kardas, Michael J. see Min, Bokyoung, 1582
- Kasbekar, Nishamini Telithromycin: the first ketolide for the treatment of respiratory infections, 905
- Kastango, Eric S. Blueprint for implementing USP chapter 797 for compounding sterile preparations, 1271
- Kelly, Brandi Inaccessibility of online PDR to pharmacists (letter), 355
- Kennedy, Pamela L. see Faris, Richard J., 1067
- Khandaria, Ujjaini see Walker, Paul C., 2495
- Kietthubthaw, Suparp see Ungphaihoon, Suwipa, 485
- Kilbourne, Amy M. Algorithm for assessing patients' adherence to oral hypoglycemic medication, 198
- Kim, Dennis D. see Kolterman, Orville G., 173
- Kim, Helen see Stull, Dawn Marie, 83
- Kingsford, Tim see Ragan, Robert, 1075
- Kinowski, Jean Marie see Bouguin, Christelle, 2001
- Kishi, Donald T. see Ishikawa, Kazuhiro, 1617
- Kluger, Jeffrey see Gillespie, Effie L., 1370

- Kluger, Jeffrey see also Min, Bokyoung, 1582
 Knapp, Katherine K. ASHP survey of ambulatory care pharmacy practice in health systems—2004, 274
 Knapp, Katherine K. Update on the pharmacist shortage: national and state data through 2003, 492
 Knoer, Scott J. Student rotations in health-system pharmacy management and leadership, 2539
 Kolesar, Jill M. Bevacizumab: improved survival at what cost? (editorial), 1017
 Kolesar, Jill M. see also Sullivan, Meaghan, 1567
 Kolesar, Jill M. see also Wilhelm, Lindsey, 1365
 Kolterman, Orville G. Pharmacokinetics, pharmacodynamics, and safety of exenatide in patients with type 2 diabetes mellitus, 173
 Kolterman, Orville G. see also Weyer, Christian, 816
 Koo, Peter J. S. Postoperative pain management with a patient-controlled transdermal delivery system for fentanyl, 1171
 Kountz, Randy see Weber, Eric, 2466
 Koumis, Tina Update of directory of drug information centers (letter), 1348
 Kozakiewicz, Janet M. Safe chemotherapy administration: using failure mode and effects analysis in computerized prescriber order entry (Management Case Study), 1813
 Kraft, Michael D. Treatment of electrolyte disorders in adult patients in the intensive care unit, 1663
 Kreiner, Thane Moving toward whole-genome analysis: a technology perspective, 296
 Kriz, Otomar see van Rij, Catharina M., 2608
 Kruep, Eric J. Cost-minimization analysis of darbepoetin alfa versus epoetin alfa in the hospital setting, 2597
 Kucukarslan, Suzan see O'Dell, Kate M., 606
 Kudsk, Kenneth A. see Kraft, Michael D., 1663
 Kwok, C. Kent see Ansani, Nicole T., 1184
- L**
- LaCivita, Cynthia Crosswalk for the 2015 Initiative, 1392
 Laekeman, Gert see Willems, Ludo, 321
 Lai, Katie Managing the drug regimens of immigrants from other cultures (Practice Spotlight), 205
 Lajeunesse, Joel D. see Trissel, Lawrence A., 285
 Lal, Lincy S. Clinical pharmacy education in India (Pharmacy Abroad), 1510
 Lam, Sum Impact of an interdisciplinary team on drug therapy outcomes in a geriatric clinic, 626
 Lance, Charles E. see Chisholm, Marie A., 1775
 Lannigan, Jeffrey see Dilkush, Dimple, 2260
 Lawton, Geoff Bar-code verification of medication administration in a small hospital (Medication-Use Technology), 2413
 Lederer, James W. Jr. see Hartis, Charles E., 1683
 Lee, Chun-Nin see Lee, Tzung-Yi, 828
 Lee, David A. Duplicate publication (letter), 1979
 Lee, David A. Glaucoma and its treatment: a review, 691
 Lee, Derek K. T. Compatibility of fentanyl citrate, ketamine hydrochloride, and droperidol in 0.9% sodium chloride injection stored in polyvinyl chloride bags, 1190
 Lee, Seung-Bin see Harris, Jessica, 1543
 Lee, Tzung-Yi Compatibility and osmolality of inhaled N-acetylcysteine nebulizing solution with fenoterol and ipratropium, 828
 Lee, Wei C. see Swart, Eleonora L., 2459
 Leifheit, Michael see Gonzalez, Luis S. III, 1890
 Leininger, Aaron see Spencer, Donald C., 416
 Lensmeyer, Gary see Steiner, MaryAnn E., 896
 Leonard, Thomas see Sakowski, Julie, 2619
 Leo-To, Wing Fun see Than, Min, 1550
 Levy, Jerrold H. Advancing patient safety and improving coronary artery bypass graft outcomes. Overview of clinical efficacy and safety of pharmacologic strategies for blood conservation, Sep 15 suppl S15
 Lew, Indu see Adamson, Robert, 2416
 Li, Edward Oncology pharmacy practice residency programs (New Practitioners Forum), 1980
 Ling, Jennifer M. Documentation of pharmacist interventions in the emergency department, 1793
 Linnebur, Sunny A. Cholinesterase inhibitor use in geriatric outpatients with dementia, 923
 Lipton, Helene Levens see Duke, Kathryn Saenz, 726
 Lipton, Richard B. see Malone, Daniel C., 1983
 Liu, Gwen see Raybardhan, Sumit, 1782
 Liu, Mei T. see Mathis, A. Scott, 1976
 Liu, Shanshan see Chin, Alfred, 1073
 Llop, J. M. see Berlana, David, 39
 Lloyd, Kimberly Braxton see Scolari, Kelly L., 1802, 1894
 Luis, Meritxell see Gratacós, Laura, 1388
 Lobo, Bob see Grafenreed, Kimm M., 356
 Lodolce, Amy E. see Adachi, Wayne, 917
 Lodolce, Amy E. see also Berberet, Bradley R., 2344
 Loewen, Peter see Raybardhan, Sumit, 1782
 Longshore, Daniel S. Residency programs in primary and ambulatory care pharmacy practice (New Practitioners Forum), 1868
 López, Beatriz see Gratacós, Laura, 1388
 Lovely, Jenna K. see Wilson, John W., 499
 Lovly, Ronald see Favale, Maria, 1385
 Lubarsky, David see Macario, Alex, 63
 Luyen, Tuonglan T. see Gandhi, Pritesh J., 1494
 Lyakhovetskiy, Aleksandr see Rivkin, Kirill, 1159
- M**
- Macario, Alex Meta-analysis of trials comparing postoperative recovery after anesthesia with sevoflurane or desflurane, 63
 MacKinnon, George E. III see Faris, Richard J., 1067
 MacKinnon, Neil J. see Faris, Richard J., 1067
 MacLeod, Andrea K. see Young, Shaun F., 2528
 Maddox, Ray R. see Williams, Carolyn K., 530
 Maillard, Christian see Bouguin, Christelle, 2001
 Major, Kelly see Ragan, Robert, 1075
 Malacrida, Paul see Adamson, Robert, 2416
 Malone, Daniel C. Assessment of potential drug-drug interactions with a prescription claims database, 1983
 Malone, Daniel C. see also Romero, Andrew V., 1375
 Malone, Patrick M. see Wilson, Amy Friedman, 2514
 Maloney, Lesley R. ASHP's role in eliminating health disparities (editorial), 1871
 Manahan, Janice M. see Wilson, John W., 499
 Manasse, Henri R. Jr. 2005 Report of the Executive Vice President and Chief Executive Officer: the power of pharmacy leadership, 1700
 Manasse, Henri R. Jr. The other side of the human genome, 1080
 Mandal, Tarun K. Inhaled insulin for diabetes mellitus, 1359
 Maneenuan, Duangkhae see Ungphaiaboon, Suwipa, 485
 Manke, Dean J. Dog days (Reflections), 95
 March, Kristi L. Providing pharmaceutical care to Hispanic patients, 210
 Maricic, Michael J. see Jones, William N., 1350
 Marlowe, Karen F. see Amato, Alaina, 2295
 Marseglia, Janet B. see Kozakiewicz, Janet M., 1813
 Martin, B. Shane see Pell, Lindsay J., 400
 Martin, Craig Results of an antimicrobial control program at a university hospital, 732
 Martin, Jill E. Inaugural address of the President-elect and Vice Chair of the Board: from coal to diamond: transforming health-system pharmacy, 1693
 Martin, Kathryn Anne Specialized pediatric residency programs (New Practitioners Forum), 1766
 Martindale, Robert G. Treatment options and formulary considerations in the management of acid suppression in critically ill patients. Contemporary strategies for the prevention of stress-related mucosal bleeding, May 15 suppl S11
 Mason, Anne R. see Cooke, Jonathan, 189
 Massoomi, Firouzan (Fred) Pharmacists in the Omaha Metropolitan Medical Response System, 1290
 Masters, Kelly P. A resident's perspective on professionalism in pharmacy (New Practitioners Forum), 142
 Mateu-de Antonio, Javier see Ferrández, Olivia, 1444
 Mathis, A. Scott Corticosteroids: an important cause of hyperglycemia (letter), 1976
 Matuszewski, Karl see Cummings, Joseph, 2626
 Mazur, Jennifer N. see Ragucci, Kelly R., 927
 McAllister, James C. III see Miller, April D., 2236
 McBride, Brian F. see Min, Bokyoung, 1582
 McClain, Walter J. see Possidente, Carl J., 1311, 2343
 McCree, Donna Hubbard Status of and pharmacists' role in patient-delivered partner therapy for sexually transmitted diseases, 643
 McDaniel, Molly R. see Mycyk, Mark B., 1592
 McIntosh, Jennifer Effects of media coverage of Women's Health Initiative study on attitudes and behavior of women receiving hormone replacement therapy, 69
 McIntosh, Shadrecka T. Using data from automated dispensing units to identify adverse drug reactions, 2397
 McKaveney, Theresa P. see Ansani, Nicole T., 1184
 McKenney, James M. Efficacy and safety of rosuvastatin in treatment of dyslipidemia, 1033
 McKercher, Patrick L. Book Review, 1840
 McMahon, M. Molly see Wilson, John W., 499
 McMichael, Ewan see Strassels, Scott A., 1904, 2019
 McQueen, Joanna Pramlintide acetate, 2363
 Mehlich, Theodore see Peltz, Gayle, 420
 Mehta, Bella H. Advancing patient care through innovative practice: the Clinical Partners Program, 2301
 Melchioris, Ana Carolina Humanistic-outcomes questionnaires in diabetes research and practice (letter), 354
 Mercadal, Gabriel see Juvany, Roser, 36
 Mersfelder, Tracey L. Linezolid pharmacokinetics in an obese patient (letter), 464
 Michaelson, Beverly see Sakowski, Julie, 2619
 Michaud, Laura B. Adjuvant use of aromatase inhibitors in postmenopausal women with breast cancer, 266
 Mike, Leigh Ann see Ling, Jennifer M., 1793
 Miller, April D. ASHP's Clinical Skills Competition: a problem-solving framework (New Practitioners Forum), 2236
 Miller, Chad see Stubbings, Troy, 406
 Miller, Laura M. see Knapp, Katherine K., 492
 Miller, Stephanie see Gonzalez, Luis S. III, 1890
 Min, Bokyoung Hemodynamic impact of an ephedra-free multicomponent weight-loss supplement, 1582
 Misuro, Andrew see Adamson, Robert, 2416
 Mitchell, John F. see Walker, Paul C., 2495
 Moberg, Lori see Brackbill, Marcia L., 397
 Modrzejewski, Krystyn Electronic access to *AJHP*, (Q8A), 134
 Mogalian, Erik M. see Hoyer, William L., 2271
 Moist, Louise see Wazny, Lori, 1548
 Moldenhauer, Edward T. Remote checking of prescriptions in Navy health facilities (letter), 1866
 Montagne, Michael see Wu, Wenchen Kenneth, 1552
 Montgomery, Tanasha see Poon, Ivy O., 464
 Moon, Hongseop see Oh, Junghyun, 289
 Moore, Sandra C. Book Review, 1210
 Moores, Kevin G. see Wilson, Amy Friedman, 2514
 Moranville, Michael P. see Shields, Kelly M., 1012
 Morgan, Timothy O. Advancing patient safety and improving coronary artery bypass graft outcomes. Cost, quality, and risk: measuring and stopping the hidden costs of coronary artery bypass graft surgery, Sep 15 suppl S2
 Morita, Richard see Palmieri, James, 1586
 Morreale, Anthony P. see Harris, Jessica, 1543
 Morreale, Anthony P. see also Ploewman, Brian K., 537
 Morrill, Gregory B. see Singla, Dana L., 1062
 Motl, Susannah Bevacizumab in combination chemotherapy for colorectal and other cancers, 1021
 Motl, Susannah E. see also Timpe, Erin M., 2511
 Moudgil, Asha see Ingle, Gordon R., 391
 Mozzachio, Alicia M. A world away (Reflections), 753
 Muenzen, Patricia M. Updating the Pharmacy Technician Certification Examination: a practice analysis study, 2542
 Mullins, C. Daniel Health disparities: a barrier to high-quality care, 1873
 Mulloy, Laura L. see Chisholm, Marie A., 1775
 Murphy, Christine see Kahaleh, Abir (Abby), 246
 Murphy, John E. Book Review, 2047
 Murphy, John E. Prediction of gentamicin peak and trough concentrations from six extended-interval dosing protocols for neonates, 823
 Mycyk, Mark B. Hospitalwide adverse drug events before and after limiting weekly work hours of medical residents to 80, 1592
 Myers, Charles E. Improving clinical services through the ASHP 2015 Initiative (editorial), 145
 Myers, Erin see Johnson, Cary E., 2518
 Myrdal, Paul B. see Hoyer, William L., 2271

N

- Nabeshima, Toshitaka see Ishikawa, Kazuhiro, 1617
 Nagel, Kathryn R. Prohibited abbreviations (letter), 1559
 Nahata, Milap C. see Caballero, Joshua, 864
 Nahata, Milap C. see also Mehta, Bella H., 2501
 Namjoshi, Madhav see Russo, Patricia A., 610
 Nawarskas, James J. Paclitaxel-eluting stents in coronary artery disease, 2241
 Nelson, Kent M. see Stubbings, Troy, 406
 Nelson, Tanya Selecting the right residency program (New Practitioners Forum), 1138
 Nemchausky, Bernard see Shah, Palak S., 74
 Netzer, Jennifer Comparison of state requirements for preprinted prescriptions, 2278
 Newberry, Jack see Dunchew, Allen R., 422
 Newman, Jeffrey M. see Sakowski, Julie, 2619
 Nguyen, Timothy V. Standardized doses of epoetin alfa for hemodialysis patients (letter), 1867
 Nicolás, Josep M. see Gratacós, Laura, 1388
 Nielsen, Loretta L. see Kolterman, Orville G., 173
 Nittayananta, Wipawee see Ungphaihoon, Suwipa, 485
 Nogué, Santiago see Gratacós, Laura, 1388
 Norgard, Nick Possible drug rash with eosinophilia and systemic symptoms syndrome after exposure to epoetin alfa, 2524
 Noskin, Gary A. see Scheetz, Marc H., 1967
 Nourjah, Parivash see Brinker, Allen, 739
 Noviasky, John see Guharoy, Roy, 1864
 Noviasky, John A. see Peltz, Gayle, 420
 Nutescu, Edith A. Uncertain times for oral anticoagulation therapy (editorial), 1449
 Nutescu, Edith A. see also Haines, Stuart T., 593

O

- O'Connor, Paul J. Balancing costs and outcomes through partnerships with consultants (Management Consultation), 139
 O'Dell, Kate M. Nesiritide for secondary pulmonary hypertension in patients with end-stage heart failure, 606
 Ofotokun, Ighoverwa see Martin, Craig, 732
 Ogundele, Abayomi B. see Trissel, Lawrence A., 834
 Oh, Jennifer see McCree, Donna Hubbard, 643
 Oh, Jungshyan Stability of roxatidine acetate in parenteral nutrient solutions containing different amino acid formulations, 289
 Ohri, Linda K. see Wilson, Amy Friedman, 2514
 Okamoto, Mark P. see Knapp, Katherine K., 274
 Olin, Jacqueline L. Tiotropium: an inhaled anticholinergic for chronic obstructive pulmonary disease, 1263
 Olsen, Keith M. Treatment options and formulary considerations in the management of acid suppression in critically ill patients. Use of acid-suppression therapy for treatment of non-variceal upper gastrointestinal bleeding, May 15 suppl S18
 Osborn, Larry A. see Nawarskas, James J., 2241
 Osial, Thaddeus A. see Ansani, Nicole T., 1184
 Ou, Narith N. see Wilson, John W., 499
 Oyen, Lance J. see Wilson, John W., 499

P

- Pachucki, Constance T. see Shah, Palak S., 74
 Pacific, Domenica M. see Peltz, Gayle, 420
 Padiyara, Rosalyn S. see Fit, Kathy E., 2226
 Page, Robert Lee II Physical therapists' knowledge, attitudes, and professional use of nonprescription analgesics (letter), 1440
 Palmieri, James Goal attainment in patients referred to a telephone-based dyslipidemia program, 1586
 Parikh, Mansi J. Physical compatibility of neonatal total parenteral nutrient admixtures containing organic calcium and inorganic phosphate salts, 1177
 Partovi, Nilufar see Raybardhan, Sumit, 1782
 Pass, Steven E. Antihyperglycemics during the perioperative period (letter), 467
 Pastor, John see Shetka, Mike, 2288

- Patel, Jean A. Comparison of treatment of patients with congestive heart failure by cardiologists versus noncardiologists, 168
 Patel, Kamlesh Compatibility of argatroban with abiximab, eptifibatide, or tirofiban during simulated Y-site administration, 1381
 Patka, John see Ling, Jennifer M., 1793
 Peak, Amy Sutton see Farthing-Papineau, Emily Christel, 2401
 Pedersen, Craig A. ASHP national survey of pharmacy practice in hospital settings: prescribing and transcribing—2004, 378
 Pedersen, Craig A. see also Savage, Scott W., 2265
 Pedroff, Tressa see Dilkush, Dimple, 2260
 Pell, Lindsay J. Epoetin alfa protocol and multidisciplinary blood-conservation program for critically ill patients, 400
 Peltz, Gayle Seizures associated with memantine use, 420
 Pepping, Joseph see Adams, Jamie, 1574
 Perrin, John H. Hazard of compounded anesthetic gel (letter), 1445
 Peters, Byron G. see Connor, Thomas H., 475
 Petropoulos, Jerilyn B. see McIntosh, Shadrecka T., 2397
 Phadoongsombat, Narubodsee see Ungphaihoon, Suwipa, 485
 Phelps, Pamela see Shetka, Mike, 2288
 Plakogiannis, Roda Effects of morning versus evening administration of atorvastatin in patients with hyperlipidemia, 2491
 Plowman, Brian K. Sleep attacks in patients receiving dopamine-receptor agonists, 537
 Plowman, Brian K. see also Harris, Jessica, 1543
 Pochop, Sarah Pharmacy practice residency programs (New Practitioners Forum), 1562
 Pollack, Michael F. see Benner, Joshua S., 1468
 Pomeroy, Claire see Martin, Craig, 732
 Pontarolo, Roberto see Melchior, Ana Carolina, 354
 Poon, Ivy O. Compliance of a VA pharmacy with documentation requirements for human research (letter), 464
 Poret, Amy W. see Young, Christopher H., 2381
 Possidente, Carl J. Motivational interviewing: a tool to improve medication adherence? 1311
 Possidente, Carl J. Putting motivational interviewing in perspective (letter), 2343
 Postelnick, Michael J. see Scheetz, Marc H., 1967
 Power, Luci A. Demand clean vials (editorial), 471
 Pretty, Jack R. see Connor, Thomas H., 475
 Primeau, Marie Noel see Hamilton, Robert G., 1822
 Prognon, Patrice see Hennere, Gaëlle, 506
 Pruemer, Jane Cancer-associated thrombosis: new considerations in the treatment and prevention of recurrent venous thromboembolism. Prevalence, causes, and impact of cancer-associated thrombosis, Nov 15 suppl S4
 Pucalau, Georgeta Reliability of preparation procedure for sphingosine vincristine, 1606

Q

- Quinn, Daniel W. Jr. Efficacy of statins in preventing progression of aortic stenosis, 979
 Quist, Ryan M. see Knapp, Katherine K., 492

R

- Rabi, Suzanne M. see Fit, Kathy E., 2226
 Radwan, Mahasen A. see Abanmy, Norah O., 1299
 Raehl, Cynthia L. see Bond, C. A. (CAB), 1596
 Ragan, Robert Improved control of medication use with an integrated bar-code-packaging and distribution system (Medication-Use Technology), 1075
 Ragucci, Kelly R. Objective structured clinical examinations for an ambulatory care pharmacy rotation, 927
 Randazzo, Michael A. see Bauer, Jered B., 2639
 Rao, Padma G. see Lal, Lincy S., 1510
 Rapp, Robert see Martin, Craig, 732
 Ratiney, Robert see Hafirassou, Halim, 1192
 Raube, Kristiana see Duke, Kathryn Saenz, 726
 Ray, Max D. Continuity of care: a basis for professional unity in pharmacy (editorial), 1654

- Raybardhan, Sumit Documenting drug-related problems with personal digital assistants in a multisite health system, 1782
 Raymakers, Albert see Willems, Ludo, 321
 Reasonable, Raymond R. Clinical update on opportunistic infections in transplantation. Epidemiology of cytomegalovirus disease in solid organ and hematopoietic stem cell transplant recipients, Apr 15 suppl S7
 Redline, Shannon see Palmieri, James, 1586
 Regal, Randolph E. see Walker, Paul C., 2495
 Regalado, Jane see Mycyc, Mark B., 1592
 Reines, Scott A. Look-alike, sound-alike drug errors with Reminyl and Amaryl (letter), 35
 Reiter, Arthur see Favale, Maria, 1385
 Ribas, Josep see Gratacós, Laura, 1388
 Rice, Ted L. Folic acid in alcohol-withdrawal delirium (letter), 355
 Riddle, Anthie see Dilkush, Dimple, 2260
 Rivkin, Anastasia M. Hepatocellular enzyme elevations in a patient receiving ceftriaxone, 2006
 Rivkin, Kirill Treatment of nonvariceal upper gastrointestinal bleeding, 1159
 Rodis, Jennifer L. see Mehta, Bella H., 2501
 Rodrigue, Phara G. see Muenzen, Patricia M., 2542
 Rodvold, Keith A. see Schriever, Christopher A., 1145
 Rodvold, Keith A. see also Sprandel, Kelly A., 88
 Romanelli, Frank see Smith, Kelly M., 2283
 Romero, Andrew V. Accuracy of adverse-drug-event reports collected using an automated dispensing system, 1375
 Rosenberg, Eric see Smith, Wendy D., 714
 Rosenberg, Jack M. see Koumis, Tina, 1348
 Rossignol, Evan N. Increasing hospital pharmacy revenue (letter), 462
 Rossignoli, Paula see Melchior, Ana Carolina, 354
 Rough, Steve see Knoer, Scott J., 2539
 Rubin, Julie see Ling, Jennifer M., 1793
 Ruby, Christine M. see Lam, Sum, 626
 Rudy, Anita C. see Davis, George A., 48
 Ruggles, James A. see Kolterman, Orville G., 173
 Ruscin, J. Mark see Linnebur, Sunny A., 923
 Rusho, William J. see Barker, Brian, 1969
 Russo, Patricia A. Health care costs for schizophrenia patients started on olanzapine versus risperidone, 610

S

- Sacks, Gordon S. see Kraft, Michael D., 1663
 Sahni, Sona Guggulipid use in hyperlipidemia: case report and review of the literature, 1690
 Sakowski, Julie Using a bar-coded medication administration system to prevent medication errors in a community hospital network (Medication-Use Technology), 2619
 Sanborn, Michael D. see Thomas, Mark, 2386
 Saseen, Joseph J. ASHP therapeutic position statement on the daily use of aspirin for preventing cardiovascular events, 1398
 Sauer, Brian C. see Smith, Wendy D., 714
 Sauer, Karen Ann see Sahni, Sona, 1690
 Sauerwein, Wolfgang A. G. see van Rij, Catharina M., 2608
 Sautou-Miranda, Valérie see Bagel-Boithias, Sandrine, 182
 Savage, Scott W. Utility of an online medication-error-reporting system, 2265
 Scarsi, Kimberly K. see Scheetz, Marc H., 1967
 Schaefer, Monica G. see Plowman, Brian K., 537
 Schauble, James F. see Hamilton, Robert G., 1822
 Scheckelhoff, Douglas J. see Pedersen, Craig A., 378
 Scheckelhoff, Douglas J. see also Thompson, Kasey K., 1393
 Scheetz, Marc H. Effect of on-call infectious-diseases pharmacists on antibiotic expenditures (letter), 1967
 Scherer, Susan A. see Page, Robert Lee II, 1440
 Schlatter, Joel see Hafirassou, Halim, 1192
 Schiro, Timothy see Sakowski, Julie, 2619
 Schneider, Brandi L. Computer program to assist pharmacy management of an inpatient warfarin dosing service, 2393
 Schneider, James see Sakowski, Julie, 2619
 Schneider, Philip J. see Allinson, Temitayo T., 78

- Schneider, Philip J. see also Pedersen, Craig A., 378
 Schneider, Philip J. see also Savage, Scott W., 2265
 Schneider, Sandra M. see Coughlin, Daniel J., 1832
 Schommer, Jon C. see Gordon, Jenny O., 1917
 Schriever, Christopher A. Daptomycin: a novel cyclic lipopeptide antimicrobial, 1145
 Schucker, Jason J. Hyperphosphatemia and phosphate binders, 2355
 Schwartz, Rowena N. Cancer-associated thrombosis: new considerations in the treatment and prevention of recurrent venous thromboembolism. Considerations and challenges with existing treatments for thrombosis in cancer patients, Nov 15 suppl S7
 Scolaro, Kelly L. Devices for ambulatory and home monitoring of blood pressure, lipids, coagulation, and weight management, part 1, 1802
 Scolaro, Kelly L. Devices for ambulatory and home monitoring of blood pressure, lipids, coagulation, and weight management, part 2, 1894
 Scott, James D. Simplifying the treatment of HIV infection with ritonavir-boosted protease inhibitors in antiretroviral-experienced patients, 809
 Sedrakyan, Artyom Advancing patient safety and improving coronary artery bypass graft outcomes. Improving clinical outcomes in coronary artery bypass graft surgery, Sep 15 suppl S19
 Sereika, Susan M. see Kilbourne, Amy M., 198
 Sermeus, Walter see Willems, Ludo, 321
 Sessink, Paul J. M. see Connor, Thomas H., 475
 Shah, Nilay D. see Hoffman, James M., 149
 Shah, Palak S. Controlling antimicrobial use and decreasing microbiological laboratory tests for urinary tract infections in spinal-cord-injury patients with chronic indwelling catheters, 74
 Shah, Sachin Practical considerations for the use of IGIV therapy. Introduction, Aug 15 suppl S3
 Shah, Sachin Practical considerations for the use of IGIV therapy. Pharmacy considerations for the use of IGIV therapy, Aug 15 suppl S5
 Shah, Sachin Use of i.v. immune globulin and occurrence of associated acute renal failure and thrombosis, 720
 Shah, Tariq see Ingle, Gordon R., 2252
 Shane, Rita Expanding pharmacy's reach across the care continuum, 430
 Shatla, Ahmed see Peltz, Gayle, 420
 Sheikh-Taha, Marwan Intermittent nesiritide therapy in outpatients with chronic heart failure, 196
 Shen, Larry see Kolterman, Orville G., 173
 Shen, Larry see also Weyer, Christian, 816
 Sherman, Craig R. Availability of different dosage forms of scopolamine (letter), 2350
 Shetka, Mike Evaluation of the defined daily dose method for estimating antineoplastic use in a university hospital, 2288
 Shields, Amy see Lawton, Geoff, 2413
 Shields, Kelly M. Guggul for hypercholesterolemia (Alternative Therapies), 1012
 Shields, Kelly M. see also Boone, Sarah A., 574
 Shirk, Mary Beth see Pell, Lindsay J., 400
 Sibley, Carolyn see Sprandel, Kelly A., 88
 Silvestri, Anthony see Parikh, Mansi J., 1177
 Singla, Dana L. Warfarin maintenance dosages in the very elderly, 1062
 Sinha, Vinita see Min, Bokyung, 1582
 Sinjewel, Arno see Swart, Eleonora L., 2459
 Sinjewel, Arno see also van Rij, Catharina M., 2608
 Sirio, Carl A. see Ansani, Nicole T., 1498
 Sisson, Debra C. see Schneider, Brandi L., 2393
 Skledar, Sue see Tortorici, Michael A., 1350
 Skledar, Susan J. see Ansani, Nicole T., 1498
 Skrabal, Maryann Z. see Stading, Julie A., 2293
 Sleijfer, Dirk T. see Jansman, Frank G. A., 1788
 Slimowitz, Richard Book Review, 1838
 Smit, Willem M. see Jansman, Frank G. A., 1788
 Smith, Curtis L. see Mersfelder, Tracey L., 464
 Smith, Douglas see Cummings, Joseph, 2626
 Smith, Kelly M. Adoption of duty-hour standards in a pharmacy residency program (New Practitioners Forum), 800
 Smith, Kelly M. Use of an electronic survey to assess the training and practice experiences of pharmacy residency graduates, 2283
 Smith, Kelly M. see also Miller, April D., 2236
 Smith, Marcia B. see Page, Robert Lee II, 1440
 Smith, Mark W. see Russo, Patricia A., 610
 Smith, Miriam A. Mobley see Muenzen, Patricia M., 2542
 Smith, Randall B. see Ansani, Nicole T., 1184
 Smith, Robert E. see Herrington, Jon D., 54
 Smith, Timothy W. see Benner, Joshua S., 1468
 Smith, Wendy D. Causes of hyperglycemia and hypoglycemia in adult inpatients, 714
 Smith, Wendy D. Corticosteroids an important cause of hyperglycemia (letter), 1979
 Smitherman, Thomas see Ansani, Nicole T., 1498
 Smull, David L. Concomitant use of nesiritide and milrinone in decompensated congestive heart failure, 291
 Sokos, Denise R. Pharmacists' role in increasing pneumococcal and influenza vaccination, 367
 Solomon, Steve L. see Malone, Daniel C., 1983
 Song, Adreahna SOAP note: why I want to complete a pharmacy practice residency (Reflections), 2041
 Soy, Dolores see Gratacos, Laura, 1388
 Spencer, Donald C. Effect of a computerized prescriber-order-entry system on reported medication errors (Medication-Use Technology), 416
 Spinler, Sarah A. Direct thrombin inhibitors in heparin-induced thrombocytopenia (letter), 248
 Spinler, Sarah A. see also Quinn, Daniel W. Jr., 979
 Sprandel, Kelly A. Stability and compatibility of levofloxacin and metronidazole during simulated and actual Y-site administration, 88
 Stading, Julie A. Development of diabetes after gatifloxacin therapy, 2293
 Stamm, Pamela L. see Scolaro, Kelly L., 1802, 1894
 Starz, Terence see Ansani, Nicole T., 1184
 Stein, Gary C. Battle for funding of pharmacy residency programs (editorial), 1019
 Steinberg, Michael Patients' response to revised practices for treating chemotherapy-induced nausea and vomiting (letter), 463
 Steiner, MaryAnn E. Stability and sterility of dolasetron mesylate in syringes stored at room temperature (letter), 896
 Stokes, Herbert see Duneheew, Allen R., 422
 Stoneking, Kent Initiating basal insulin therapy in patients with type 2 diabetes mellitus, 510
 Strassels, Scott A. Postoperative pain management: a practical review, part 1, 1904
 Strassels, Scott A. Postoperative pain management: a practical review, part 2, 2019
 Strobel, Susan see Weyer, Christian, 816
 Strum, Matthew W. Effects of a medication assistance program on health outcomes in patients with type 2 diabetes mellitus, 1048
 Stubbings, Troy Telepharmacy in a health maintenance organization, 406
 Stull, Dawn Marie Comparison of sargamostim and filgrastim in the treatment of chemotherapy-induced neutropenia, 83
 Styrzcula, Diane E. see Sprandel, Kelly A., 88
 Subramanian, Jeeva see Daugherty, Kimberly K., 2630
 Suleman, Rosy see Strassels, Scott A., 1904, 2019
 Sullivan, Christine L. see Shah, Palak S., 74
 Sullivan, Meaghan Azacitidine: a novel agent for myelodysplastic syndromes, 1567
 Sundberg, Aleksandra see Tran, Kim, 1442
 Swart, Eleonora L. Visual compatibility of atosiban acetate with four drugs (letter), 2459
 Sylvestri, Mario F. see Weyer, Christian, 816
 Szeinbach, Sheryl L. see Allison, Temitayo T., 78
 Szumita, Paul M. Vasopressin for vasopressor-dependent septic shock, 1931
- T**
- Taft, David see Plakogiannis, Roda, 2491
 Talbert, Robert L. see Boggs, Douglas Lee, 1352
 Talley, C. Richard Book Review, 2048
 Talley, C. Richard New online services for AJHP readers and authors (editorial), 146
 Talley, C. Richard Researching the human genome (editorial), 1018
 Than, Min Technique for removing samples from bags of dialysate solution (letter), 1550
 Thelcide, Chloe see Bougouin, Christelle, 2001
 Thielke, Thomas S. Searching for excellence in leadership transformation, 1657
 Thomas, Mark I.V. admixture contamination rates: traditional practice site versus a class 1000 cleanroom, 2386
 Thompson, Cheryl A. Audible medication vials slowly gain momentum (News), 116
 Thompson, Cheryl A. Better renal-function estimates not expected to alter drug dosing right away (News), 2442
 Thompson, Cheryl A. Billing codes for pharmacy clinical services advance (News), 20
 Thompson, Cheryl A. Biometrics offers alternative to password entry (News), 1115
 Thompson, Cheryl A. Changes in IVIG marketplace challenge pharmacists (News), 2329
 Thompson, Cheryl A. COX-2 inhibitors still eyed for cancer prevention (News), 890
 Thompson, Cheryl A. Drug information confuses pregnant patients' health care providers (News), 1342
 Thompson, Cheryl A. Government answers need for cultural competency resource (News), 676
 Thompson, Cheryl A. International pharmacy group to pursue better medication access in developing countries (News), 2216
 Thompson, Cheryl A. ICAHO views medication reconciliation as adverse-event prevention (News), 1528
 Thompson, Cheryl A. Language, reporting of safety undergoing change (News), 2451
 Thompson, Cheryl A. Longer life span not in foreseeable future (News), 24
 Thompson, Cheryl A. National billing codes announced for pharmacists' clinical services (News), 1640
 Thompson, Cheryl A. New heart-failure therapy takes race into account (News), 1745
 Thompson, Cheryl A. Oklahoma allows limited medication recycling (News), 1437
 Thompson, Cheryl A. Pharmacy helps hospital win national quality award (News), 343
 Thompson, Cheryl A. Regions work to exchange health information (News), 788
 Thompson, Cheryl A. Revisions continue on USP sterile-compounding chapter (News), 1856
 Thompson, Cheryl A. Safety advisory group gets mixed marks from members (News), 236
 Thompson, Cheryl A. Safety expert receives \$500,000 MacArthur grant (News), 2222
 Thompson, Cheryl A. Some firms will use pharmacists in Medicare chronic care project (News), 1009
 Thompson, Cheryl A. Technology hasn't eliminated medication errors yet, USP reports (News), 243
 Thompson, Cheryl A. Use of new CPT codes depends on practice arrangement (News), 1956
 Thompson, Casey K. ASHP Health-System Pharmacy 2015 Initiative: baseline statistics, 1393
 Thompson, Casey K. see also Maloney, Lesley R., 1871
 Thompson, Rodney L. see Wilson, John W., 499
 Timpe, Erin M. Frequency and complexity of queries to an academic drug information center, 1995-2004, 2511
 Ting-Chan, Jennifer see Chin, Alfred, 1073
 Tittle, Mary see Dilkush, Dimple, 2260
 Tomita, Dianne K. see Herrington, Jon D., 54
 Tomlinson, Brian see Cheng, Caroline W. R., 411
 Tomsche, James J. see Schneider, Brandi L., 2393
 Tortorici, Michael A. Hazards of colchicine (letter), 1350
 Towse, Adrian K. see Cooke, Jonathan, 189
 Tramier, Violaine see Bagel-Boithias, Sandrine, 182
 Tran, Kim The Student Leadership Institute (letter), 1442
 Tran, Maichi T. see Gandhi, Pritesh J., 1494
 Trapskin, Philip J. see Smith, Kelly M., 800
 Traynor, Kate CMS releases 2005-06 rule for inpatient Medicare payments (News), 1854
 Traynor, Kate Defense and Veterans Affairs move toward patient information sharing (News), 680
 Traynor, Kate Experts find huge gaps in understanding, treating menopause symptoms (News), 889
 Traynor, Kate Experts take on tuberculosis (News), 1431
 Traynor, Kate FDA advisers vote against nonprescription lovastatin (News), 455
 Traynor, Kate FDA's adverse-event surveillance needs improvement, advisers say (News), 1336
 Traynor, Kate Heart failure guidelines revised (News), 1953
 Traynor, Kate HIV occupational exposure guidelines revised (News), 2332

- Traynor, Kate Infectious diseases expected to capture headlines, attention in months ahead (News), 1748
- Traynor, Kate Insomnia sufferers need better care, experts say (News), 1532
- Traynor, Kate Milton W. Skolaut, ASHP past president, dies at 84 (News), 792
- Traynor, Kate Money matters in infection control policy (News), 1650
- Traynor, Kate More Americans than ever lack health insurance (News), 2583
- Traynor, Kate New drug and biological product approvals, 2004 (News), 348
- Traynor, Kate PTCB turns 10 (News), 119
- Traynor, Kate Quality of Medicare services a mixed picture, experts say (News), 1234
- Traynor, Kate Race is on for electronic medical record adoption (News), 2222
- Traynor, Kate Report urges scientific standards for alternative medicine (News), 562
- Traynor, Kate Standards-setting group seeks to improve medication adherence (News), 2440
- Traynor, Kate U.S. pharmacists respond to global AIDS crisis (News), 1108
- Triller, Darren M. Book Review, 437
- Triller, Darren M. Risk of adverse drug events by patient destination after hospital discharge, 1883
- Trissel, Lawrence A. Compatibility of anidulafungin with other drugs during simulated Y-site administration, 834
- Trissel, Lawrence A. Using a medium-fill simulation to evaluate the microbial contamination rate for USP medium-risk-level compounding, 285
- Trissel, Lawrence A. see also Xu, Quanyun A., 1998
- Tsouounis, Candy see Dennehy, Cathi E., 1476
- Tsuyuki, Ross T. see Charrois, Theresa L., 1798
- Tu, Tran C. see Gandhi, Pritesh J., 1494
- Turner, Jeanie Chinaye see Chisholm, Marie A., 1482
- U**
- Uknis, Marc E. Clinical update on opportunistic infections in transplantation. Prophylaxis of cytomegalovirus disease in transplant patients, Apr 15 suppl S3
- Ungphaiboon, Suwipa Formulation and efficacy of triamcinolone acetate mouthwash for treating oral lichen planus, 485
- V**
- Valora, Pedro D. see Volonté, Maria G., 630
- Van Bergen, Robin C. see Malone, Daniel C., 1983
- van Loenen, Arie C. see van Rij, Catharina M., 2608
- van Reij, Elisabeth M. L. see Swart, Eleonora L., 2459
- van Rij, Catharina M. Stability of ¹⁸B-l-boronophenylalanine-fructose injection, 2608
- VanDeKoppel, Shawna see Johnson, Cary E., 2518
- Vanderpool, Hannah K. see Maloney, Lesley R., 1871
- Veggeland, Turid Visual compatibility of clonidine with selected drugs (letter), 1968
- Veltri, Michael A. see Hamilton, Robert G., 1822
- Verme-Gibboney, Catherine Direct thrombin inhibitors in heparin-induced thrombocytopenia (letter), 247
- Vermeulen, Lee C. see Hoffman, James M., 149
- Vermeulen, Lee C. see also Steiner, MaryAnn E., 896
- Vervan, Marne see Shah, Sachin, 720
- Vigliotti, Debbie see Ling, Jennifer M., 1793
- Vieugels, Arthur see Willems, Ludo, 321
- Vo, Ashley see Ingle, Gordon R., 391
- Vogt, Molly see Ansani, Nicole T., 1184
- Volonté, Maria G. Stability of ibuprofen in injection solutions, 630
- Vuddhakul, Varaporn see Ungphaiboon, Suwipa, 485
- W**
- Walker, Paul C. Medication use as a risk factor for falls among hospitalized elderly patients, 2495
- Walker, Scott see Wazny, Lori, 1548
- Wall, Geoffrey C. see Norgard, Nick, 2524
- Walton, Surrey M. see Knapp, Katherine K., 492
- Wang, Da-Peng see Lee, Derek K. T., 1190
- Ward, Kristina E. see Schucker, Jason J., 2355
- Wasko, Mary Chester M. see Tortorici, Michael A., 1350
- Wazny, Lori Visual compatibility of gentamicin sulfate and 4% sodium citrate solutions (letter), 1548
- Weber, Eric Pharmacy technicians supporting clinical functions (Management Consultation), 2466
- Weber, Robert J. see Ansani, Nicole T., 1184, 1498
- Weber, Thomas P. see Puscalau, Georgeta, 1606
- Wechsler, Michael E. see Szumita, Paul M., 1931
- Welage, Lynda S. Treatment options and formulary considerations in the management of acid suppression in critically ill patients. Overview of pharmacologic agents for acid suppression in critically ill patients, May 15 suppl S4
- Wen, Lonnie Number needed to treat: a descriptor for weighing therapeutic options, 2031
- Wermeling, Daniel P. see Davis, George A., 48
- West, Donna S. see Strum, Matthew W., 1048
- Westanmo, Anders D. Duloxetine: a balanced and selective norepinephrine- and serotonin-reuptake inhibitor, 2481
- Westmoreland, Bonnie see Birk, Carol W., 34
- Weyer, Christian Properties of pramlintide and insulin upon mixing, 816
- White, C. Michael see Gillespie, Effie L., 1370
- White, C. Michael see also Min, Bokyoung, 1582
- White, Sara J. Will there be a pharmacy leadership crisis? An ASHP Foundation Scholar-in-Residence report, 845
- Wilhelm, Abraham J. see van Rij, Catharina M., 2608
- Wilhelm, Lindsey Role of adjuvant chemotherapy in the treatment of non-small-cell lung cancer, 1365
- Willems, Ludo Survey of hospital pharmacy practice in Flemish-speaking Belgium (Pharmacy Abroad), 321
- Willey, Vincent J. see Benner, Joshua S., 1468
- Williams, Carolyn K. Implementation of an i.v. medication safety system, 530
- Williams, Setareh A. see Benner, Joshua S., 1468
- Wilson, Amy Friedman Expansion of drug information services in response to an increased clerkship teaching load, 2514
- Wilson, John W. Hospital rules-based system: the next generation of medical informatics for patient safety, 499
- Winterstein, Almut G. see Smith, Wendy D., 714
- Witmer, David R. Making ASHP's 2015 Initiative a reality, 1391
- Wittig, Andrea see van Rij, Catharina M., 2608
- Wittkowsky, Ann K. see Nutescu, Edith A., 1449
- Wolfe, R. Brian see Birk, Carol W., 34
- Wolfe, Thomas A. see Birk, Carol W., 34
- Wong, Chi-Yin see Lee, Derek K. T., 1190
- Wongpoowarak, Wibul see Ungphaiboon, Suwipa, 485
- Woo, Kam-sang see Cheng, Caroline W. R., 411
- Woods, T. Mark 2005 Report of the President and Chair of the Board: honoring our commitments to members and patients, 1697
- Wu, Helen T. Clinical pharmacy in an inpatient leukemia and bone marrow transplant service, 744
- Wu, Wenchen Kenneth Darbepoetin versus epoetin (letter), 1552
- X**
- Xu, Quanyun A. Compatibility of palonosetron with cyclophosphamide and with ifosfamide during simulated Y-site administration, 1998
- Y**
- Yamamoto, Masato see Ishikawa, Kazuhiro, 1617
- Yan, Jun Book Review, 438
- Yang, Hui-Wen Keri see Mullins, C. Daniel, 1873
- Yost, R. David New economics of the pharmaceutical supply chain, 525
- You, Joyce H. S. see Cheng, Caroline W. R., 411
- Young, Christopher H. Patterns of antihypertensive therapy in new users of angiotensin II-receptor blockers, 2381
- Young, Donna Afghanistan struggles to rebuild health care system (News), 1950
- Young, Donna ASHP joins Mexican, Canadian societies in compact (News), 123
- Young, Donna Clinical pharmacy demonstration program gets a review (News), 454
- Young, Donna CMS Web site reports hospital quality (News), 1118
- Young, Donna Conference focuses on health care reform, lack of technology (News), 570
- Young, Donna Drug regulatory process is focused on safety, officials claim (News), 1754
- Young, Donna FDA labors over NSAID decisions (News), 668
- Young, Donna FDA ponders future of NSAIDs (News), 997
- Young, Donna FDA revisits DTC advertising (News), 2580
- Young, Donna FDA's drug safety initiative: resolutions or more questions? (News), 1333
- Young, Donna Five years after IOM report, experts gauge progress of patient safety (News), 12
- Young, Donna Four countries shed light on drug-review policies (News), 1122
- Young, Donna Government leadership, investment crucial to health care's IT success (News), 1228
- Young, Donna Health centers squeezed by tightened Medicaid budgets (News), 1852
- Young, Donna Impact to health systems unclear after OPSS, Part B payment changes (News), 124
- Young, Donna Importation reports spur more debate about drug prices (News), 233
- Young, Donna IOM panel hears concerns about U.S. drug safety system (News), 1428
- Young, Donna IOM panel mulls over adverse-event reporting (News), 2590
- Young, Donna IOM panel reviews lessons for medication safety (News), 1340
- Young, Donna Long-awaited patient safety bill enacted (News), 1740
- Young, Donna Medicare Part D creates challenges for safety-net providers and law enforcement (News), 1646
- Young, Donna Nation is unprepared for bioterrorism threat, study finds (News), 239
- Young, Donna Nature is vital to drug product discovery (News), 779
- Young, Donna Pharmacists play vital roles in Katrina response (News), 2202
- Young, Donna Pharmacy teams lack FEMA support (News), 2321
- Young, Donna Policymakers, experts review evidence-based medicine (News), 342
- Young, Donna Project advances health system's clinical pharmacy services (News), 560
- Young, Donna Racial, ethnic minorities less likely to receive good cardiac care, studies find (News), 886
- Young, Donna Residency program fills medication safety void (News), 2450
- Young, Donna Scientists focus on pharmacogenomics at FDA Science Forum (News), 1226
- Young, Donna Senate tackles Medicaid fraud and abuse (News), 1537
- Young, Donna States, hospitals learn emergency-preparedness lessons in TOPOFF 3 (News), 1000
- Young, Donna Student's death sparks concerns about compounded preparations (News), 450
- Young, Shaun F. Influencing prescribing through effective communication skills (Management Case Study), 2528
- Yuen, Courtney W. see Wu, Helen T., 744
- Z**
- Zaghoul, Iman Y. see Abanmy, Norah O., 1299
- Zed, Peter J. Book Review, 438
- Zed, Peter J. Outpatient treatment of venous thromboembolic disease based in an emergency department, 616
- Zellmer, William A. Reason and history as guides for hospital pharmacy practice leaders, 838
- Zellmer, William A. Unresolved issues in pharmacy, 259
- Zhang, Kui see Young, Christopher H., 2381

Advertising Index

A

Abbott Laboratories
Symposium, 2331

Abington Memorial Hospital
Position Available, 1205

Allina Hospitals and Clinics
Position Available, 325, 985, 1938

American Health Packaging
Institutional, 1119

American Pharmaceutical Partners, Inc.
Anti-Infectives, Dec 1 IBC
Piperacillin for Injection, 569

American Red Cross
Polygam S/D, 15

American Regent Laboratories
Venofer, Jan 15 IFC, Feb 15 IFC, Mar 15 IFC, Apr 15 IFC, May 15 IFC, Jun 15 IFC, Jul 15 IFC, Aug 15 IFC, Sep 15 IFC, Oct 15 IFC, Nov 15 IFC, Dec 15 IFC

American Society of Health-System Pharmacists
AHFS DI Essentials 2004-05, 141, 350, 461, 619, 682, 799, 1016, 1110, 1244
AHFS DI Essentials 2005-06, 1623, 1689, 1781, 1863, 1991, 2184, 2426, 2523
AHFS Drug Information 2005, 100, 217, 318, 366, 544, 651, 761, 789, 957, 1089, 1130, 1289
AHFS Drug Information 2006, 2304, 2412, 2647
AJHP Classified Advertising, 97, 218, 434, 542, 652, 762, 984, 1090, 1205, 1412, 1620, 1723, 1836, 1937, 2044, 2159, 2472, 2636
AJHP Reprints, 102, 434, 545, 656, 803, 875, 1096, 1102, 1315, 141, 1537, 1645, 1841, 1940, 2066, 2306, 2309, 2469, 2573

AudioMed, 1134, 2238

CareerPharm, Jan 1 IBC, 144, 349, Mar 1 IBC, 654, 787, May 1 IBC, May 15 IBC, 1199, 1233, 1417, 1513, 1635, 1839, 1865, 1965, 2133, 2191, 2362, 2527, 2592

Clinical Pharmacokinetics, 98, 209, 396, 653, 711, 1086, 1194, 1493, 1699, 1699

Competence Assessment Tools for Health-System Pharmacies, 92, 363, 636, 764, 1092

Compounding Sterile Preparations, 32, 62, 213, 219, 353, 540, 609, 747, 1009, 1112, 1318, 1768, 1869, 2010

Developing Clinical Practice Skills for Pharmacists and Concepts in Clinical Pharmacokinetics, 1961, 2182, 2327, 2517, 2638

Drug-Induced Diseases, 1094, 1237, 1356, 1446, 1682, 1857, 2042, 2292, 2328, 2507

Extended Stability for Parenteral Drugs and Pocket Guide to Injectable Drugs, 1270, 1397, 1467, 1702, 1893, 1982, 2277, 2500

George P. Provost Editorial Internship, 101, 214, 324, 432, 541, 650, 762, 867, 982, 2568, 2643

Handbook on Injectable Drugs, 143, 436, 646, 68, 759, 804, 916, 1032, 1120, 1316, 1559, 1758, 2352, 2477

Handbook on Institutional Pharmacy Practice, 2326, 2644

HighWire, 1772, 1851, 1942, 2121, 2587

Medication Safety, 1621, 1712, 1872, 2049, 2270, 2551

Medication Teaching Manual, 204

Pain Management, 188

Pharmaceutical Reimbursement Resource Center, 1418, 1516

Pharmacy Leadership, 250

Pharmacy Technician Products, 377, 633, 738, 833, 2186

PharmPrep, 410, 1079, 1183, 1938, 2419

Position Available, 214, 324, 432, 541, 650, 655, 765, 868, 982, 1090, 1620

Preceptor's Handbook for Pharmacists, 1242, 1501, 1861, 2259, 2458, 2625

SkyScape, 96, 215, 390, 546, 649, 725, 791, 934, 1020, 1246

AmerisourceBergen
Institutional, 939, 1117, 1345, 1523

Amgen Inc.
Aranesp, Jan 1 IFC, Feb 1 IFC, Mar 1 IFC, Apr 1 IFC, May 1 IFC, Jun 1 IFC, 1235, Jul 1 IFC, Aug 1 IFC, Sep 1 IFC, Oct 1 IFC, Nov 1 IFC, 2584

Institutional, 2073

Neulasta, 2205, Dec 1 IFC

Antietam Health Services
Position Available, 2645

Aroostook Medical Center
Position Available, 2046, 2183, 2298, 2556

ASHP Advantage
Baxter Web-Based CE Program, 1351
Best Practices Award, 2589
Merck Cutting-Edge CE on Timely Topics, 2117
The Tenth Annual ASHP Conference for Leaders in Health-System Pharmacy, 1427

ASHP Research and Education Foundation
Awards Programs, 1450
Institutional, 1770, 2341
2004 Award for Excellence in Medication-Use Safety, 470

Astellas Pharma US, Inc.
Institutional, 1001
Mycamine, 771, 991, 1139, 1423, 1531, Sep 15 OBC, 2315, 2467

AstraZeneca
Merrem, 1632, 1730, 2054, 2310, 2432

B

The Baker Company
Institutional, 885, 2065

Banner Health System
Positions Available, 99, 218, 329, 763, 870

Baxter Healthcare Corporation
Bar Code, 1641, 1847, 1963, 2351
Brevibloc, 1141
Ceftriaxone, 1121, 1349, 1541, 1555, 1755, 2071, 2203
Institutional, 2300, 2470
Propofol, 2335
Suprane, 1124, 2086, 2564

B Braun
DUPLEX, 1566, 1759, 2059, 2354

Beaumont
Position Available, 2562

Bedford Laboratories
Octreotide, 955, 1243
Propofol, 1432, 1560, 1752, 2112

Berkshire Medical Center
Position Available, 101

Berlex Laboratories, Inc.
Leukine, 447, Mar 15 OBC, 677, 943, 2095

B. E. Smith Associates Inc.
Position Available, 1937, 1205

Bon Secours, Richmond Health System
Position Available, 2305

Bristol-Myers Squibb Company
Abilify, 135, 557, 2011, 2101, 2227, 2373, 2531, 2611
Eribut, Jan 15 OBC, 251, 457, 773, 891, 1135

C

California Department of Corrections
Positions Available, 435, 765, 1624, 2043, 2556

Cardinal Health/Alaris
Institutional, 571, 777, 900, 1133

Carilion Health System
Positions Available, 983

Carolinas HealthCare System
Positions Available, 1317

Centra Health
Position Available, 986

Central Washington Hospital
Position Available, 652

Children's Healthcare of Atlanta
Positions Available, 2560

Children's Hospital of Wisconsin
Position Available, 2183

Children's Medical Center (Dallas)
Positions Available, 1515, 1937

City of Hope Cancer Center
Positions Available, 433

Cognigen Corporation
Position Available, 1837

Columbus Regional Healthcare System
Position Available, 2046

Containment Technologies Group, Inc.
Institutional, Apr 1 IBC, 1649, 1765, 2077, 2215, 2473, 2577

Continuum Health Partners, Inc.
Positions Available, 2303

Contra Costa Health Services
Positions Available, 1319, 1414

Cooper-Atkins Corporation
Temp Trak, 249, 947, 1127, 1563

Covance
Institutional, 1970, 2210, 2452

Cubist Pharmaceuticals, Inc.
Cubicin, 120, 344

D

Dallas VA Medical Center
Positions Available, 1835

Danville Regional Health System
Position Available, 1622

Department of Veterans Affairs
Positions Available, 2045, 2299

Design Write
Pfizer Symposium, 1003

Diagnostica Stago, Inc.
Institutional, 998, 1220, 1538, 1746, 1954, 2346
Rotachrom, 554, 780

Duke University Health System
Position Available, 101, 325

E

Endo Pharmaceuticals
Exhibitors' Theater, 2457

Epic Systems Corporation
Positions Available, 433, 1203

ePocrates
ePocrates Rx Online Plus AHFS DI, 23, Feb 1 IBC, 472, 687, 1209, 1415, 1518, 1652, 2147

EPS, Inc.
Institutional, 887, 1109, 1429, 1529, 1739, 2063

F

FFF Enterprises
Institutional, 227, 567, 2478
Verified Electronic Pedigree, 5

Fletcher Allen Health Care
Positions Available, 1317, 2305, 2555

ForHealth Technologies Inc.
Institutional, 793
IntelliFill I.v., 965, 1115

Forsyth Medical Center
Positions Available, 983

Fujisawa
AmBisome, 107, 551

G

Garrett Associates Inc.
Position Available, 329

Genentech, Inc.
Tarceva, 335, 783, 1229, 1553

Geritex Corporation
Topical Light Mineral Oil/USP, 1123

GlaxoSmithKline
Alvimopan, 2061

Group Health Cooperative
Positions Available, 1205

H

Hardy Diagnostics
Institutional, 1853, 2463

Harrison Hospital
Position Available, 1722

Hawaii College of Pharmacy
Position Available, 1207

Health First

Positions Available, 1317

HIMSS

2005 Conference and Exhibition, 125, 330

Hoag Hospital

Position Available, 1835, 2043

HospiraCeftriaxone, 1527, 1767
Diltiazem, 111, 1331
Institutional, 133, 237, 255, 584, 681, 1098, 1339, 1639,
1757, 2099, 2240, 2480, 2579**Howard Young Medical Center**

Position Available, 1201

I**Inova Health System**

Positions Available, 2562

International Journal of Pharmaceutical Compounding
CompoundingToday.com, 19**J****Jackson Health System**

Positions Available, 984

JB Austin Group Inc.

Anemia Management, 2343

Jeane Hospital

Position Available, 545

John Muir/Mt. Diablo Health System

Positions Available, 1203

Johns Hopkins HospitalPharmacists' Involvement in Medication Management,
667

Positions Available, 2180, 2560

Joint Commission Resources, Inc.

Position Available, 2305

K**Kaiser Permanente**

Positions Available, 2556

Kalispell Regional Medical Center

Positions Available, 542, 655, 763, 869, 983, 2298, 2423

L**Lancaster General**

Positions Available, 1721

Lander Valley Medical Center

Position Available, 1514

Lexi-Comp Inc.

Institutional, 1343, 1849, 2079, 2199, 2569

Little Company of Mary Hospital

Position Available, 433

Loma Linda University Medical Center

Position Available, 870, 1722

Long Beach Memorial Medical Center

Positions Available, 2044

Long Island University

Positions Available, 869

Lovelace Sandia Health SystemPositions Available, 652, 1091, 1201, 1319, 1416, 1515,
1939, 2425, 2563**M****Mallinckrodt Inc.**Fentanyl Patch, 7
Unit Dose Packaging, 25, 113**Mayne Pharma (USA) Inc.**

CARBOplatin, 21

McKessonInstitutional, 2068, 2333, 2464
Positions Available, 545, 1205**MedCath Corporation**

Positions Available, 2563

Medicis Pharmaceutical Corp.

Ammonul, 1544, 2090, 2460

Medi-Dose, Inc.

MILT, 13, 225, 561, Apr 1 OBC, 1335, 1947, 2201, 2581

MedScape PharmacistsInstitutional, 295, 491, 766, 855, 1158, 1387, 1581,
1930, 2151, 2530, 2633**MemorialCare**

Positions Available, 2046

Memorial Healthcare System

Positions Available, 1203, 2428

Memorial Sloan-Kettering Cancer Center

Positions Available, 2555

Meridian Medical Technologies, Inc.

Institutional, 581, 669, 959, 1231, 1557

Merle West Medical Center

Position Available, 2187

MGI Pharma, Inc.Aloxi, 9, 147, 241, 339, 465, 575, 673, 921, 995, 1113,
1239, 1353, 1435, 1525, 1643, 1761, 1859, 1977,
2083, 2217, 2323, 2521
Dacogen, 1533, 1749**Miami VA Medical Center**

Position Available, 543

Mills-Peninsula Health Services

Positions Available, 2562

MMI

Institutional, 33, 245, 451, 679, 967, 1355, 1764, 2237

Moffitt Cancer Center

Cancer Control, 1751

N**Natividad Medical Center**

Position Available, 1835

New York-Presbyterian Hospital

Positions Available, 2424

North Dakota State University

Position Available, 2556

North Florida Regional Medical Center

Positions Available, 1723, 1939, 2185, 2427, 2643

Northeast Medical Center

Position Available, 435, 985

Norton Healthcare

Positions Available, 1837

NuAireNuair Pharmagard, 2, 235, 453, 675, 963, 1111, 1951,
1358, 1551, 1774, 2221, 2561**NYU Medical Center**

Position Available, 1093

O**Ohio Northern University**

Position Available, 1836

Omniceil

Institutional, 937, 1144, 2223, 2439

Ortho BiotechProcrit, 37, 127, 257, 357, 473, 563, 689, 795, 903,
1005, Jun 1 OBC, 1223, Jul 1 OBC, Aug 1 OBC,
1655, Sep 1 OBC, Oct 1 OBC**Ortho-McNeil**

IONSYS 2005, 1949, 2081, 2225, 2449

Razadyne, 1217, Jul 15 OBC, 1637

OSF Saint Anthony Medical Center

Positions Available, 2427

Our Lady of Lourdes Medical Center

Position Available, 435

Overlake Hospital Medical Center

Position Available, 1413

P**Paddock Laboratories, Inc.**

EZCHAR, 115, 579

Palm Beach Atlantic University

Position Available, 2186

Parkview Hospital

Positions Available, 1093, 1201

Pfizer US Pharmaceuticals

Inspira, 229, 683, 1131, 1535

Position Available, 2187

Sutent, 2579

Symposium, 2089

Vfend, Jan 1 OBC, Feb 1 OBC, Mar 1 OBC, 662, 880,
1326, 1734, 2194Zyvox, Feb 15 OBC, Apr 15 OBC, Jun 15 OBC, Aug 15
OBC, Oct 15 OBC, Dec 15 OBC**Pharmacy Computer Services, Inc.**

Institutional, 117

Poudre Valley Hospital

Positions Available, 2568

Primary Children's Medical Center

Positions Available, 329

PSI

Institutional, 2441

Q**QS/1 Data Systems**

Institutional, 109, 573, 993, 1439, 1549, 2097, 2443

Queen of the Valley Hospital

Positions Available, 2302

R**Reston Hospital Center**

Positions Available, 2560

Roswell Park Cancer Institute

Position Available, 2563

Roxane Laboratories

Calcitriol, 445, 1323, 1945

Clarithromycin, 1727

Cocaine Hydrochloride, 875, 1101

Levorphanol, 659, 1521, 2437

Midazolam, 2319

Pilocarpine Hydrochloride Tablets, 1246

Rush North Shore Medical Center

Positions Available, 2428

Rutgers University-Ernest Mario School of PharmacyPositions Available, 871, 1413, 1622, 2181, 2183, 2185,
2187**S****St. Francis Hospital and Health Centers**

Position Available, 1625

St. John's Hospital

Positions Available, 2302

St. John's Hospital (Missouri)

Positions Available, 1413

St. Luke's (Idaho)

Position Available, 1319, 1414, 1515

St. Luke's Episcopal Hospital

Position Available, 1622

St. Luke's Regional Medical Center

Position Available, 2046

St. Mary's Hospital

Position Available, 2568

St. Vincent's Medical Center

Position Available, 2424

Salinas Valley Memorial Healthcare System

Position Available, 326

Scios Inc.

Natreacor, 2552

Sentara Healthcare

Position Available, 216, 2563

Shands Hospital at University of Florida

Positions Available, 1722, 1939, 2185

Siemens

Institutional, 1129, 2559

Spectrum Health

Position Available, 2646

The State University of New York at Buffalo

Positions Available, 871

Susan B. Allen Memorial Hospital

Position Available, 99

Sutter Health

Positions Available, 2302

Continued on page 2674

and 0.0; rash 1.4 and 7.1; oral moniliasis 0.9 and 4.0; fever 0.5 and 3.0; pruritus at non-application site 0.0 and 2.0; and anaphylaxis 0.0 and 10.1[†] respectively. **Laboratory Changes** ZYVOX has been associated with thrombocytopenia when used in doses up to and including 600 mg every 12 hours for up to 28 days. In Phase 3 comparator-controlled trials, the percentage of adult patients who developed a substantially low platelet count (defined as less than 75% of lower limit of normal and/or baseline) was 2.4% range among studies: 0.5 to 10.0% with ZYVOX and 1.5% range among studies: 0.4 to 7.0% with a comparator. In a study of hospitalized pediatric patients ranging in age from birth through 11 years, the percentage of patients who developed a substantially low platelet count (defined as less than 75% of lower limit of normal and/or baseline) was 12.9% with ZYVOX and 13.4% with vancomycin. In an outpatient study of pediatric patients aged from 5 through 17 years, the percentage of patients who developed a substantially low platelet count was 0% with ZYVOX and 0.4% with cefadroxil. Thrombocytopenia associated with the use of ZYVOX appears to be dependent on duration of therapy (generally greater than 2 weeks of treatment). The platelet counts for most patients returned to the normal range/baseline during the follow-up period. No related clinical adverse events were identified in Phase 3 clinical trials in patients developing thrombocytopenia. Bleeding events were identified in thrombocytopenic patients in a compassionate use program for ZYVOX; the role of linezolid in these events cannot be determined (see **WARNINGS**). Changes seen in other laboratory parameters, without regard to drug relationship, revealed no substantial differences between ZYVOX and the comparators. These changes were generally not clinically significant, did not lead to discontinuation of therapy, and were reversible. The percent of adult patients with at least one substantially abnormal hematologic[†] value in patients treated with ZYVOX 400 mg q12h or clarithromycin 250 mg q12h for uncomplicated skin and skin structure infections were as follows: hemoglobin (g/dL) 0.9 and 0.0; platelet count (x 10⁹/mm³) 0.7 and 0.8; WBC (x 10⁹/mm³) 0.2 and 0.6; neutrophils (x 10⁹/mm³) 0.0 and 0.2 respectively. The percent of adult patients with at least one substantially abnormal hematologic[†] value in patients treated with ZYVOX 600 mg q12h or a comparator[†] were as follows: hemoglobin (g/dL) 7.1 and 6.6; platelet count (x 10⁹/mm³) 3.0 and 1.8; WBC (x 10⁹/mm³) 2.2 and 1.3 and neutrophils (x 10⁹/mm³) 1.1 and 1.2 respectively. The percent of adult patients with at least one substantially abnormal serum chemistry[†] value in patients treated with ZYVOX 400 mg q12h or clarithromycin 250 mg q12h for uncomplicated skin and skin structure infections were as follows: AST (IU/L) 1.7 and 1.3; ALT (IU/L) 1.7 and 1.7; LDH (IU/L) 0.2 and 0.2; alkaline phosphatase (IU/L) 0.2 and 0.2; lipase (IU/L) 2.8 and 2.6; amylase (IU/L) 0.2 and 0.2; total bilirubin (mg/dL) 0.2 and 0.0; BUN (mg/dL) 0.2 and 0.0; and creatinine (mg/dL) 0.2 and 0.0 respectively. The percent of adult patients with at least one substantially abnormal serum chemistry[†] value in patients treated with ZYVOX 600 mg q12h or a comparator[†] were as follows: AST (IU/L) 5.0 and 6.8; ALT (IU/L) 9.6 and 9.3; LDH (IU/L) 1.8 and 1.5; alkaline phosphatase (IU/L) 3.5 and 3.1; lipase (IU/L) 4.3 and 4.2; amylase (IU/L) 2.4 and 2.0; total bilirubin (mg/dL) 0.9 and 1.1; BUN (mg/dL) 2.1 and 1.5; and creatinine (mg/dL) 0.2 and 0.6 respectively. The percent of pediatric patients with at least one substantially abnormal hematologic[†] value in patients treated with ZYVOX or cefadroxil for uncomplicated skin and skin structure infections were as follows: hemoglobin (g/dL) 0.0 and 0.0; platelet count (x 10⁹/mm³) 0.0 and 0.4; WBC (x 10⁹/mm³) 0.8 and 0.8; neutrophils (x 10⁹/mm³) 1.2 and 0.8 respectively. The percent of pediatric patients with at least one substantially abnormal hematologic[†] value in patients treated with ZYVOX or vancomycin for any other indication[†] were as follows: hemoglobin (g/dL) 15.7 and 12.4; platelet count (x 10⁹/mm³) 12.9 and 15.4; WBC (x 10⁹/mm³) 12.4 and 10.3 and neutrophils (x 10⁹/mm³) 5.9 and 4.3 respectively. The percent of pediatric patients with at least one substantially abnormal serum chemistry[†] value in patients treated with ZYVOX or cefadroxil for uncomplicated skin and skin structure infections were as follows: ALT (IU/L) 0.0 and 0.0; lipase (IU/L) 0.4 and 1.2; and

creatinine (mg/dL) 0.4 and 0.0 respectively. The percent of pediatric patients with at least one substantially abnormal serum chemistry[†] value in patients treated with ZYVOX or vancomycin for any other indication[†] were as follows: ALT (IU/L) 10.1 and 12.5; amylase (IU/L) 0.6 and 1.3; total bilirubin (mg/dL) 6.5 and 5.2; and creatinine (mg/dL) 2.4 and 1.0 respectively. **Postmarketing Experience** Myelosuppression (including anemia, leukopenia, pancytopenia, and thrombocytopenia) has been reported during postmarketing use of ZYVOX (see **WARNINGS**). Peripheral neuropathy, and optic neuropathy sometimes progressing to loss of vision, have been reported in patients treated with ZYVOX. Lactic acidosis has been reported with the use of ZYVOX (see **PRECAUTIONS**). Although these reports have primarily been in patients treated for longer than the maximum recommended duration of 28 days, these events have also been reported in patients receiving shorter courses of therapy. Serotonin syndrome has been reported in patients receiving concomitant serotonergic agents and ZYVOX (see **PRECAUTIONS**). These events have been chosen for inclusion due to either their seriousness, frequency of reporting, possible causal connection to ZYVOX, or a combination of these factors. Because they are reported voluntarily from a population of unknown size, estimates of frequency cannot be made and causal relationship cannot be precisely established. **OVERDOSAGE** In the event of overdosage, supportive care is advised, with maintenance of glomerular filtration. Hemodialysis may facilitate more rapid elimination of linezolid. In a Phase 1 clinical trial, approximately 30% of a dose of linezolid was removed during a 3-hour hemodialysis session beginning 3 hours after the dose of linezolid was administered. Data are not available for removal of linezolid with peritoneal dialysis or hemoperfusion. Clinical signs of acute toxicity in animals were decreased activity and ataxia in rats and vomiting and tremors in dogs treated with 3000 mg/kg/day and 2000 mg/kg/day, respectively.

[†] MDSP refers to isolates resistant to 2 or more of the following antibiotics: penicillin, second-generation cephalosporins, macrolides, tetracyclines, and trimethoprim/sulfamethoxazole.

[†] Comparators included cefepodoxime proxetil 200 mg PO q12h; ceftriaxone 1 g IV q12h; clarithromycin 250 mg PO q12h; dicloxacillin 500 mg PO q6h; oxacillin 2 g IV q6h; vancomycin 1 g IV q12h.

[†] The most commonly reported drug-related adverse events leading to discontinuation in patients treated with ZYVOX were nausea, headache, diarrhea, and vomiting.

[†] Comparators included cefepodoxime proxetil 200 mg PO q12h; ceftriaxone 1 g IV q12h; dicloxacillin 500 mg PO q6h; oxacillin 2 g IV q6h; vancomycin 1 g IV q12h.

[†] Patients 5 through 11 years of age received ZYVOX 10 mg/kg PO q12h or cefadroxil 15 mg/kg PO q12h. Patients 12 years or older received ZYVOX 600 mg PO q12h or cefadroxil 500 mg PO q12h.

[†] Patients from birth through 11 years of age received ZYVOX 10 mg/kg IV/PO q6h or vancomycin 10 to 15 mg/kg IV q6-24h, depending on age and renal clearance.

[†] These reports were of "red-man syndrome," which were coded as anaphylaxis.

[†] <75% (<50% for neutrophils) of Lower Limit of Normal (LLN) for values normal at baseline; <75% (<50% for neutrophils) of LLN and <75% (<50% for neutrophils, <90% for hemoglobin if baseline LLN) of baseline for values abnormal at baseline.

[†] >2 x Upper Limit of Normal (ULN) for values normal at baseline; >2 x ULN and >2 x baseline for values abnormal at baseline.

[†] <75% (<50% for neutrophils) of Lower Limit of Normal (LLN) for values normal at baseline; <75% (<50% for neutrophils) of LLN and <75% (<50% for neutrophils, <90% for hemoglobin if baseline LLN) of baseline for values abnormal at baseline.

[†] >2 x Upper Limit of Normal (ULN) for values normal at baseline; >2 x ULN and >2 x 1.5 for total bilirubin x baseline for values abnormal at baseline.

Rx only

Rev. May 2005

ZV63170

© 2005 Pfizer Inc.

All rights reserved.

 U.S. Pharmaceuticals

ANNUAL INDEX

Continued from page 2673

T

Takeda Pharmaceuticals

Symposium, 2085

Talecris Biotherapeutics

Gamunex, 2475

Hypermunes, 2435

Thrombate III, 2339, 2557

Temple University School of Pharmacy

Positions Available, 2425

Teva Sicor

Institutional, 1107, 1337, 1547, 1769, 2219

Methylprednisolone, 897

Texas Children's Hospital

Positions Available, 984, 1624

Tulane University Hospital and Clinic

Positions Available, 765

U

United States Army Medical Service

Positions Available, 99, 434, 655, 1413, 1624, 2427

University Hospital of Arkansas

Position Available, 868

University of California, San Diego

Position Available, 326

University of California, San Francisco

Positions Available, 543, 2044

University of Illinois at Chicago

Online Continuing Education Program, 1241

The University of Iowa Hospitals and Clinics

Position Available, 871, 2562

University of New Mexico Hospitals

Position Available, 2645

The University of Pittsburgh Medical Center

Position Available, 2567

University of Rochester Medical Center

Position Available, 2560

The University of Sidney

Position Available, 1624

University of Tennessee

Position Available, 1091

The University of Texas MD Anderson Cancer Center

Position Available, 1416, 1625

University of Washington Medical Center

Positions Available, 2183, 2645

Upon Regional Medical Center

Position Available, 1834

U.S. Pharmacopeia

MedMarx, 11

The 2005 USP Pharmacists' Pharmacopeia, 1103, 1448, 2547

V

VA Medical Center (Iowa)

Position Available, 1414

VA National Center for Patient Safety

Position Available, 2423, 2645

VA Puget Sound Health Care System

Position Available, 101

VHA

Position Available, 1834

W

Wake Forest University Baptist Medical Center

Positions Available, 2303

WakeMed

Position Available, 326, 2568

Washington Hospital Center

Positions Available, 327

WellStar Health System

Positions Available, 216

West Virginia University Hospital

Position Available, 2180

Whidbey General Hospital

Position Available, 2046, 2180, 2298

Wingate University School of Pharmacy

Position Available, 1093

Wishard Health Services

Position Available, 1837

WoltersKluwer

eFacts, 951, 1425

Wyeth Pharmaceuticals Inc.

Anti-Infective Series, May 1 OBC, May 15 OBC, 1105,

1227, 1341, 1443, 1647, 1741

Positions Available, 765

Tyagil, 1957, Nov 1 OBC, Nov 15 OBC, 2445

